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ABSTRACT
Research and design of drugs for treatment against microbial infections require the study of
pathogenic proteins involved during infection and replication. Drugs can be designed to interfere with the
interaction network of these pathogenic proteins and inhibit the infection process. Determination of the
structure and ligands of the target proteins in microbes is essential for designing mechanistic-based drugs.
Two Chlamydia proteins involved in host cell invasion were investigated in this study. The goal is to identify
amino acids involved at the binding interface of Chlamydia chaperon proteins Scc1 and Scc4 by solution
NMR spectroscopy. This information will give a lead in designing drugs that will interfere with Scc1:Scc4
binding, thus preventing Chlamydia invasion. Two new purification methods for isolating untagged Scc4
and the formation of mixed heterodimer complexes for NMR studies are described. The experimental NMR
spectroscopy data was recorded and used to analyze the structural conformations of Scc4 when
transitioning from homodimer to the heterodimer complex. Research presented in the second section is a
novel structural modification method for therapeutic peptides through glycoalkylation. The modification is
intended to improve the pharmacokinetic properties of lysine-containing peptide drugs, through half-life
elongation and increased oral bioavailability. Specifically, the therapeutic tripeptide, Ac-KPV-NH2, was
modified with a sugar derivative. Although the effect of the modification could not be assessed through
antimicrobial and anti-inflammatory tests, the glycoalkylated peptides are shown to be stable against
pronase cleavage. The unmodified tripeptide was cleaved by pronase in less than 24 hours, indicating that
the glycoalkylation confers proteolytic stability.
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CHAPTER 1
INTRODUCTION: PRODUCTION OF PROTEINS AND PEPTIDES FOR DRUG DISCOVERY
1.1 Proteins and peptides
Proteins and peptides are chains of amino acids linked by peptide bonds to form the primary
structure.1 Secondary structures are formed by local folding aided by hydrogen bonds, leading to the
formation of α-helices or β-sheets, depending on the amino acid sequence and side chain interactions. 1
Other sequences may form loops or coils. The regions of the secondary structure fold into tertiary structure
giving the three-dimensional arrangement of the protein or peptide.2
Approximately 20,000 unmodified proteins are encoded in the human genome. Additionally, about
100 variant protein structures can be derived from a single gene through processes such as post
translational modification, alternative splicing, and single amino acid polymorphism. 3 These proteins play a
central role in biological systems through their interaction with each other or with molecules such as DNA,
or RNA.4 Improper folding and mutation of protein sequences interfere with their interaction network, leading
to various diseases and disorders.4
Mechanism-based drugs that target proteins in biological systems are designed based on the
molecular understanding of the protein structure and function. Protein targets are derived from the human
genome5 or from pathogens that cause infections.6 Pathogenic proteins are transferred to the host cell by
bacteria or viruses, through various mechanisms, to interfere with the host’s cellular activities and allow the
pathogen to thrive. To design drugs that target pathogenic proteins, there is a need for structural knowledge
of the proteins involved and how they are transferred to the host cell. Bacterial systems, such as gramnegative bacteria, have complex microstructures used for host-pathogen interaction. These dedicated
secretion systems form β-barrel channels classified into six types, called type I secretion system (T1SS) to
type VI secretion system (T6SS), depending on the class of proteins being secreted. 7 Therapeutic
approaches that interfere with these systems will inhibit microbial host cell invasion.
In addition to being used as drug targets, proteins and peptides have been utilized as therapeutic
agents. A large number of bioactive peptides with varying activities have been isolated in animals. 8 These
peptides are derived from pro-peptides (longer protein sequences), which are activated during post
translational modification by enzymes such as prohormone convertases.9 Protein or peptide drugs with
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longer sequences are synthesized through recombinant methods,10 while short peptides can be chemically
synthesized. Biological activity of peptide motifs in large multifunctional proteins can be mimicked using
short peptides bearing the same amino acid sequence as the peptide motif. 11 In most cases, specificity is
enhanced and production costs are lower when short peptide sequences are used in place of the full-length
proteins.
1.2 Therapeutic peptides
There are over 1000 known signaling peptides in animals that have been classified into different
groups depending on their function. These classes include antimicrobial peptides, toxin and venom
peptides, cytokines and growth factors, neuropeptides, peptide hormones, anti-inflammatory, and
antifreeze peptides.8 Studies on the therapeutic activities of both endogenous and exogenous peptides
have shown that some peptides are multifunctional. Alpha melanocyte stimulating hormone (α-MSH), for
example, is an endogenous peptide with melanogenic effects, immunomodulatory effects, and antimicrobial
activity.12 Other examples of endogenous peptides are neurokinins, insulin, gastrin, glucagon,
adrenocorticotropic hormone (ACTH).13 Exogenous bioactive peptides are largely derived from food.14 Food
proteins encrypt bioactive peptide sequences that are activated by proteolytic enzymes during fermentation,
hydrolysis or digestion.15 Food-derived peptides are essential for different physiological activities in the
immune, nervous, gastrointestinal, and cardiovascular systems. 15, 16 Examples of short bioactive peptides
are listed in Table 1.
Peptide-based therapeutics are produced by chemical synthesis, recombinant methods, transgenic
systems, or isolated from natural sources. They have been used in the treatment of various diseases,
including multiple sclerosis, cancer, Alzheimer’s disease, congestive heart failure, deep vein thrombosis,
lupus, ulcerative colitis, rheumatoid arthritis, and hepatitis C.17 In terms of molecular size, peptide drugs fill
the gap between small molecule drugs and protein drugs. Peptide drugs combine the positive features
afforded by the small molecule drugs, such as homogeneity and ease in cellular uptake, with those of
biologics, such as high target specificity and minimal side effects. 18 Short peptide sequences can be
synthesized in solution or through solid phase peptide synthesis. Chemical synthesis enables structural
manipulation to protect peptide drugs from enzymatic recognition and degradation. These modifications
can be introduced during the stepwise synthesis with the use of modified building blocks. In contrast to the
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structural modification of biologics in cellular systems, it is possible to control the extent and site of
modifications using protecting groups.
Table 1. Examples of bioactive peptides.15, 19
Peptide

Activity

Function

IP, MP, VP, LP

Anti-oxidants

Scavenge hydroxyl radicals

PTGADY

Immunomodulatory

Increases production of IL-2, IL-4, IL-6

ADVFNPR, VVLYK

Antihypertensive

Reduces endothelin-1 levels

LGTAVFK

Antimicrobial

Causes membrane destruction in bacteria and
yeast

GPAE, GPGA

Anti-type 2 diabetes

Inhibits dipeptidyl peptidase-IV

mellitus
FIMGPY

Anticancer

Antiproliferation activity by inducing apoptosis

1.3 Antimicrobial peptides
Cationic and amphiphilic properties of antimicrobial peptides (AMPs) allow their interaction with
negatively charged bacterial membrane, distinguishable from positively charged mammalian membranes.
The presence of lipopolysaccharide, anionic phospholipids, lipoteichoic acid, and teichoic acid in the
bacterial membranes enable electrostatic interaction with cationic peptides. 20 At the water-membrane
interface, antimicrobial peptides form an amphipathic structure segregating cationic (hydrophilic) residues
from hydrophobic residues. This structure enables electrostatic interaction of the cationic residues with the
negatively charged membrane.21 The hydrophobic domain can interact with the fatty acyl chains in the
bilayer membrane, thus creating pores that may lead to cell death through the loss of membrane potential
or ions. Apart from disrupting microbial cytoplasmic membranes, other mechanisms have been identified
that target cellular processes such as enzymatic activity, DNA and protein synthesis, protein folding, and
synthesis of the cell wall.22 Four main modes of actions have been proposed for both membrane-active and
intracellular active AMPs. These are barrel-stave, toroidal, detergent, and carpet modes,23 represented in
Figure 1. In the barrel stave mode, the peptides form a transmembrane pore with the hydrophobic groups
facing outward toward the membrane acyl chains while the hydrophilic groups face inward lining the pore.24
The toroidal pore mode is like the barrel stave mode except that the peptides are intercalated with the
membrane lipids to line the pore. In the carpet mode, the peptides accumulate on the membrane surface
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through electrostatic interaction leading to membrane thinning. The detergent mode is characterized by
initial accumulation of peptides at the membrane surface followed by lipid/peptide micellization. 24,

25

Examples of peptides utilizing these modes of action are cecropin (detergent), alamethicin (barrel-stave),
magainin 2 (toroidal), and LL-37 (carpet).25

Figure 1. A pictorial representation of the different modes of action of AMPs adapted from Zhang et al.25
1.4 Structural modification of therapeutic peptides
Some of the challenges that limit full exploitation of therapeutic peptides are low oral bioavailability
and short half-life due to renal filtration or proteolytic degradation.26 Proteases in bodily fluids, tissues, and
cells easily degrade recognizable peptide sequences.27 To overcome renal filtration and degradation,
extensive modification of bioactive peptides, by incorporating unnatural amino acid(s), partial structural
modifications, or covalent attachment with polymers, has been implemented. Peptide drugs have been
coupled to polymers of sialic acid (polysialylation), ethylene glycol (PEGylation), and the carbohydrate
polymer hydroxyethyl starch (HESylation).28 The attachment of such polymers increases the hydrodynamic
volume of the drug, which places it above the renal elimination cut-off, thereby allowing longer circulation
times. In addition, some polymers are highly hydrophilic in nature, increasing the solubility of the drug. The
bulky modifications sterically hinder proteolytic degradation.
PEGylation is the covalent attachment of polyethylene glycol (PEG) to protein or peptide drugs.
Conjugation processes depend on the PEG, which may be an activated ester that can be reacted with an
amine in the protein or PEG aldehyde or glutaraldehyde coupled to amines through reductive alkylation.
The aldehyde-amine reaction forms an intermediate Schiff base, which is reduced by NaBH 3CN (Figure
2).29, 30
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Figure 2. Alkylating PEGylation adapted from Moosmann et al.30
Polysialylation is the coupling of polysialic acid to therapeutics. Unlike PEG polymers, polysialic
acid is a naturally occurring biodegradable polymer that is as effective as PEG but shows minimal toxicity.
The covalent attachment of this polymer to biopharmaceuticals is achieved through enzymatic conjugation
methods or synthetic steps via carboxylate groups, hydroxyl groups, or cleavage of the 1,2-diols at the nonreducing end.28 The 1,2 diols of polysialic acid can be cleaved by NaIO 4 to give an aldehyde functional
group at the position indicated by the arrow in Figure 3. The aldehyde group is then coupled to an amine
group of the peptide drug. Polysialylation has been effectively used in half-life elongation and immunogenic
reduction of insulin and asparaginase drugs.31, 32, 33
HESylation links the drug of interest to hydroxyethyl starch (HES) to increase solubility,
hydrodynamic volume, and prevent enzymatic degradation. HES is a biodegradable polymer, a modified
form of amylopectin, which may be used as a plasma volume expander (in place of albumin), since it is not
susceptible to hydrolysis by plasma amylases as is the case with other starches. 28, 34 Conjugation to other
molecules has been achieved using the enzyme, transglutaminase. 33 For site specific coupling, the acetal
group at the reducing end, indicated by the arrow in Figure 3, is used to couple to the peptide drug. Other
modifications include recombinant extension by the addition of a polypeptide sequence at the N- or Cterminus of a recombinant drug sequence.35 PASylation is an example of an extension method that uses
proline, alanine, and serine in the extended chain. Significance of some modifications are highlighted in
Table 2.
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Figure 3. Polysialic acid and hydroxyethyl starch structures with arrows indicating the potential site of
conjugation with peptide drugs.
In addition to polymers, several small organic molecules have been covalently bound to
therapeutics peptides. The modifications include N-terminal acetylation or alkylation, glycosylation,
phosphorylation, thiolation, and fatty acid conjugation.36 Replacement of L-amino acids with D-amino acids
has been successful in the case of vasopressin and desmopressin. Vasopressin is a naturally occurring
antidiuretic hormone (Cys1-Tyr2-Phe3-Gln4-Asn5-Cys6-Pro7-LArg8-Gly9-NH2), the analogue desmopressin
*SH2C-H2C-C1-Tyr2-Phe3-Gln4-Asn5-Cys6*-Pro7-DArg8-Gly9-NH2, is a non-peptide drug in which the
L-arginine at position 8 has been replaced with a D-arginine and the in cystine 1 is removed (a disulfide
bridge between the thiols is identified with asterisks).37,38 Conjugation of 2-(3-maleimidopropanamido)-6-(4(4-iodophenyl)butanamido) hexanoate (“Albu” tag, Figure 4) to an antibody fragment, scFv, reported by
Trussel et al., increased its serum-drug affinity, hence elongating the time in blood circulation.39
Hydrocarbon stapling is used to hold together the alpha helical structures in peptide drugs and prevent
unfolding upon exposure to harsh environmental conditions. 40 The amino acids within a helix structure are
coupled by a hydrocarbon linker to make the structure more rigid.
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Table 2. Effects of different structural modifications on drugs.36, 41

Method
Post translational modifications

Significance
Enhanced solubility

Cyclization, Phosphorylation,
N-alkylation, Thiolation
N- or C- terminus modification

Half-life elongation

PEG conjugation, methylation, formylation,

Increase functional diversity

acetylation, esterification

Enhanced solubility

Conjugation with fatty acids

Improved lipophilicity, metabolic stability, and

Reversible and irreversible lipidation

bioavailability

Hydrophobic ion pairing

Enhance permeation, increased bioavailability and
solubility

Complexation with cyclodextrin

Protection against degradation and suppression of
aggregation

Figure 4. “Albu” tag 2-(3-maleimidopropanamido)-6-(4-(4-iodophenyl)butanamido) hexanoate link to a
cysteine residue of an antibody fragment adapted from Trussel et al.39
No modification method is universally applicable to all drugs. Some modifications are cause
adverse side effects due to induced immunogenicity. Therefore, research is ongoing to define simple
modification methods that will enhance the drug’s pharmacokinetics and pharmacodynamics without
drawbacks.
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1.5 Recombinant protein expression
The recent advancement in recombinant DNA technology42 has lowered the production costs and
increased the annual sales of biopharmaceuticals. Biopharmaceuticals are therapeutic proteins and nuclei
acids produced using biotechnology.43 The market for biopharmaceuticals was valued at USD 176.9 billion
globally in 2015 and is estimated to reach USD 291 billion in 2021, with a compound annual growth rate of
8.6 %.44 Progressively, there has been a notable increase in the annual approval rates for biologics and
peptide drugs over small molecule drugs. Compared to small molecule drugs, biologics and peptides
typically have high target specificity, thus causing minimal side effects and low immunogenicity.
Additionally, their structural similarity to existing biological molecules shortens their FDA approval time,
which make them more attractive for production and marketing purposes. 45 The biological systems used in
the production of protein therapeutics depend on the recombinant protein size and the desired posttranslational modifications. These systems include bacteria, yeast, fungi, insects, mammals, and transgenic
animals and plants.46, 47
Recombinant DNA technology10 involves heterologous expression of proteins in non-native
systems.48 The cells are transfected with self-replicating DNA molecules encoding the protein of interest.
The cloned vector (cyclic DNA) allows expression of proteins in high yields for different studies. 49 Besides
expressing proteins from the human genome, proteins in other organisms such as fungi, bacteria, or viruses
have been expressed and investigated as disease-causing agents or having therapeutic effects.
Additionally, bacterial systems allow expression of isotopically labeled proteins that can be analyzed using
NMR spectroscopy.
Bacterial plasmids used for making recombinant DNA carry a specific antibiotic resistance gene for
selecting transformed cells. Gene fragments from a donor organism are inserted into these plasmids
(vectors) to form a recombinant DNA.49 Other vector systems used for gene transfer are vaccinia,
baculovirus, adenovirus, and retroviral vectors.50 Plasmids with specific cleavage sites are commercially
available. The DNA inserts are constructed to have the same cleavage sites as the plasmid, which allows
insertion of the gene of interest into the plasmid DNA sequence through double digestion (by restriction
enzymes) and ligation. The restriction enzymes cut specific DNA sequences in both the plasmid and the
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insert. Examples of commercially available restriction enzymes are XhoI, NcoI, EcorI, and NdeI. The sticky
ends (complementary bases) of the cut DNA are joined together by a ligase (cloning steps are illustrated in
Figure 5) to form a cyclic DNA that is incorporated into biological protein expression systems.
Before selecting an expression system, one must consider several factors such as yield, post
translational modification, solubility, cost, purification, toxicity, and function. 50 The biological systems used
in the production of protein depend on the recombinant protein size and the desired post-translational
modifications. These systems include bacteria, yeast, fungi, insects, mammals, transgenic animals, and
plants.46, 47 Bacterial systems (mainly Escherichia coli) dominate heterologous expression of recombinant
proteins. However, post translational modification required for certain protein sequences may not be
achieved in this system, thus limiting the nature of proteins that can be expressed.

Figure 5. Illustration of A) cloning steps and B) cleavage sites for some restriction enzymes.
Mammalians cells induce proper folding and glycosylation of eukaryotic proteins. Their major
application is in the production of therapeutic proteins, vaccines, and diagnostics. 50 Commonly used cell
lines are human embryonic kidney (HEK) and Chinese hamster ovary (CHO) cells. Many industrial enzymes
are produced in yeast or fungi.51 These systems produce high yields of recombinant proteins at low costs.
Yeast has been engineered to produce glycoproteins for human use by eliminating the production of high-
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mannose proteins (naturally produced by yeast), which induce immunogenicity and are easily degraded in
humans.51
Baculovirus-insect cell systems are also efficient in producing eukaryotic proteins. 52 Essential
glycosylation patterns such as the incorporation of terminal sialic acids in therapeutic glycoproteins have
been achieved using transgenic insect cells.53 The Sf9 transgenic insect cells used in production of terminal
sialylated N-glycans encode rat α2,6-sialyltransferase and bovine β1,4-galactosyltransferase.53 The use of
plant cell expression systems is slowly rising in the pharmaceutical industry. The advantages of using this
cell line are the notably high batch-to-batch reproducibility and the elimination of pathogen contamination
that can incur when mammalian cells are used.54
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CHAPTER 2
EXPRESSION AND NMR ANALYSIS OF CHLAMYDIA PROTEINS SCC1/SCC4
2.1 Protein NMR
Nuclear magnetic resonance occurs when nuclei are placed in a static magnetic field (B0), and a
second oscillating magnetic field (radio frequency pulse perpendicular to B 0)55 is applied to cause the nuclei
to transition between energy levels. A fundamental property known as spin generates nuclear magnetic
moments in some nuclei.56 A spin can be zero, positive, or negative and exist in multiples of ½. 57 Each
unpaired electron, neutron, or proton has spin ½. When placed in a magnetic field, the torque generated
causes the magnetic moment to rotate (precess) around the magnetic field at a characteristic frequency of
the nuclei known as the Larmor frequency.57 The Larmor frequencies of nuclei detected in protein NMR,
such as 1H,

15N, 13C,

and

31P,

differ because of an intrinsic property known as the gyromagnetic ratio,58

which defines the sensitivity of different nuclei to the external magnetic field. Protein NMR experiments are
used to determine protein structure and molecular dynamics by studying the interaction of nuclei. 58 When
the spin ½ nuclei are placed in a strong magnetic field, two energy states are generated. The lower energy
state spins (magnetic quantum number +½) align in the direction of the external magnetic field (B 0), while
the higher energy state spins (magnetic quantum number -½) align in the opposing direction of B0.59 The
energy gap, ΔE, between the two energy states is proportional to the strength of B0. Irradiation of the nuclei
with a radio frequency pulse (short, discrete energy equal to ΔE) causes the spins to align in one direction
(coherence) and transition between the energy states.60 Following excitation, two relaxation processes
occur: Longitudinal relaxation, which is the realignment of the bulk magnetization (net magnetic moment)
in the B0 direction, and transverse relaxation, which is caused by the loss of spin coherence.57 The loss of
coherence gradually causes reduction of the detected signal and is known as the free induction decay
(FID).61 The Fourier transform of the FID converts the signal from the time domain to the frequency domain.
This transformation gives information about the population of the nuclei, chemical environment of the nuclei,
and protein dynamics represented by the peak intensity, chemical shift, and linewidth in the frequency
spectrum, respectively.58 The chemical shifts are influenced by hydrogen bonding, the local electron cloud,
torsion angles, and the secondary structure of proteins.58
Four basic steps are taken during NMR data acquisition: Preparation, evolution, mixing, and
detection.62 Preparation is a relaxation time delay that recovers the longitudinal magnetization of spins. A
11

selective 90° radio frequency pulse directed to a specific nucleus (determined by the Larmor frequency)
creates a transverse bulk magnetization of spins, which are detected in 1D experiments.63 After pulsing the
nuclei with radio frequency energy, they can precess at their characteristic frequencies defined by their
chemical environment in a process known as evolution.59 The evolution time is regulated such that when
another pulse is induced, it can cause transfer of coherence from one nuclei to another (mixing period). 60
The transferred coherence is then detected in 2D experiments. 64 Unique pulse sequences have been
created for different experiments with examples shown in Figure 6.

Figure 6. Illustrative pulse sequences for A) 2D NMR B) 3D NMR experiments, and C) conventional
representation of 2D NMR pulse sequences.

The pathway used for coherence transfer determines the kind of correlation observed. This transfer
can occur along the covalent bond (through-bond) or between neighboring non-covalently attached nuclei
(through-space).65 Homonuclear through-bond or J-correlated spectroscopy includes COSY (correlation
spectroscopy),66 DQF-COSY (double quantum filtered COSY), and TOCSY (total correlation spectroscopy).
In COSY experiments, magnetization is transferred to the nuclei within a 3-bond distance, while TOCSY
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experiments allow successive transfer of magnetization throughout the amino acid spin system. The
TOCSY spectrum is useful for protein side-chain assignments. Homonuclear through-space spectroscopy
includes NOESY (nuclear Overhauser effect spectroscopy) and ROESY (rotating frame Overhauser effect
spectroscopy). NOESY experiments correlate protons using the dipolar interaction of spins.67 Correlation
of spins within a 5 Å distance can be observed. The NOESY signal intensity is inversely proportional to the
sixth power distance between the protons. This information is useful for the determination of protein tertiary
structure. Heteronuclear J-correlated spectroscopy includes HMQC (heteronuclear multiple quantum
coherence), HSQC (heteronuclear single quantum coherence), and refocus HSQC. These experiments
correlate different nuclei such as 13C-1H or 1H-15N and are used in the protein backbone assignments.
The pulse sequences for 3D NMR experiments are built from 2D NMR pulse sequences with an
additional coherence transfer step. The 3D experiments are done by insertion of another evolution-mixing
period before detection. Triple resonance experiments are used for protein backbone and side-chain
assignments, 3D structure determination, and ligand binding studies. The three nuclei observed are 1H,
13C,

and

15N.

A set of NMR data used for backbone and side chain assignment are selected from the

following experiments: N15-HSQC, C13-HSQC, HNCO, HCCH-TOCSY, CBCA(CO)NH, HNCACB,
HN(CO)CA, CCH-TOCSY, HNCA, HNCB, CB(CO)NH, HCCH-COSY, HN(CA)CO, HN(CO)CACB,
C(CO)NH, CCH-COSY, H(CCO)NH, HBHA(CO)NH, HA(CO)NH.68,69 Proteins that have less than 200
amino acid residues typically have sufficient signal for C nuclei and therefore CBCANH and CBCA(CO)NH
spectra are used for backbone assignment (Figure 7). In large proteins; however, the C

signal intensity is

low and HNCA/HN(CA)CO and HN(CO)CA/HNCO spectra are used (Figure 8).70
Protein-ligand interactions play a major role in signal transduction, as in the case of hormones,
antigen-receptor, transcription-translation processes, and disease development. The ability of NMR to
reveal these interactions at the atomic level is possible with experiments that monitor interactions by
exchange of saturation transfer, changes in diffusion constants, changes in chemical shifts, relaxation time
changes, and NOEs changes.71 Two methods are mainly used to monitor these interactions. The first
method monitors the chemical shift changes of the protein. The presence of a ligand causes environmental
changes around the interface amino acids of the protein, which in turn alters their chemical shifts. Other
amino acids further from the binding interface often do not experience any changes and their chemical-
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shifts are unchanged. However, in cases where the binding process induces global structural changes, the
chemical shift changes may occur in all signals, making it challenging to single out the changes at the
binding surface. The second experimental approach uses transfer NOEs between the ligand and protein.
This method gives information on the binding sites, conformation of ligands complexed with proteins,
binding kinetics, and protein-ligand complex structure in solution.71, 72

Figure 7. Backbone assignment using CBCANH and CBCA(CO)NH spectra.
It is possible to distinguish proton signals arising from different heavy atoms and their isotopes in
protein-protein or protein-ligand complexes. To distinguish proton signals of ligands from those of protein,
the protein is isotopically labeled with

13C/15N

(uniform or site specific). Intramolecular NOEs within the

ligand are observed using isotope-filtered experiments while those of protein are observed using isotopeedited 2D experiments.72 For intermolecular NOEs, one dimension of proton is isotope filtered while the
other dimension is isotope edited, Figure 9 shows a schematic representation of protons in a protein-ligand
system.
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Figure 8. Backbone assignment using HNCA/HN(CA)CO and HN(CO)CA/HNCO.
Saturation transfer difference NMR has been used to screen for ligands (with medium to fast
exchange rates), identify competing ligands, and determine the binding epitopes. Saturation transfer
experiments selectively saturate the protein signals. This saturation is achieved by identifying and
saturating protein resonance signals far from the ligand signal. The saturation will disseminate throughout
the protein through spin diffusion and transfer to the ligand at the binding surface.73 The signal intensity of
the ligand, when the protein is saturated (saturated spectrum, Figure 10), will be lower than when it is not
saturated (reference spectrum). The difference signal (difference spectrum) from the two conditions
corresponds to the signal of the ligand protons responsible for binding. The STD NMR is applicable for high
molecular weight complexes with a low molecular weight, medium-to-fast exchanging ligand. It has high
sensitivity and requires minimal amounts of ligand; it can be coupled with other NMR pulse sequences
giving rise to STD-HSQC, STD-HMQC, or STD-TOCSY.74
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Figure 9. Illustration of intermolecular and intramolecular coherence transfer on a ligand-protein system
adapted from Breeze et al.72

Figure 10. Schematic representation of signal observed in an STD experiment adapted from Yu et al.73
2.2 Chlamydia
Chlamydia is an intracellular bacterium that relies on the host cell for biosynthetic and metabolic
pathways. Chlamydiae consists of three main species; namely, Chlamydia trachomatis (CT), Chlamydia
pnemoniae, and Chlamydia psittaci.75 Chlamydia trachomatis is the major cause of bacterial sexually
transmitted infection worldwide. Untreated genital infections lead to proctitis, urethritis, and epididymitis in
men, and tubal factor infertility, ectopic pregnancy, salpingitis, cervicitis, and pelvic inflammatory disease
16

in women.76, 77 Ocular infection causes inclusion conjunctivitis and trachoma.78 Chlamydia pneumoniae and
Chlamydia psittaci cause pneumonitis and psittacosis, respectively. 79 Serotypes A, B, and C of CT are the
main causes of blindness, while serotype D-K cause both ocular and genital disease through sexual
transmission.79 The genetic manipulation of CT species has not been possible; hence, the underlying
mechanism of CT infection and replication is not well known.
The developmental cycle of CT is divided into the early stage (elementary body (EB) to reticulate
body (RB) differentiation), mid-stage (RB division and growth), and late stage (RB to EB differentiation). 80
When the RNA polymerase (RNAP) holoenzyme with the primary sigma factor, sigma 66 (σ 66), interacts
with the specific Chlamydia chaperon 4 (Scc4) in CT, the transcription process is inhibited.80 Scc4 regulates
transcription as a component of the RNAP holoenzyme, and the σ 66 RNAP holoenzyme is reported to
accumulate at the beginning of the RB to EB transition in the developmental cycle. 80 RNAP has four
subunits viz. α, α, β, and β’. The σ66 subunit has four regions. Scc4 binds to the flap of the β subunit in
RNAP and region four of σ66.81 The two subunits are essential for recognition of the specific -35 promoter
regions of genes for transcription initiation. T3S proteins such as the Chlamydia outer membrane protein N
(CopN) and specific Chlamydia chaperon 1 (Scc1) can interact with Scc4 and are hypothesized to hinder
or reverse its anti σ66 activity.
Chlamydia infect a variety of host species including arthropods, vertebrates, and amoeba.75 Typical
hosts for different species are listed in Table 3. The species affecting humans are mainly C. trachomatis,
C. pneumoniae, and C. psittaci. According to a 2012 report, there were 131 million new cases of CT
infection globally, which translated to 4.2% among women and 2.7% among men aged 15-49; the regional
prevalence was highest in the Americas and western pacific region. 82
The Centers for Disease Control and Prevention report for 2017 indicates that CT infection is the
most notifiable sexually transmitted disease in the United States. In 2016 alone, over 1.5 million cases were
reported, which corresponded to 497.3 cases per 100,000 population, an increase of 4.7% from the
previous year.83 Between the years 2000 and 2016 there was a continuous rise in the Chlamydia infection
rate. The infection was more prevalent in females than males. Both groups were highest at age 20-24 of
sexually active individuals.83
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Table 3. Chlamydia species and their respective hosts.75

Species

Typical host

C. muridarum

Mice, hamsters

C. suis

Swine

C. pneumoniae

Humans, horses, koalas

C. psittaci

Birds, poultry

C. abortus

Ruminants, swine

C. caviae

Guinea pigs

C. felis

Cats

C. pecorum

Ruminants, swine, koalas

Simple chlamydial infections can be treated by primary antibiotics, such as azythromicins and
tetracyclines. However, if the developmental cycle assumes the persistent stage, these drugs are
ineffective. Additionally, co-infection with other STIs such as gonorrhea can complicate the treatment
process.84 The β-lactam antibiotics used for the treatment of gonorrhea induces persistence in Chlamydia
infections. Therefore, successful treatment of co-infection can be achieved by broad spectrum antibiotics.84
Other chlamydial antibiotics that have been used include fluoroquinolone, rifampin, lincomycin
aminoglycosides, and trimethoprim.85, 86
Antimicrobial resistance by Chlamydia is attributed to a point mutation in the gyrA, foreign genomic
island Chlamydia chromosome, a mutation in the peptidyl transferase region of 23S rRNA genes, and
nucleotide substitution in the rpoB gene.86 Some studies have shown that natural immunity to CT infections
can be acquired with long term exposure.87 Lower prevalence was also observed in mice with increasing
age, indicating that individuals may acquire adaptive physiological processes to resist infection. 88 However,
since the immunity acquired is serovar specific, the individuals who are immune to one serotype are
susceptible to another. Therefore, there is a need to develop drugs to non-traditional antibiotic targets, such
as virulence, the T3SS, and the unique developmental cycle of CT or develop broad-spectrum vaccines.
Studies on different forms of vaccines have been conducted; these forms include the use of whole cell (live,
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live attenuated, or UV-inactivated) or subunit vaccines. The subunit vaccines utilize antigens such as major
outer membrane protein (MoMP), plasmid glycoprotein 3, chlamydial protease-like activity factor,
polymorphic membrane proteins, and multivalent vaccines.88
Chlamydia uses T3S apparatus to invade the host cell. The T3S injectisome serves as a channel
to transfer effector proteins from the bacterial cell to the host cell. Effectors interfere with the host cell
defense mechanism and facilitate endocytosis of the EB. The injectisome is made of multiple subunits of
about 20 proteins that create a pathway for direct injection of effector proteins to the host cell, bypassing
the extracellular matrix.89 The injectisome comprises ATPase, effectors, translocators, a needle-like protein
structure, and chaperons.90-92 The structural arrangement is represented in Figure 11. A broad spectrum of
diseases caused by T3SS-containing pathogens are outlined in Table 4.

Figure 11. Illustration of T3S apparatus spanning the bacterial membranes to the host membrane.
The commonly reported arrangement of T3S proteins in CT is illustrated in the model shown in
Figure 12. The protein CT559 spans the periplasmic region connecting the inner membrane (IM) to the
outer membrane (OM), while CT674 forms the outer membrane pore. The inner membrane proteins,
CT562, CT563, CT564, CT091 (Cds1), and CT090 (Cds2), form the base.93 The cytoplasmic protein,
CT669, is presumed to be the ATPase that energizes the system in association with CT561. The other two
proteins, CT576 and CT088 (Scc1), are chaperons.
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Chlamydial infection slows down the host cell cytokinesis through two mechanisms. The first
mechanism is the regulation of the G2/M transition by cleavage of the mitotic cyclin B1.94 The second
mechanism involves mitotic arrest effected by CopN, which binds directly to αβ-tubulin to hinder tubulin
polymerization to microtubules.90 Apart from modulating the host cell cycle, CopN functions as a plug for
the T3SS, inhibiting protein secretion until activated by an external signal. It has been shown that CopN
interacts with a class II chaperon Scc3 (specific Chlamydia protein 3) at its C-terminus and the class I
chaperons, Scc1/Scc4 (in a heterodimer complex), at the N-terminus in Chlamydia pneumoniae (CP).91
The three chaperons aid in the stabilization, secretion regulation, and translocation of CopN to the host cell.
The CP protein complex Scc1/Scc4/CopN/Scc3 may function to regulate the secretion of translocators and
effectors similarly to SycN/YscB/YopN/TyeA in Yersinia.92

Figure 12. A model of Chlamydia T3S apparatus, with Yersinia protein orthologs shown in parenthesis,
adapted from Fields et al.93
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Table 4. Disease causing pathogens that use a T3SS.7
Pathogen

Disease

Pseudomonas aeruginosa

Pneumonia, urinary tract infection, wound
infection, septicemia, and endocarditis

Chlamydia trachomatis

Trachoma and conjunctivitis

Chlamydia pneumonia

Pneumonia, atherosclerotic disease

Shigella, Salmonella, and Yersinia species

Intestinal disease, plaque

Salmonella serovar Typhi

Enteric fever

Bordetella

Whooping cough

Pseudomallei

Bacteremia and pneumonia

This study investigated the binding interface of the Scc1:Scc4 heterodimer complex using solution
NMR spectroscopy. The ultimate goals are to identify a therapeutic approach to interfere with this interface
and inhibit CopN translocation, which will prevent chlamydial invasion. Recombinant expression of Scc1
alone is challenging due to its insolubility. However, co-expression of Scc1 with Scc4 removes the challenge
by forming a soluble heterodimer complex.95 Four protein sequences were used in this study, named
Scc1His, HisScc4, Scc4, and HisScc4-22-end (amino acid sequence for Scc1His and HisScc4 provided in
Appendix A-1). The first three proteins contain the full-length sequence of Scc1 or Scc4; the last protein
has a shortened sequence of Scc4 beginning from amino acid number 22, which was expected to be a
highly soluble protein with well resolved peaks in solution NMR spectra. The hexa-histidine tag (His) added
to some protein sequences is used as a purification tag via Ni-affinity chromatography.
2.3 Cloning and protein expression
2.3.1 Materials
Cloned vectors, pACYC184-Scc1His, pET28-Scc4, and pCDF-HisScc4, were generously provided
by Dr. Li Shen (LSU Health Sciences Center, New Orleans, LA).95 pET28a vector was purchased from
Novagen (Merck Sigma). The DNA insert (Scc4-22-end gene block fragment), pET 3’ primer (CTA GTT
ATT GCT CAG CGG), and pET upstream primer (ATG CGT CCG GCG TAG A) were purchased from IDT.
The NcoI, XhoI, EcoR1, and T4 DNA ligase enzymes, NEB 10 Beta electrocompetent cells, BL21 (DE3)
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Gold E. coli cells, SOC, NEB buffer 3.1, NEB buffer 2.1, and T4 ligase buffer were purchased from New
England Biolabs (NEB). Polymerase chain reaction (PCR) purification kit and QIAprep spin miniprep kit
were purchased from Invitrogen. Luria-Bertani (LB) broth, sodium phosphate dibasic, glycerol, methanol,
glacial acetic acid, and 100X BME vitamin solution were purchased from VWR. Lennox LB agar was
purchased from BD Biosciences. Isopropyl β-D-1-thiogalactopyranoside (IPTG) was purchased from
Anatrace. Spectinomycin (Spec) and sodium azide were purchased from Alfa Aesar. Kanamycin (Kan),
hydrochloric acid, sodium hydroxide, acetonitrile, trifluoroacetic acid, iron (III) chloride, calcium chloride,
zinc sulfate, copper (II) sulfate, sodium selenite, dithiothreitol (DTT), β-mercaptoethanol (βME), nickel (II)
chloride, manganese sulfate, ammonium bicarbonate, chloramphenicol (Cam), EDTA-free SIGMAFAST
protease inhibitor tablets, tris (hydroxymethyl) aminomethane (Tris), sodium dodecyl sulfate (SDS),
thiamine, cobalt chloride, sodium molybdate, and imidazole were purchased from Sigma-Aldrich (Merck).
Sodium phosphate monobasic and glycine were purchased from Amresco. Nickel (II) chloride hexahydrate
and ammonium chloride were purchased from Acros. Mini-PROTEAN TGX precast gels (4-20%
Tris/glycine), 2x Laemmli sample buffer, Bio-gel® P4 gel, and Profinity IMAC uncharged resin were
purchased from Bio-Rad. EDTA-free Pierce protease inhibitor mini tablets, Coomassie Plus protein assay
reagent, bovine serum albumin standard (BSA), sodium chloride, boric acid, agarose, and EZ-Run Rec
protein ladder were purchased from Thermo Fisher Scientific. Benzonase nuclease (25-29 U/µL), sodium
lauroyl sarcosinate (sarkosyl), ethidium bromide, and BugBuster 10x protein extraction reagent were
purchased from Novagen (Millipore Sigma). Magnesium sulfate, molecular weight cut-off centrifugal filters,
and polyethersulfone membrane (0.025 µm) were purchased from EMD Millipore (Millipore Sigma). Sinapic
acid and Coomassie brilliant blue R 250 were purchased from Fluka. 13C-glucose (U-13C6, 99%), deuterium
oxide (D2O, D, 99.9%), and 15N-ammonium chloride (15NH4Cl, 15N, 99%) were purchased from Cambridge
Isotope

Laboratories.

4,4-Dimethyl-4-silapentane-1-sulfonic

acid

(DSS)

was

purchased

from

Millipore-Sigma. Phenylmethylsulphonyl fluoride (PMSF) was purchased from Calbio Chem.
All water was supplied by a Millipore Direct-Q3 ultrapure water system. Solid and liquid sterilization
was accomplished using an AMSCO autoclave. Colonies were grown in an Imperial III incubator (Labline
Instruments). Shigemi NMR tubes matched to D2O’s magnetic susceptibility were purchased from Shigemi.
Centrifugation was done on a Sorvall RC 6 centrifuge (Thermo Fisher Scientific). Protein purification was
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done on a Biologic DuoFlow 10 chromatography system from Bio-Rad. Other apparatuses included a
PowerWave XS2 microplate reader (BioTek), an Excella E24 incubator shaker (New Brunswick Scientific),
a PCR cabinet (ESCO Technologies), an orbital shaker (Forma Scientific), a VCX 130 sonicator (SONICS),
a compact UV lamp UVGL-25 (UVP), and a French pressure cell press (SLM Aminco). Lyophilization was
done using a FreeZone Plus 6 liters freeze dry system (Labconco). Electroporation was done with an
Eppendoff electroporator 2510. PCR was conducted using a Bio-Rad S1000 thermal cycler.
2.3.2 Cloning of pET28a-Scc4-22-end plasmid
The Scc4-22-end DNA was cloned into the pET28a (+) vector using NcoI and XhoI restriction
enzymes. EcoR1 restriction enzyme was utilized post ligation to linearize any empty pET28a vector. The
vector, pET28a (+), and the DNA insert, Scc4-22-end, were digested separately in the digestion buffer (5
µL NEB buffer 3.1, 1 µL NcoI, 1 µL XhoI, and 43 µL sterile water) at 37 ⁰C for 1 h. The enzymes were heat
inactivated at 80 ⁰C for 20 min. The digestion products were purified using the PCR purification kit, with B2
and B3 binding buffers for the insert and the vector, respectively.
The purified vector and insert (5 µL each, 1:1 molar ratio and 2:1 molar ratio) were ligated in the
ligation buffer (2 µL 10X T4 ligase buffer, 2 µL T4 DNA ligase, 11 µL sterile water) at room temperature for
1 h. The ligase was heat inactivated at 65 ⁰C for 20 min. Post ligation digestion was done by adding 0.2 µL
of EcoR1 enzyme and 5 µL of 10X NEB buffer 2.1 to the ligation mixture and incubating at 37 ⁰C for 2 h.
EcoR1 was heat inactivated at 65 ⁰C for 20 min. The mixtures were transferred to a polyethersulfone
membrane suspended in sterile water in a petri dish to desalt for 15 min.
The ligation mixtures were transformed into NEB 10 Beta electrocompetent cells following the
standard electroporation protocol. The transfected cells were cultured overnight on LB agar plates
(kanamycin, 50 µg/mL). Five colonies were selected and cultured in 10 mL of LB broth overnight. DNA was
purified from 5 mL of the starter culture using the standard protocol for the QIAprep spin miniprep kit (using
microcentrifugation). The purified DNA was analyzed by PCR amplification using the pET 3’ (CTA GTT ATT
GCT CAG CGG, Tm 53.7 ⁰C) and pET upstream (ATG CGT CCG GCG TAG A, Tm 60.8 ⁰C) primers, at an
annealing temperature of 45 ⁰C. The DNA sequence was confirmed by gene sequencing at LSU’s GeneLab.
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2.3.3 Expression and purification of HisScc4-22-end, Scc1His:Scc4, HisScc4, and untagged Scc4
proteins
The plasmids were individually transformed or co-transformed into BL21 (DE3) Gold E. coli
expression cells using the heat shock protocol.96 Single cell colonies of the transformed BL21 (DE3) Gold
E. coli cells were grown on LB agar plates. The antibiotics in the agar and culture media were kanamycin,
chloramphenicol, spectinomycin, and tetracycline. The respective concentrations of the antibiotics are listed
in Table 5.

A starter culture of each transformed cell line was prepared by inoculating 100 mL of LB medium
(containing the respective antibiotics) with cells from a single colony on the agar plate. The cells were
incubated overnight in the incubator shaker at 250 rpm and 37°C. For the expression of unlabeled proteins,
50 mL starter cultures were transferred to 1 L culture flasks containing 950 mL of LB broth and the
antibiotics. The cells were incubated in the shaker to an optical density (OD) of 0.6 at 37 °C, followed by
induction with 0.5 mM IPTG. The cells were incubated for another 3 h and harvested by centrifugation at
3000 x g for 30 min at 4°C. The isotopically labeled proteins were expressed in minimal media97 (Appendix
A-2) supplemented with

15NH

4Cl

and

13C-glucose.

Triple labeled proteins were expressed in deuterated

minimal media supplemented with 13C-glucose and 15NH4Cl. A 10 mL starter culture was used to inoculate
1 L of the minimal media. The cells were grown at 37 °C to 0.9 OD, and protein expression was induced
with 0.5 mM IPTG. The cell culture was incubated at 16 ˚C for 20 h.
Table 5. Concentrations of different antibiotics used in the cell culture media.
Plasmid

Protein

Antibiotic resistance

Concentration (µg/mL)

pET28a(+)-Scc4-22-end

HisScc4-22-end

Kanamycin

Kan, 50

pACYCScc1-His &

Scc1His &

Chloramphenicol

Cam, 35

pET28-Scc4

Scc4

Kanamycin

Kan, 50

pET28-Scc4

Untagged Scc4

Kanamycin

Kan, 50

pCDF-His-Scc4

HisScc4

Spectinomycin

Spec, 100

The cells were harvested by centrifugation at 3000 × g for 30 min at 4°C and re-suspended in 25
mL of the loading/wash buffer (20 mM Tris pH 8.0, 150 mM NaCl, 15 mM imidazole, and 5% glycerol)
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containing 1X BugBuster protein extraction reagent, one-half of an EDTA-free protease inhibitor tablet, 1
mg phenylmethylsulphonyl fluoride (PMSF), and 1.25 µL benzonase nuclease. Mechanical lysis was done
using a French pressure cell or sonication. The lysed cells were centrifuged at 20,000 x g for 30 min at 4°C
to obtain a cleared lysate. The hexahistidine (His) tagged proteins were purified using 4 mL of Ni-charged
Profinity IMAC resin (Ni-column) packed on a column with a flow adaptor attached to a BioLogic DuoFlow
FPLC. The cleared lysate was loaded into a Ni-column, the bound proteins were washed with 20 mL of
loading/wash buffer, and the purified protein was eluted with 10 mL of 20 mM Tris pH 8.0, 150 mM NaCl,
250 mM imidazole, and 5% glycerol (elution buffer). A similar FPLC set up was used during protein desalting
or to exchange the buffer, except that the column was packed with 15 mL Bio-gel P4 gel (P4-column). The
purified proteins were exchanged into 10 mM ammonium bicarbonate buffer (ABC buffer, pH ~8.0, pH not
adjusted) using the P4-column, lyophilized, and stored at -20 ˚C. All the buffers used in the purification
steps contained 0.02% NaN3 as a bacteriostat except for the ABC buffer.
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was performed to check
the purity of the protein. The SDS-PAGE running buffer (800 mL) was 25 mM Tris, 192 mM glycine, and
0.1% SDS. The sample buffer was prepared by adding 5% βME to 2x Laemmli buffer. Equal volumes of
sample buffer and protein solution were mixed and heated at 95 ˚C for 5 min. The denatured proteins were
loaded into 30 µL-wells in Mini-PROTEAN TGX precast gels, 4-20% Tris/glycine, and separated at 150 V
for 50 min. The protein bands were stained by placing the gel in Coomassie stain (0.25% w/v Coomassie
Blue G-250, 10% acetic acid, and 40% methanol in water) for 1 h and transferred to de-stain solution (10%
acetic acid and 25% methanol in water) for 1 h.
The Coomassie (Bradford) assay was used to quantify the purified proteins. Using a 96-well plate,
200 µL of Coomassie Plus protein assay reagent was added to each well (for both samples and standards).
Protein solution (2 µL-15 µL) was added to the sample wells and increasing volumes of 80 µg/mL BSA
solution (0, 10, 20, 30, and 40 mL) were transferred to separate wells. All volumes were adjusted to 250 µL
with water. The absorbance at 595 nm was recorded on a microplate reader, and the proteins were
quantified using a calculated BSA standard calibration curve.
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2.3.4 Isolation of 15N-Scc4 and 15N-Scc1His from 15N-Scc1His:15N-Scc4 complex
Cleared lysate of the co-expressed 15N-Scc1His:15N-Scc4 complex (25 mL) was loaded onto a Nicolumn at a flow rate of 1 mL/min. The unbound proteins were washed (20 mL of wash buffer), and the
complex was disrupted by elution of 15N-Scc4 with 0.5% sarkosyl in wash buffer (20 mL). The 15N-Scc1His
trapped in the column was eluted with 10 mL of elution buffer or used to form on-column mixed heterodimer
complex (discussed in the next section). The eluted

15N-Scc4

fractions were combined and diluted (3X)

with Tris buffer (20 mM Tris, 150 mM NaCl, 0.02% NaN 3 at pH 7.4) to lower the sarkosyl concentration to
less than the critical micelle concentration (0.4%). The diluted

15N-Scc4

protein was concentrated using a

10 kDa molecular weight cut-off centrifugal filter. The buffer was exchanged to 20 mM Tris, 150 mM NaCl,
0.02% NaN3 at pH 7.4 using a P4 column. The collected fractions were then passed through a freshly
equilibrated Ni-column to remove any residual
through (pure

15N-Scc4)

15N-Scc1His

that may have eluted with

The flow

was collected, and the buffer was exchanged to ABC buffer. The sample was

lyophilized and stored at -20 ˚C or analyzed by NMR. Alternatively, pure
purified

15N-Scc4.

15N-Scc1His:15N-Scc4

complex. After loading the purified

15N-Scc4

was isolated from the

15N-Scc1His:15N-Scc4

onto a Ni-column

(at a flow rate of 0.25 mL/min), the complex was disrupted, and the two proteins eluted following the same
protocol describe above.
2.3.5 On-column formation of complexes with chain-selective isotopic labeling
The 15N-labeled protein complex, 15N-Scc1His:15N-Scc4 (purified and desalted) was loaded onto a
Ni-column at a flow rate of 0.25 mL/min. The column was washed with 20 mL wash buffer, and

15N-Scc4

was eluted from the complex with 20 mL of 0.5% sarkosyl in wash buffer. Residual sarkosyl was removed
from the column using additional wash buffer (15 mL). The unlabeled Scc4-lysate was loaded onto the
column containing the trapped

15N-Scc1His

at a flow rate of 0.5 mL/min. The unbound proteins were

washed with 20 mL of wash buffer, and the newly formed mixed complex,

15N-Scc1His:Scc4,

was eluted

with 10 mL of elution buffer. Following a similar protocol, the mixed complex, Scc1His: 15N-Scc4, was
formed. In this case, Scc1His:Scc4 complex was not isotopically labeled, but Scc4-lysate was 15N-labeled.
The mixed complexes were also formed on-column starting with a cleared lysate of
complex, in place of the purified complex following the same procedure.
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15N-Scc1His:15N-Scc4

2.3.6 NMR analysis of the purified proteins
The lyophilized proteins were reconstituted in 250 µL of phosphate NMR buffer: 50 mM sodium
phosphate, pH 7.4, 0.02% NaN3, 50 µM DSS, 10% D2O. The proteins analyzed in Tris NMR buffer (20 mM
Tris, 150 mM NaCl, pH 7.4, 0.02% NaN3, 50 µM DSS, 10% D2O) are indicated in their respective spectra.
Dithiothreitol (DTT, 10 mM) was added to NMR samples containing 15N-Scc1His protein to prevent disulfide
bond formation. The Scc4 sequence does not have a cysteine, so there was no need to add DTT to the
Scc4 samples. The NMR analysis of

15N-Scc1His

alone was done in elution buffer, with 10 mM DTT, 50

µM DSS, and 10% D2O added, due to its insolubility in phosphate buffer.
The reconstituted proteins were transferred to Shigemi NMR tubes for NMR analysis. NMR data
were collected on a Bruker Avance III HD NMR spectrometer (500 MHz) and a Varian NMR spectrometer
(700 MHz) at the LSU NMR facility, and a Bruker Avance III (600 MHz) and a Bruker Avance III HD (900
MHz) at NMRFAM (University of Wisconsin). Some protein samples were shipped to NMRFAM for 3D NMR
analysis (in collaboration with Dr. Marco Tonelli). The recorded 3D NMR data included HNCA, HN(CO)CA,
HNCO, HN(CA)CB, and HN(CO)(CA)CB experiments. All the 3D NMR spectra were TROSY-based and
recorded at 25 °C on Bruker instruments equipped with cryogenic probes. The NMR data was acquired
using a non-uniform sampling (NUS) rate of 40% to 50%. The data were processed using NMRPipe and
the NUS data were reconstructed using SMILE (Bax group). 98 Detailed acquisition parameters for these
experiments are provided in the Appendix A-3.
2.3.7 Triple Resonance NMR experiments for backbone assignment
To identify the amino acids at the binding interface of the Scc1His:Scc4 complex, it is essential to
do the backbone assignment. Due to the low yield and multiple preparation steps in the formation of the
mixed complexes, it is more efficient to run 3D protein backbone experiments on the uniformly labeled
complexes rather than the mixed labeled complexes. To use this 3D data for backbone assignment, 1H15N-HSQC

NMR spectra of the mixed labeled complexes are required to identify the individual protein peaks

belonging to each protein. Once these peaks are identified, restricted peak picking in the 3D data sets can
be used to assign the 1H, 15N, and 13C nuclei in the backbone of each protein to the NMR peaks (illustrated
in Figure 13). The peaks in one spectrum can be selected with respect to peaks in another spectrum. It is
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therefore possible to pick peaks belonging to Scc4 in an 1H-15N-HSQC NMR spectrum of 15N-Scc1His:15NScc4 complex using the restricted peak picking tool in the NMR SPARKY software. 99
Triple resonance backbone assignment for Scc4 and Scc1His can be accomplished separately
using the same set of 2D and 3D NMR data for the

15N-Scc1His:15N-Scc4

complex. The pick peaking

procedure for Scc4 backbone assignment is as follows: The peaks in the 2D 1H-15N-HSQC spectrum of the
mixed complex, Scc1His:15N-Scc4, are picked, followed by restricted peak picking of Scc4 peaks in the 2D
1H-15N-HSQC

spectrum of

15N-Scc1His:15N-Scc4.

The peaks belonging to the Scc4 protein in the 3D

spectra, such as HNCA, HN(CO)CA, HNCO, HNCACB, and HN(CO)CACB, can be picked using restricted
peak picking with respect to the Scc4 peaks in the 2D 1H-15N-HSQC spectrum of the 15N-Scc1His:15N-Scc4
complex. Figure 14 is an illustration of how the same data set can be used to separately do backbone
assignment for Scc1His and Scc4.

Figure 13. Illustration on how to apply restricted peak picking on 1H-15N-HSQC spectra of the
15N-Scc1His:15N-Scc4 using mixed labeled samples. The peaks in one spectrum can be selected with
respect to peaks in another spectrum using the ‘kr’ command in SPARKY.
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Figure 14. An illustration of how to use the same data set to separately conduct backbone assignment for
each protein. The peaks in the 2D 1H-15N-HSQC spectrum of the mixed complex, Scc1His:15N-Scc4 or
15N-Scc1His:Scc4, are picked, followed by restricted peak picking of 15N-Scc4 or 15N-Scc1His peaks in the
2D 1H-15N-HSQC spectrum of 15N-Scc1His:15N-Scc4, respectively, and final peak picking in 3D spectra.
2.4 Results and discussion
2.4.1 Cloning of pET28a-Scc4-22-end plasmid
A shorter sequence of the Scc4 protein (12.3 kDa) was predicted to be a better candidate for NMR
studies compared to the full-length protein (14.7 kDa) due to its smaller size. The DNA sequence of the first
21 amino acids in the full-length protein is missing in the Scc4-22-end DNA construct. The Scc4-22-end
DNA was cloned into the pET28a plasmid by double digestion and ligation. To verify that the cloning was
successful, the purified plasmid was amplified using pET 3’ and pET upstream primers. The amplification
of the vector containing the Scc4-22-end DNA insert yields DNA strands of 565 bp, while the empty vectors
yield DNA strands of 326 bp as illustrated in the pDRAW32 (AcaClone Software) images in Figures 15 and
16. The PCR amplification products were analyzed by agarose gel electrophoresis shown in Figure 17. The
bands around 565 bp indicate that the cloning was successful (C5, C3, C2, C1 from the 2:1 ratio ligation
and C5, C3, C2, C1 from the 1:1 ratio ligation). The purified plasmid from colony 2 (C2, analyzed in lane 4
of the agarose gel image in Figure 17 was submitted for DNA sequencing (LSU Genelab) and was
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confirmed to be the correct sequence (Appendix A-4.1). The Scc4-22-end DNA sequence with the
NcoI-XhoI restriction sites is provided in Appendix A-4.2.

Figure 15. pDRAW images of the Scc4-22-end linear DNA and pET28-a (+) circular DNA indicating the
NcoI and XhoI restriction sites.

Figure 16. pDRAW32 primer analysis of the circular DNA of the A) empty and B) cloned vectors.
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Figure 17. Agarose gel image of the PCR products from the pET28a(+) ligation with Scc4-22-end. Two
ligation insert/vector ratios were used in the ligation reactions. Five colonies (C1, C2, C3, C4, C5) from cells
transformed with each ligation reaction mixture are shown with the 2:1 insert/vector ratio (left) and 1:1
insert/vector ratio (right).
The translation of the Scc4-22-end DNA sequence in the pET28a-Scc4-22-end plasmid is shown
below (HisScc4-22-end). The complete sequence of the Scc4 protein without the hexa-histidine tag is also
shown.

The

full

length

Scc4

sequence

includes

the

first

21

N-terminal

amino

acids,

MLEKLIKNFVAYMGVASELEF, omitted in HisScc4-22-end sequence, which begins from amino acid
number 22. After confirming the correct sequence, the purified plasmid from C2 was transformed into BL21
Gold (DE3) cells for Scc4-22-end protein expression.
MGSSHHHHHHSSDADGSYVFPISSLVRMRVRQNADEEIIISAFLGEIPASMDIEKAYARMMEGNLFGQET
GGAALGLDSDGHAVLVRRVPGEVSQEDFASYIESVLNYAEAWLEDLGLSKTEQE
Theoretical pI/Mw: 4.18 / 12259.65; 124 amino acids
Scc4 amino acid sequence:
MLEKLIKNFVAYMGVASELEFDADGSYVFPISSLVRMRVRQNADEEIIISAFLGEIPASMDIEKAYARMMEG
NLFGQETGGAALGLDSDGHAVLVRRVPGEVSQEDFASYIESVLNYAEAWLEDLGLSKTEQE
Theoretical pI/Mw: 4.25 / 14674.55; 133 amino acids
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2.4.2 Expression and purification of HisScc4-22-end, Scc1His:Scc4, HisScc4, and untagged Scc4
proteins
HisScc4-22-end was expressed in minimal media supplemented with 15NHCl4. The elution fraction
from Ni-IMAC purification of

15N-HisScc4-22-end

protein was analyzed by SDS-PAGE (lane-2 Figure 18).

Compared to the protein expressed in LB medium (lane-7), the band in lane-2 is faint and has almost the
same intensity as the non-specific Ni-binding protein (the band between the 43 kDa and 55 kDa protein
standards in lane-1) in the same lane. The yield was insufficient (about 0.5-1 mg per L culture) for 3D NMR
studies, which require a minimum of 2 mg. Optimization is possible, but efforts were diverted to determine
the best method for isolating full-length Scc4 (untagged) from the Scc1His:Scc4 protein complex.

Figure 18. SDS PAGE gel image of HisScc4-22-end protein expression in LB and minimal media. Lanes
2-4 are the analysis of minimal media expression and lanes 5-7 are the analysis of LB media expression.
Lane-2 is 15N-HisScc4-22-end elution, Lane-3 is the column wash, Lane-4 is the 15N-HisScc4-22-end-lysate
after flowing through the Ni-column, Lane-5 is the HisScc4-22-end-lysate after flowing through the Nicolumn, Lane-6 is the column wash, and Lane-7 is HisScc4-22-end elution.
Based on the preceding NMR experiments of 15N-HisScc4 protein performed by Octavia Goodwin,
it was determined that the histidine tag interfered with the stability of the protein. Expression of the full-length
15N-Scc4

protein without a histidine tag was achieved in our collaborator’s, Dr. Li Shen’s, laboratory;

however, it required multiple purification steps that lead to the loss of protein. Non-denaturing conditions
were established and used to isolate untagged Scc4 from the Scc1His:Scc4 protein complex.

15N-Scc1His

and 15N-Scc4 proteins were co-expressed together. Because of their tight binding, the proteins co-purify in
a 1:1 ratio using a Ni-column. The SDS-PAGE analysis of the purified
Figure 19A, shows the two bands corresponding to
isolate untagged

15N-Scc4

15N-Scc1His

15N-Scc1His:15N-Scc4

(18.8 kDa) and

15N-Scc4

protein, the complex was reloaded to the Ni-column, and
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complex,

(14.7 kDa). To

15N-Scc4

was eluted

with 0.5% sarkosyl in wash buffer. The remaining

15N-Scc1His

protein was eluted with elution buffer. The

two proteins were isolated with high purity as shown in the SDS-PAGE gel image, Figure 19B.

15N-Scc4

eluted with the non-specific, Ni-binding protein at around 72 kDa. After successful isolation of pure

15N-

Scc1His and 15N-Scc4 protein, the impact of sarkosyl on the structure of Scc4 was assessed.

Figure 19. SDS-PAGE analysis of the purified proteins; A) Co-purification of the 15N-Scc1His:15N-Scc4
complex; B) purification of 15N-Scc4 (lane-1) and 15N-Scc1His (lane-2); C) purification of 15N-HisScc4
(lane-3).
For NMR spectral comparison and assessment of sarkosyl’s effects on the Scc4 structure,
15N-HisScc4

protein was expressed and purified so its NMR spectrum could be compared to

15N-Scc4’s

spectrum. The SDS-PAGE analysis of purified 15N-HisScc4 (Figure 19C) shows a thick band corresponding
to

15N-HisScc4

(15.8 kDa) in lane-3. Since the

15N-HisScc4

purification steps do not require sarkosyl, the

NMR spectra of 15N-Scc4 and 15N-HisScc4 were used to compare the backbone structures of each protein
and show possible changes to 15N-Scc4 due to sarkosyl (discussed in Section 3.3.3).
Interface NMR experiments require chain selective isotopic labeling of the proteins in the complex.
Having established the conditions for isolating Scc1His and Scc4. The next step was to form mixedheterodimer complexes of Scc1His:Scc4; in which only one protein was isotopically labeled. Two protein
expressions, one in LB media and the other in labeled minimal media were performed to yield unlabeled
Scc1His:Scc4 and labeled

15N-Scc1His:15N-Scc4

protein complexes. Isolation of each protein in the

complex with 0.5% sarkosyl and the exchange of the proteins yield

15N-Scc1His:Scc4

and

Scc1His:15N-Scc4 mixed labeled complexes, respectively. The complex was favorably reconstituted using
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untagged Scc4 protein lysate that was separately expressed and loaded to Scc1His protein trapped in the
Ni-column. The SDS-PAGE analysis (Figure 20) indicates successful on-column formation of the mixed
heterodimer complex,

15N-Scc1His:Scc4.

The flow through (lane 1) is the lysate of the complex after

passing through the Ni-column to trap 1:1 bound

15N-Scc1His:15N-Scc4.

corresponds to the excess untagged-Scc4 not bound to

The thick band around 14.7 kDa

15N-Scc1His.

The lysate of the separately

expressed Scc4 is shown in lane 4 on the SDS-PAGE gel (Figure 20). After loading the Scc4 lysate onto
the Ni-column containing

15N-Scc1His,

Scc4 was successfully trapped, confirmed by the faded Scc4 band

in the flow through (lane 5), indicating the formation of the on-column mixed complex (lane 6, the eluted
complex).

Figure 20. SDS-PAGE analysis of the 15N-Scc1His:15N-Scc4 complex disruption and mixed label complex
formation (starting with the purified complex): Lane-1, the complex lysate flow through; Lane-2, the purified
complex 15N-Scc1His:15N-Scc4; Lane-3, 15N-Scc4 eluted from the complex with 0.5% sarkosyl; Lane-4
lysate of the separately expressed Scc4; Lane-5 is Scc4 flow though; Lane-6, on-column formed mixed
complex 15N-Scc1His:Scc4.
The mixed complexes were also formed without the initial purification of Scc1His:Scc4. In this
procedure, the lysate of the complex was loaded onto the Ni-column, the unbound proteins washed, and
Scc4 eluted with sarkosyl. The lysate of the separately expressed Scc4 was then loaded onto the column
containing the trapped Scc1His, which formed the mixed labeled complex that was then eluted. The SDSPAGE gel image (lane-4 and lane-9 Figure 21) depicts the newly formed mixed heterodimer complexes. It
is important to note that the Scc4 eluted with 0.5% sarkosyl was not always pure (lane-2 and lane-7 Figure
21); a faint Scc1His protein band and other E. coli proteins were observed. Therefore, careful washing is
necessary before elution of Scc4 to enhance its purity. The mixed complexes were analyzed by NMR to
validate the purification method.
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Figure 21. SDS PAGE analysis of the on-column mixed complex formation (starting with the lysate of the
complex); Lane-1 15N-Scc1His: 15N-Scc4 flow through, Lane-2 15N-Scc4 elution with sarkosyl, Lane-3 Scc4
lysate flow through, Lane-4 15N-Scc1His:Scc4 mixed complex elution; and Lane-6 Scc1His: Scc4 flow
through, Lane-7 Scc4 elution with sarkosyl, Lane-8 15N-Scc4 lysate flow through, Lane-9 Scc1His:15N-Scc4
mixed complex elution.
2.4.3 NMR analysis of the purified proteins
1H,15N-HSQC

spectra were recorded for the isotopically labeled proteins. Although the

15N-Scc1His:15N-Scc4

heterodimer complex is large (33.5 kDa), it tumbles as a single unit in solution due

to its strong binding. The spectrum displayed in Figure 22 was recorded in phosphate NMR buffer. Most
peaks are well dispersed except for a few clusters. The variation in the peak intensities may be attributed
to the presence of flexible regions in the protein structure, the presence of higher oligomeric states, or the
presence of the un-complexed protein. The 1H,15N-HSQC spectrum of

15N-Scc4

has well dispersed peaks

(Figure 23), indicating that the protein is properly folded and highly soluble in phosphate NMR buffer.

35

Figure 22. 1H,15N-HSQC spectrum of 0.75 mM 15N-Scc1His:15N-Scc4 recorded at 700 MHz (Varian).

Figure 23. 1H,15N-HSQC spectrum for 0.50 mM 15N-Scc4 recorded at 700 MHz (Varian).

36

To determine if the use of sarkosyl affected the structure of Scc4,

15N-HisScc4

protein was

expressed and purified (with no sarkosyl exposure) to compare its NMR spectrum with that of

15N-Scc4.

The overlaid spectra of 15N-HisScc4 and 15N-Scc4 (Figure 24) show ~70% peak overlap, indicating that the
use of sarkosyl in the isolation step did not change the backbone conformation of Scc4. The non-overlapped
peaks show small shifts and are likely the effect of the hexahistidine tag on 15N-HisScc4.

Figure 24. Overlay of the 1H,15N-HSQC spectra for 0.50 mM 15N-HisScc4 (black/green for positive/negative
signals, respectively) and 15N-Scc4 (red) recorded at 500 MHz (Bruker).
The spectra for the Scc1His:15N-Scc4 mixed complex and the untagged 15N-Scc4 were compared
to determine the extent to which Scc4 changes when bound to Scc1. The minimal peak overlap (42%)
observed in the Scc1His:15N-Scc4 and 15N-Scc4 spectra (Figure 25) implies that there is a conformational
change when Scc4 binds to Scc1His. This change may be in accordance with the dual functionality of Scc4.
The heterodimeric state is necessary for Scc4 to serve as a chaperon in the T3SS, while the homodimer
Scc4 may be necessary for Scc4 to function as a transcriptional regulator of σ66-mediated transcription.
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Since the Scc4 homodimer and heterodimer assume different structures, it is necessary to study the Scc4
heterodimer and Scc4 homodimer structures separately.

Figure 25. Overlay of the 1H,15N-HSQC spectra for Scc1His:15N-Scc4 (red) and 15N-Scc4 (black/green for
positive/negative signals, respectively) recorded at 700 MHz (Varian).
Due to the limited solubility of Scc1His, it was not possible to acquire a meaningful 1H,15N -HSQC
spectrum of 15N-Scc1His alone. The absence of many peaks for 15N-Scc1His in Figure 26 indicates that the
protein is oligomerized or insoluble. The peaks observed are from flexible regions, particularly the amidecontaining side chains. The NMR data was collected in the elution buffer because the protein precipitates
in phosphate NMR buffer. Except for the clustered side chain peaks in Figure 27, there is no peak overlap
between 15N-Scc1His (red) and 15N-Scc1His:15N-Scc4 (black) spectra.
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Figure 26.1H,15N-HSQC spectrum for 15N-Scc1His (in elution buffer, with 10 mM DTT, 50 µM DSS, and
10% D2O recorded at 700 MHz (Varian).

Figure 27. 1H,15N-HSQC overlay spectra of 15N-Scc1His (red, in 20 mM Tris pH 8.0, 150 mM NaCl, 250
mM imidazole, and 5% glycerol) and 15N-Scc1His:15N-Scc4 (black) recorded at 700 MHz (Varian).
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2.4.4 NMR analysis of complexes with chain-selective isotopic labeling
The successful formation of mixed heterodimer complexes was evaluated by comparing the 1H,15NHSQC spectra of Scc1His:15N-Scc4 (Figure 28) and

15N-Scc1His:Scc4

Scc1His:15N-Scc4 (Figure 22) complex spectrum. The spectrum of

(Figure 29) with that of the

15N-Scc1His:Scc4

15N-

(Figure 29) shows

many more peaks from Scc1His when it is in complex with Scc4 than the number of peaks observed in the
spectrum of

15N-Scc1His

alone (Figure 26), which reflects the enhanced solubility of Scc1His when

complexed with Scc4. Comparing the spectrum of 15N-Scc1His:Scc4 (Figure 29) with the spectrum of 15NScc1His:15N-Scc4 (Figure 22), there are additional peaks (colored red in Figure 29) that do not correspond
with either free

15N-Scc1His

(Figure 26) or free

15N-Scc4

(Figure 23). These peaks may originate from a

contaminating protein or peptide. In Figure 30, the spectrum of the complex ( 15N-Scc1His:15N-Scc4, black)
is overlapped with the spectra of the two on-column formed mixed complex proteins (Scc1His:15N-Scc4 and
15N-Scc1His:Scc4).

The overlap of the spectra of the three protein samples confirms that the heterodimer

complex and the mixed complexes have similar structural conformations. The spectra for the mixed labeled
samples were used to uniquely assign peaks corresponding to
15N-HSQC

15N-Scc1His

and

15N-Scc4

in the 2D

spectrum of the 15N-Scc1His:15N-Scc4 complex.

Figure 28. 1H,15N-HSQC spectrum for 0.20 mM Scc1His:15N-Scc4 recorded at 700 MHz (Varian). The
black/green peaks correspond to positive/negative signals, respectively.
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Figure 29. 1H,15N-HSQC spectrum for 0.2 mM 15N-Scc1His:Scc4 recorded at 900 MHz (Bruker). The red
colored peaks indicate peaks not observed in the 15N-Scc1His:15N-Scc4 spectrum. The black/green peaks
correspond to positive/negative signals, respectively.

Figure 30. 1H,15N-HSQC spectra for 15N-Scc1His:15N-Scc4 (black/green for positive/negative peaks,
respectively) and Scc1His:15N-Scc4 (cyan) in phosphate buffer recorded at 700 MHz (Varian), and 15NScc1His:Scc4 (red) in Tris NMR buffer recorded at 900 MHz (Bruker). Tris buffer was used to prevent the
precipitation of Scc1His, which was thought to have led to the release of 15N-Scc4 (Scc1His is slightly
soluble in Tris buffer).
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It is expected that the on-column formed mixed complexes have a 1:1 ratio of Scc1His and Scc4
proteins. Early samples, such as those in Figure 30, only showed a few extra peaks in the 15N-Scc1His:Scc4
sample.

However, free

15N-Scc4

peaks were observed in

1H,15N-HSQC

spectrum of recent

Scc1His:15N-Scc4 samples analyzed at NMRFAM. (Figure 34). To check the purity of the mixed complex
samples (after elution from the Ni-column), Scc1His:15N-Scc4 and 15N-Scc1His:Scc4 elution fractions were
separately loaded onto a size exclusion chromatography column (SEC 3-70), which separate proteins
based on their molecular weights. The impurity present in the mixed complex samples is free 15N-Scc4 (not
bound to Scc1His). Scc1His:Scc4 (33.5 kDa, heterodimer) and Scc4 (29.4 kDa, homodimer) have different
elution volume/time from the SEC column because of their different molecular sizes. For comparison, the
complex,

15N-Scc1His:15N-Scc4,

peaks for the

was also purified by SEC. The chromatograms (Figure 32) show two

15N-Scc1His:15N-Scc4

complex and three peaks for each of the on-column formed mixed

complexes. The SDS-PAGE analysis of the fractions obtained from the SEC column for a mixed complex
sample (Figure 33), indicates that peak 1 is the higher oligomeric form of the complex (which eluted with
some impurities), peak 2 is the heterodimer Scc1His:15N-Scc4 mixed complex, and the additional peak
(peak 3 not observed in the 15N-Scc1His:15N-Scc4 complex) is free 15N-Scc4. This confirmed that the extra
peaks (red peaks Figure 31) observed in the Scc1His:15N-Scc4 NMR spectrum belonged to

15N-Scc4

homodimer. Tris buffer was used to prevent the precipitation of Scc1His, which was thought to have led to
the release of

15N-Scc4

(Scc1His is slightly soluble in Tris buffer); however, extra

15N-Scc4

peaks are still

visible. Additional purification by SEC is required for the mixed complexes after the initial Ni-column
purification.
To further confirm that the extra peaks in Scc1His:15N-Scc4 sample were for free
NMR spectra of

15N-Scc1His:15N-Scc4

(black), Scc1His:15N-Scc4 (red), and

15N-Scc4

15N-Scc4,

the

(lime green) were

overlaid. Figure 34 shows the two forms of Scc4 in the Scc1His: 15N-Scc4 sample. The homodimer Scc4
(not in complex) is shown by the red intense peaks overlapped by the lime green peaks, and the
heterodimer form (in complex with Scc1His) is shown by the red less intense peaks overlapping the black
peaks.
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The presence of Scc4 homodimer in the eluted Scc1His:15N-Scc4 mixed complex was unexpected.
The binding ratio of Scc1His and Scc4 is 1:1, and it is unusual for Scc1His to trap excess Scc4 from the
lysate during the formation of the mixed complex. There is a possibility that the on-column complex is
Scc1His:Scc4 mixed complex secondarily bound to Scc4 homodimer. The secondary binding may fail
during centrifugation or when the sample buffer is changed leading to the presence of free Scc4 in solution.
A second possibility is non-specific binding of Scc4 to the Ni-column, which elutes together with the mixed
complex. The third possibility is that some Scc1His dissociates from the complex and precipitates leaving
free Scc4, which is soluble and visible in both NMR and SEC.

Figure 31. 1H,15N-HSQC spectrum of 0.2 mM Scc1His:15N-Scc4 (black/green for positive/negative peaks,
respectively) in Tris buffer (20 mM Tris, 150 mM NaCl, 0.02% NaN 3 pH 7.4) recorded on 800 MHz NMR
spectrometer (Agilent). The extra peaks colored red are for the free Scc4.
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Figure 32. Size exclusion chromatograms for the 15N-Scc1His:15N-Scc4 complex and the on-column
formed complexes (Scc1His:15N-Scc4 and 15N-Scc1His: Scc4) in 50 mM phosphate buffer, pH 7.4.

Figure 33. SEC chromatogram of the on-column mixed labeled complex, Scc1His:15N-Scc4 (after isolating
the crystalline portion), and the SDS-PAGE analysis of the SEC fractions.
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Figure 34. 1H,15N-HSQC HSQC overlay spectra of
and 15N-Scc4 (green).

15N-Scc1His:15N-Scc4

(black), Scc1His:15N-Scc4 (red),

After eluting the on-column mixed complex samples from the Ni-column, the fractions are combined
and concentrated using molecular weight cut-off centrifugal filters. During centrifugation, tiny crystals were
observed in the residual sample. The crystalline portion was separated and analyzed by SDS-PAGE. The
gel image, lane-4 Figure 33, indicates that the crystals contain the Scc1His:Scc4 complex. These crystals
will be tested for diffraction in collaboration with Dr. Marcia Newcomer, Department of Biological Sciences,
LSU.
Before carrying out protein backbone NMR experiments, it was necessary to check the 13C signal
intensity in the protein samples. Due to the size of the Scc1His:Scc4 complex (about 33 kDa), the double
labeled

15N,13C-Scc1His:15N,13C-Scc4

did not give strong signals for Cβ (green peaks) nuclei in the 2D

HNCACB spectrum, shown in Figure 35A. However, there was a relatively good signal for Cα (red peaks)
nuclei in the HNCA 2D spectrum (Figure 35B). It was determined that a deuterium-labeled complex was
necessary to enhance the
36A) has a weak

13C

13C

signal (Figure 36). The spectrum for the double labeled complex (Figure

signal compared to the triple labeled complex (Figure 36B). Large proteins with slow
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tumbling rates have short transverse relaxation times (T2), which produces broad signals with low intensity.
Deuteration of proteins minimizes cross-relaxation, leading to increased 13C signal compared to protonated
proteins.

Figure.35. 1H,13C-HSQC spectra for comparison of the 13C signal intensity in A) 2D HNCACB and B) 2D
HNCA spectra of the double labeled 15N,13C-Scc1His:15N,13C-Scc4 protein complex.
The 1H,15N-HSQC spectrum for the triple labeled protein sample was not well resolved; however,
the 2D 1H,15N HNCA spectrum (Figure 37) was used in place of the 1H,15N-HSQC spectrum for automated
backbone assignment. The selected peaks (overlaid with black spots) in the 2D 1H-15N HNCA spectrum
belong to Scc4 in the complex, identified through restricted peak picking with respect to the 1H,15N-HSQC
spectrum of Scc1His:15N-Scc4. Restricted peak picking on 3D spectra with respect to the Scc4 peaks in 2D
1H,15N

HNCA spectrum (Figure 37) was preformed using the automated PINE 68 sparky assignment (PINE-

SPARKY2) software to give the 1H,15N-HSQC plot in Figure 38. The assignments may not be accurate
because a small data set (2D 1H,15N-HNCA, HNCA, HN(CO)CA, HNCO spectra) was used. More 3D data
is needed to improve the assignments, and assignments will be check manually. The backbone assignment
output (Figure 38) corresponds to the Scc4 peaks selected in the 2D 1H,15N-HNCA spectrum. A similar
procedure can be followed to conduct backbone assignments for Scc1His.
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Figure 36. 1H,13C-HSQC spectra for comparison of 13C signal intensity in the 2D HNCACB spectra of the
(A) double labelled (15N,13C) and (B) triple labelled (2H,15N,13C) Scc1His:Scc4 protein complex
2.5 Conclusion
A method to express and isolate Scc4 from the Scc1His:Scc4 complex has been developed. An
on-column protocol for the formation of the mixed labeled protein complexes has been presented. Twodimensional NMR spectra for Scc4, HisScc4, Scc1His:Scc4, and the mixed labeled complexes have given
structural insights on the proteins. The structure for Scc4 in the heterodimer complex with Scc1His differs
from the homodimer Scc4. Sarkosyl does not change the backbone structure of Scc4, and there is a slight
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change in Scc4’s structure when a hexahistidine tag is present at the N-terminus of the protein. The oncolumn mixed complexes have the same structure as the in vivo formed complex. The 2D 1H,15N-HSQC
spectra of the mixed labeled samples were used to identify peaks for each protein in the 2D 1H,15N-HSQC
of the

15N-Scc1His:15N-Scc4

complex, where both proteins were labeled. These initial assignments will

make triple resonance backbone assignments feasible.

Figure 37. 2D HNCA spectrum for deuterated 15N,13C-Scc1His:15N,13C-Scc4 recorded on a 900 MHz
spectrometer (Bruker). The selected peaks are for Scc4 identified through restricted peak picking with
respect to 1H,15N-HSQC spectrum of the Scc1His:15N-Scc4 mixed complex.
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Figure 38. Illustration of how restricted peak picking can be applied to Scc1His:Scc4 using the 1H,15NHSQC spectrum to assign peaks belonging to Scc4 alone. Featured is the I-PINE HSQC plot for sparky
automated assignment using 2D 1H,15N-HNCA, HNCA, HN(CO)CA, HNCO spectra for 15N,13CScc1His:15N,13C-Scc4 (the assignments may not be accurate, as more data and manual verification are
needed).
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CHAPTER 3
STRUCTURAL MODIFICATION OF THE TRIPEPTIDE KPV BY REDUCTIVE GLYCOALKYLATION
3.1 Alpha Melanocyte Stimulating hormone (α-MSH 1-13) and the KPV (α-MSH 11-13) tripeptide motif
Short linear peptide motifs of less than 10 amino acid residues have the ability to modulate
biological processes such as localization of proteins, post-translational modification, and ligand-receptor
interactions.100 These peptide motifs form the basis for small molecule peptidomimetic drugs. The smallest
peptide motifs reported to have biological activities have three contiguous amino acids, a minimum of 25
heavy atoms.101 Ung et al. have reviewed endogenous tripeptides and tripeptide motifs embedded in large
protein sequences,11 with varying biological activities summarized in Table 6. The activities reported for
these tripeptides, indicate that a complete protein sequence may not be necessary for some signaling or
regulatory activities to occur. The tripeptide KPV which was selected for this study, is derived from the
C-terminal amino acids of alpha melanocyte stimulating hormone (α-MSH), whose sequence is contained
in proopiomelanocortin hormone. 12
Table 6. Endogenous tripeptides and tripeptide motifs.11

________________
Portions of this chapter previously appeared in PLOS ONE, Songok, et al. PLoS ONE 2018, 13, e0199686.
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Proopiomelanocortin hormone is composed of 267 amino acids. 102 Proopiomelanocortin (POMC)
derived peptides are produced in a number of peripheral tissues including reproductive organs, anterior
and intermittent lobes of the pituitary, arcuate nucleus of the hypothalamus neurons, and neurons in the
commissural nucleus of the solitary tract.103 The genes for pomc consist of 2 introns and 3 exons. Exon 2
and 3 encode POMC which is processed to hormonal peptides including adrenocorticotropic releasing
hormone (ACTH), β-lipotropin (β-LPH), melanocyte stimulating hormone (MSH), and β-endorphin (β-EP).
These peptides influence various physiological processes including food uptake, pigmentation, stress
response, glucose balance, behavior, and energy homeostasis.104
Proopiomelanocortin preprotein undergoes multiple types of post translational processing such as
glycosylation and cleavage by the enzymes prohormone convertase 1, 2, or 3 (PC1,PC2, and PC3) to give
α-, β-, and γ-MSH functional peptides.104 Alpha melanocyte stimulating hormone was first discovered as a
pigment-inducing peptide.12 Subsequent studies revealed multiple functions of this hormone including antiinflammatory and antimicrobial effects.105, 106 Cleavage of POMC by PC1 to ACTH followed by cleavage of
ACTH by PC2/7B2 (cofactor) leads to the formation of α-MSH. Further processing of α-MSH through Cterminal amidation and N-terminal acetylation is needed for full activity. Alpha-MSH production from POMC
and the terminal acetylated/amidated sequence is shown in Figure 39.

Figure 39. C-terminal amidated and N-terminal acetylated α-MSH.
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Melanocortin peptides signal through the seven transmembrane domain G-protein-coupled
receptors (GPCRs); classified into five subtypes commonly referred to as melanocortin receptor 1 through
5 (MC1R, MC2R, MC3R, MC4R, and MC5R).107 Melanocortin receptors are expressed in different cell types
of the central nervous system or peripheral tissues. Stimulation of these receptors accomplish different
functions depending on the cell types as indicated in Figure 40.
The core sequence His-Phe-Arg-Trp (HFRW) present in α-, β-, γ-MSH, and ACTH stimulates the
MCRs for signal transduction through different signaling pathways shown in Figure 40. Melanocortin
receptors are unique in that they have both endogenous agonist and endogenous antagonists. Agouti
signaling protein (ASIP) and Agouti related protein (AgRP) are the two endogenous antagonists of MC1R,
MC3R, and MC4R. Agouti signaling protein is expressed at the hair follicle and it inhibits the stimulation of
MC1R by α-MSH at the surface of melanocytes leading to a shift of pigmentation color from eumelanin
(black/brown) to phaeomelanin (red/yellow).108-110 Agouti signaling protein has high affinity for MC1R and
therefore inhibits adenylyl cyclase stimulation which in turn prevent the synthesis of eumelanin. AgRP, on
the other hand, binds to MC3R and MC4R for metabolism and body weight regulation. 111
3.2 Anti-inflammatory and antimicrobial activity of α-MSH
Alpha melanocyte stimulating hormone inhibits the NFκB inflammatory pathway. 105 Nuclear factor
kappa B is a heterodimer complex of the Rel family of proteins (p65, cRel, RelB, p50, and p52) that binds
to the DNA sequence, κB.112 The heterodimer p65/p50 is activated in the canonical pathway, shown in
Figure 41 and translocate to the nucleus leading to expression of molecules such as cell adhesion
molecules, cytokines, and acute phase response proteins.112 Inflammatory agents such as TNF-α, LPS,
IL1, or CD40L activate this pathway through their respective receptors. The inflammation signal leads to
phosphorylation of inhibitor kB-α (IkB-α) in the inactive cytoplasmic complex IkBα/ p65/p50 by IkB-α kinase
(IKKα); followed by ubitiquination and degradation.105 This process exposes the nuclear translocation signal
in p65 leading to the translocation of the heterodimer complex to the nucleus and the onset of the
transcription process.
In addition to the pigmentary effects, α-MSH has anti-inflammatory activity. It signals through the
seven-transmembrane G-protein coupled receptors MC1R, MC3R-MC5R. Upon binding to the MC1R,
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adenylyl cyclase is activated leading to amplification of cytoplasmic cyclic adenosine monophosphate
(cAMP). The cAMP activates protein kinase A (PKA) which leads to upregulation of cAMP responsive
binding element (CREB) and microphthalmia (MITF). In melanocytes, this process leads to increased
production of the enzyme tyrosinase which initiates melanogenesis by oxygenation of the amino acid
tyrosine to produce dopaquinone.110

Figure 40. Distribution and function of melanocortin receptors. 20, 108 Mitogen activated protein kinase
(MAPK), Protein kinase A (PKA), ionositol phosphate (IP), cyclic AMP (cAMP), and Janus kinase/signal
transducers and activators of transcription (Jak/STAT).
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Figure 41. Canonical NFκB activation pathway
Increased concentration of cAMP leads to different responses in different cells. In the inflamed
cells, α-MSH inhibits the expression of proinflammatory cytokines, through induction of cAMP. 105 Increased
cAMP prevents phosphorylation of inhibitor kappa B alpha (IkB-α) in the IkBα/ p65/p50 complex by IkBα
kinase (IKK).20 The downstream process involves the inhibition of the transcription regulator nuclear factor
kappa B (NFκB, aka p65/p50 complex) from translocating to the nucleus; hence preventing the expression
on NFκB target genes with respect to the inflammatory agents. α-MSH down regulates the production of
interleukin-8 (IL-8), nitric oxide, interferon-γ (IFN-γ), interleukin-1β (IL-1β), monocyte chemoattractant
protein 1 (MCP-1), tumor necrosis factor α (TNF-α), and limits the inflammatory cells trafficking into sites of
injury.113
Several immunomodulatory peptides such as neuropeptide Y, neurokinin 1, and proenkephalin A
have been shown to additionally have antimicrobial properties (AMPs). 20 On the other hand, AMPs including
human cathelicidin LL-37 and human β defensin 2 (HBD2) exhibit immunomodulatory properties.114 Besides
its antipyretic and anti-inflammatory properties, α-MSH has potent antimicrobial activity, depicted by the αhelical structure, cationic nature, and occurrence in defense cells (keratinocytes, melanocytes, and
fibroblasts). The occurrence of α-MSH and its receptor in both defense cells and immune cells (monocytes,
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neutrophils, and macrophages)106 supports the dual functionality as an immunomodulatory and
antimicrobial peptide. Alpha MSH is known to have a broad spectrum of antimicrobial activity against
Escherichia coli (E. coli), Staphylococcus aureus (S. aureus), and Candida albicans (C. albicans).11, 115
Madhuri et al. identified membrane permeation as the mechanism by which α-MSH exerts its
antimicrobial activity against S. aureus, which paralleled cell permeation by gramicidin.106 On the other
hand, Cutuli et al. demonstrated that the killing of C. albicans by α-MSH is mediated through induction of
cAMP, comparable to forskolin,116 which confirmed an earlier report that cAMP enhancement inhibits
protein and mRNA synthesis in C. albicans.117 Adenylyl cyclase inhibitor dideoxyadenosine attenuated the
candicidal activity of α-MSH.
The antimicrobial activity of α-MSH 1-13 lies in the C-terminal tripeptide KPV (α-MSH 11-13), which
has been shown to have similar potency to full length α-MSH (1-13).116 Since KPV lacks the pigmentary
effect induced by α-MSH,118 it is the preferred candidate for antimicrobial and anti-inflammatory drug
development. A novel structural modification of therapeutic peptides by reductive “glycoalkylation” was
devised in this study and applied to the tripeptide Ac-KPV-NH2. The tripeptide was synthesized in solution
and a D-glucose derived aldehyde used to modify the lysine residue at the α- and ε-amine. The modification
is expected to stabilize the tripeptide against enzymatic degradation and to enhance solubility.
3.3 Introduction to “glycoalkylation” and aminocyclization reactions
The term “glycoalkylation” has been used to imply the modification of lysine with a generic sugar,
Figure 42A. It was earlier used by Schlimme et al. when describing the N-glycosylation of mono- and bicyclic
dicarbonic acid imides using ribose.119 Lysine was glycoalkylated at Nε through a ring opening reaction with
N-ribosylated maleimide, to afford compound 1 (Figure 42B). The term “glycoalkylation” is redefined here
to mean the capping of Nα or Nε amine groups of lysine in H-KPV-NH2 with a piperidine diol derived from
D-glucose, viz. compound 2 (Figure 42C). This modification is expected to enhance the pharmacokinetic
properties of peptide drugs by conferring stability towards proteolytic and enhancing solubility in
physiologically relevant solvents.

55

Figure 42. (A) Modification of lysine at the ε-amine with a generic sugar molecule. (B) Glycoalkylated
lysine, as described by Schlimme et al. (C) Glycoalkylated Ts-Lys-OMe, as described herein.
Aminocyclization is the formation of a heterocyclic ring wherein an amine serves as a nucleophile.
Roy et al. utilized this approach to synthesize 10-membered macrocycle 4 (Scheme 1) containing a
conformationally constrained hydroxyethylamine (HEA) derived from D-glucose.120 Hydrolysis of the acetal
in compound 5 and aminocyclization led to the seven-membered ring iminosugar 6.121 Iminosugars such
nojirimycin and 1-deoxynojirimycin are known inhibitors of glycosyl transferases and glycosidases. 121 6Amino-1-dideoxynojirimycin (8) was synthesized in an analogous fashion by Begoña et al. from D-glucose
derivative 7.122 Trihydroxyazepane 10, a glycosidase inhibitor, was synthesized from a D-glucose derivative
9 by Dhavale et al. Hydrolysis of the acetal in 9 and hydrogenolysis of the Cbz group led to the formation
of the 7-membered trihydroxyazepane 10.123
3.4. Retrosynthetic analysis of glycoalkylation reaction
“Glycoalkylation” of lysine can be accomplished following reductive alkylations similar to those
discussed above. With the ultimate goal of modifying lysine residues in therapeutic peptides, a lysine
derivative Ts-Lys-OMe (13, Scheme 2) was chosen as a model system for glycoalkylation. The N- and Cprotecting groups were to mimic the lysine residue in a peptide chain. The retrosynthetic analysis of a model
system, viz. single lysine residue, is shown in Scheme 2. The aldehyde 12, derived from commercially
available 11, was envisaged to couple to the lysine derivative 13 via intermolecular reductive alkylation.
Acid hydrolysis of the acetal functionality in the initially-formed adduct is expected to yield 14, in equilibrium
with the imine arising from condensation of the aldehyde and the secondary amine. Reduction of the imine
by cyanoborohydride will afford compound 2.
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Scheme 1. Synthesis of cyclic amines derived from D-glucose

Scheme 2. Retrosynthetic analysis of lysine glycoalkylation with the D-glucose derived aldehyde 12
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3.5 Materials and Methods
The reagents were obtained from commercial sources and used without further purification except
for methanol (MeOH), triethylamine (Et3N), piperidine, collidine, and toluene which were distilled after
overnight stirring in CaH2 with exception of MeOH which was stirred overnight with magnesium turnings.
Dry tetrahydrofuran (THF) was obtained from a solvent purification system. Deuterated solvents were
purchased from Cambridge Isotope Laboratories. Deuterated methanol (CD3OD), methanol (MeOH), ethyl
acetate (EtOAc), dichloromethane (CH2Cl2), dimethylformamide (DMF), anhydrous magnesium sulfate
(MgSO4), and hexanes were purchased from EMD Millipore. TLC silica gel 60G F 254 glass plates were
purchase from Millipore. Tetramethylsilane (TMS), triethylamine (Et 3N), diisopropyethylamine (iPr2NEt),
2,4,6-trimethylpyridine (collidine), piperidine, acetic anhydride (Ac 2O), pyridine, imidazole, petroleum ether,
sulfuric acid (H2SO4), 4 Å molecular sieves, acetonitrile, sodium periodate (NaIO4) were purchased from
Sigma Aldrich. N,N'-Dicyclohexylcarbodiimide (DCC) was purchased from Aldrich. Silica and Nα-p-TosylL-lysine methyl ester hydrochloride were purchased from Sigma. Sodium borohydride (NaBH4), NHydroxysuccinimide (NHS), L-proline, sodium cyanoborohydride (NaBH3CN), sodium hydride (NaH),
iodomethane (MeI), and tri-n-butyltinhydride (Bu3SnH) were purchased from Acros Chemicals. Hydrochloric
acid and sodium bicarbonate (NaHCO3) were purchased from Anachemia. Trifluoroacetic acid (TFA),
Fmoc-Lys(Boc)-OH,

Boc-Lys(Fmoc)-OH,

and

1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-

b]pyridinium 3-oxid hexafluorophosphate (HATU) were purchased from Chem-impex Int’l Inc. Toluene,
tetrahydrofuran (THF), valine amide hydrochloride, 1,2:5,6-di-O-isopropylidene-α-D-glucofuranose, glacial
acetic acid, and ethanol were purchased from VWR. Carbon disulfide (CS 2) was purchased from Fisher
Chemical and D-proline purchased from Alfa Aesar. 1H and

13C

NMR spectra were recorded on a Bruker

AVIII-400-Nanobay spectrometer, AV500-Prodigy or Bruker AVIII-400-3. Chemical shifts are expressed in
ppm downfield of TMS, in deuterated solvents as specified. Optical rotations were measured on a JASCODIP-370 polarimeter. HRMS was carried out using an ESI TOF 6210 (Electrospray Time-of-Flight) mass
spectrometer (Agilent Technologies). HPLC (Agilent technologies) purification was performed on a Sorbent
Purity C18 300Å 5μm column (250 × 10.0 mm), 1.0 mL/min, 20-90% acetonitrile + 0.1% formic acid, 20
min, monitoring UV-absorbance at λ = 218 nm and λ = 254 nm. Crystal data was collected on Bruker Kappa
APEX-II DUO diffractometer.
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3.6 Synthesis of the aldehyde from D-glucose
3.6.1

1,2:5,6-Di-O-isopropylidene-3-O-(S-methyldithiocarbonate)-α-D-glucofuranose

(15).124

A

solution of 1,2:5,6-di-O-isopropylidene-α-D-glucofuranose 11 (4.006 g, 15.39 mmol,1.00 equiv) and
imidazole (4 mg, 0.58 mmol, 0.03 equiv) in THF (100 mL) was stirred at 0 ºC under a nitrogen atmosphere.
60% dispersion of NaH (1.26 g, 31.50 mmol, 2.05 equiv) was added in portions over 10 min.The reaction
was warmed to rt and stirred for 30 min. To the reaction mixture was added CS2 (3.00 mL, 3.78 g, 49.64
mmol 3.23 equiv) resulting in a bright yellow solution. After 45 min, MeI (1.92 mL, 4.39 g, 30.84 mmol, 2.00
equiv) was added and stirring continued for 50 min under nitrogen at rt. The reaction was quenched by
addition of glacial acetic acid (≈ 2 mL), the mixture was filtered, and the filtrate concentrated. The residue
was taken up in ethyl acetate (150 mL), washed with NaHCO 3 (3 x 80 mL) and dried over anhydrous MgSO4,
filtered and concentrated. The residue was purified by flash column chromatography eluting with 10:1
hexanes-EtOAc to afford 15 as a yellow crystalline solid (4.13 g, 76%). Rf 0.38 (8:1 hexanes-EtOAc). [α]25
D
1
= - 27.8 (c 2.3, CHCl3). Lit.125 [α]25
D = - 23.6 (c 8.1, CHCl3). H NMR (400 MHz, CDCl3) δ 1.25 (s, 6H), 1.34

(s, 3H), 1.46 (s, 3H), 2.53 (s, 3H), 4.03-4.12 (m, 2H), 4.27-4.19 (m, 2H), 4.67(d, J = 3.8 Hz, 1H), 5.85-5.83
(m, 2H);

13C

NMR (100 MHz, CDCl3) δ 19.3, 25.3, 26.3, 26.7, 26.8, 67.0, 72.4, 79.7, 82.8, 84.2, 105.0,

109.4, 112.4, 214.8. HRMS (ESI) calcd for C14H23O6S2 (M+H)+ 351.0931, obsd 351.0938.
3.6.2 3-Deoxy-1,2:5,6-di-O-isopropylidene-α-D-glucofuranose (16).126 A solution of 1,2:5,6-Di-Oisopropylidene-3-O-(S-methyldithiocarbonate)-α-D-glucofuranose 15 (2.81 g, 8.02 mmol, 1.0 equiv) in
toluene (60 mL) was added as a whole to a solution of Bu 3SnH (5 mL, 5.4 g 18.58 mmol, 2.3 equiv) in
toluene (60 mL). The mixture was stirred on reflux (128 ºC) under N 2 for 7 h. The mixture turned from bright
yellow to pale yellow as the reaction progressed. The solvent was removed under low pressure, the residue
dissolve in acetonitrile (200 mL) and washed with petroleum ether (3 x 65 mL). The acetonitrile layer was
concentrated, and the residue purified by flash column chromatography, eluting with 3:1 hexanes-EtOAc to
give 16, as a colorless viscous liquid (1.14 g, 58%). Rf 0.28 (3:1 hexanes-EtOAc). [α]25
D = - 7.93 (c 5.19,
1
CHCl3). Lit.125 [α]22
D = - 7.60 (c 1.8, CHCl3). H NMR (400 MHz, CDCl3) δ 1.28 (s, 3H), 1.32 (s, 3H), 1.39 (s,

3H), 1.47 (s, 3H), 1.7 (ddd, J = 13.5, 10.0, 4.8 Hz, 1H), 2.15 (dd, J = 13.6, 4.0 Hz, 1H), 3.7 (ddd, J = 8.8,
6.7, 4.2 Hz, 1H), 4.04-4.15 (m, 3H), 4.72 (t, J = 4.4 Hz, 1H), 5.70 (d, J = 3.6 Hz, 1H); 13C NMR (100 MHz,
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CDCl3) δ 25.1, 25.6, 26.4, 26.7, 35.2, 67.1, 76.7, 78.5, 80.3, 105.5, 109.5, 111.2. HRMS (ESI) calcd for
C12H21O5 (M+H)+ 245.1384, obsd 245.1387.
3.6.3 3-Deoxy-1,2-O-isopropylidene-α-D-glucofuranose (17).127 A solution of 3-deoxy-1,2:5,6-di-Oisopropylidene-α-D-glucofuranose (1.025 g, 4.19 mmol) in methanol (20 mL) was stirred at rt, followed by
dropwise addition of 0.9 % H2SO4 (5 mL) over 5 min. The mixture was stirred for 5 h, neutralized with
saturated NaHCO3 (3 mL) and extracted with EtOAc (3 x 30 mL). The combined organic layers were dried
over anhydrous MgSO4, filtered, concentrated and purified by flash column chromatography eluting with
9:1 EtOAc-Hexanes, to afford compound 17 as a colorless crystalline solid (450.1 mg, 53 %) Rf 0.24 (9:1
128 [α] = -14 (c 1.2, EtOH) 1H NMR (400 MHz, CDCl )
EtOAc-Hexanes). [α]25
3
D
D = -17.2 (c 2.80, CHCl3). Lit.

δ 1.33 (s, 3H), 1.51 (s, 3H), 1.85 (ddd, J = 13.5, 10.7, 4.8 Hz, 1H), 2.07 (dd, J = 13.5, 4.5 Hz, 1H), 2.59 (t,
J = 5.4 Hz, 1H), 2.87 (d, J = 3.9 Hz, 1H), 3.56-3.62 (m, 1H), 3.65-3.74 (m, 1H), 3.91 (dt, J = 3.7, 7.5 Hz,
1H), 4.22 (td, J = 10.7, 4.4 Hz, 1H) 4.76 (t, J = 4.2 Hz, 1H), 5.81 (d, J = 3.7 Hz, 1H);

13C

NMR (100 MHz,

CDCl3) δ 26.0, 26.7, 33.6, 63.5, 72.1, 78.5, 80.5, 105.1, 111.3; HRMS (ESI) calcd for C 9H17O5 (M+H)+
205.1071, obsd 205.1073.
3.6.4 1,2-O-Isopropylidene-α-D-glucofuranose-5-carbaldehyde (12).129 A solution of 3-Deoxy-1,2-Oisopropylidene-α-D-glucofuranose (405 mg, 1.98 mol, 1 equiv) in ethanol (2 mL) was added to a stirred
solution of NaIO4 (1.048 g, 4.90 mol, ~ 2.5 equiv) in water (10 mL). The reaction mixture was stirred for 30
min at rt, diluted with ethanol (60 mL), and filtered. The filtrate was evaporated, taken up in the EtOAc and
filtered through anhydrous MgSO4. The filtrate was evaporated, and the residue purified by flash column
chromatography, using a short bed (3 in) of silica gel, eluting with 9:1 EtOAc-hexanes to afford compound
129
12 as a colorless syrup (314 mg, 92%). Rf 0.40 (9:1 EtOAc-hexanes). [α]25
D = - 33.6 (c 1.0, CHCl3). Lit.
1
[α]22
D = +32 (c 1.4, CHCl3)*. H NMR (400 MHz, CDCl3) δ 1.33 (s, 3H), 1.51 (s, 3H), 1.82 (ddd, J = 13.5,

11.1, 4.6 Hz, 1H), 2.33 (dd, J = 13.5, 5.2 Hz, 1H), 4.56 (ddd, J = 7.1, 5.2, 1.8 Hz, 1H), 4.78 (t, J = 4.1 Hz,
1H), 5.94 (d, J = 3.5 Hz, 1H), 9.68 (d, J = 1.9 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 26.2, 26.8, 34.5, 79.9,
81.5, 106.3, 112.2, 199.9; HRMS (ESI) calcd for C8H13O4 (M+H)+ 173.0808, obsd 173.0807.
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3.7 Glycoalkylation of Ts-Lys-OMe
3.7.1 Nα-Tosyl-Nε-1,2-O-isopropylidene-α-D-glucofuranose-L-lysine methyl ester (18). Flame-dried,
4 Å molecular sieves (143.0 mg) were added to a solution of 1,2-O-isopropylidene-α-D-glucofuranose-5carbaldehyde 12129, 130 (132.9 mg, 0.77 mmol, 1.0 equiv) and triethylamine (300 μL, 216.6 mg, 2.15 mmol,
2.8 equiv) in dry methanol (20 mL). Nα-p-Tosyl-L-lysine methyl ester hydrochloride 13 (270.9 mg, 0.77
mmol, 1.0 equiv) was added as a solid in a single portion. The mixture was stirred at rt under N 2 for 18 h.
The molecular sieves were removed by filtration, washing well with methanol. The filtrate was concentrated
to give imine. 1H NMR (400 MHz, CDCl3) δ 7.59 -N=CH-, d, J = 4.5 Hz.
Sodium borohydride (40.0 mg, 1.06 mmol, 1.0 equiv) was added to a stirred solution of imine in dry
methanol (15 mL) at 0 °C and stirred under N2 for 4 h. The reaction was quenched by dropwise addition of
2M HCl (600 µL), the mixture concentrated, and the residue partitioned between EtOAc (40 mL) and water
(10 mL). The aqueous layer was further extracted with EtOAc (2 x 20 mL) and the combined organic extracts
were concentrated. The residue was purified by flash chromatography on silica gel, eluting with 95:5
CH2Cl2-MeOH to afford 18 as a brownish solid (240.4 mg, 66 %). Rf 0.56 (9:1 CH2Cl2-MeOH). [α]26
D +9.53
(c 2.5, CHCl3).1H NMR (400 MHz, CDCl3) δ 1.31 (s, 3H), 1.47-1.32 (m, 4H), 1.49 (s, 3H), 1.76-1.57 (m, 3H),
2.07 (dd, J = 13.2, 4.3 Hz, 1H), 2.40 (s, 3H), 2.62 (t, J = 6.6 Hz, 2H), 2.71 (dd, J = 12.4, 7.0 Hz, 1H), 2.87
(dd, J = 12.4, 3.3 Hz, 1H), 3.47 (s, 3H), 3.89 (dd, J = 7.3, 5.2 Hz, 1H), 4.37 (ddd, J = 14.2, 3.8, 3.5 Hz, 1H),
4.72 (t, J = 4.2 Hz, 1H), 5.80 (d, J = 3.7 Hz, 1H), 7.28 (d, J = 8.0 Hz, 2H), 7.70 (d, J = 8.3 Hz, 2H); 13C NMR
(100 MHz, CDCl3) δ 21.5, 22.5, 26.1, 26.7, 28.3, 32.8, 36.5, 49.2, 52.2, 52.4, 55.6, 76.5, 80.4, 105.5, 111.0,
127.2(2C), 129.5(2C), 136.7, 143.6, 172.1. HRMS (ESI) calcd for C 22H35N2O7S (M+H)+ 471.2159, obsd
471.2149.
3.7.2 Nα-Tosyl-Nε-(2S,4R)-dihydroxypiperidine-L-lysine methyl ester (2). A solution of Nα-tosyl-Nε-1,2O-isopropylidene-α-D-glucofuranose-L-lysine methyl ester 18 (105.0 mg, 0.24 mmol, 1.0 equiv) in TFAwater120, 122 (2:1 v/v) solution was stirred for 3 h at rt. The TFA was co-evaporated with toluene, and the
residue was diluted with water and lyophilized. The dried sample was dissolved in dry MeOH (3 mL) and
cooled to 0 °C. Sodium borohydride (30.6 mg, 0.49 mmol, 2.0 equiv) was added and stirring continued for
4 h under N2. The reaction was quenched by the dropwise addition of 2M HCl (0.5 mL). The mixture was
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concentrated, and the residue purified by flash column chromatography on silica gel eluting with 9:1 CH 2Cl21
MeOH to afford compound 2 (42.0 mg, 42%). Rf 0.37 (9:1 CH2Cl2-MeOH). [α]25
D +7.3 (c 1.1, CHCl3). H

NMR (400 MHz, CDCl3) δ 1.21 (dt, J = 11.0 Hz, 1H), 1.28-1.41 (m, 2H), 1.41-1.55 (m, 2H), 1.55-1.75 (m,
2H), 1.81 (t, J = 9.7 Hz, 2H), 2.19-2.30 (m, 1H), 2.38 (t, J = 7.3 Hz, 2H) 2.45 (s, 3H), 2.94 (dd, J = 10.5,
3.4 Hz, 2H), 3.44 (s, 3H), 3.66-3.71 (m, 2H), 3.86 (dd, J = 8.6, 5.5 Hz, 1H), 7.38 (d, J = 8.1 Hz, 2H), 7.72
(d, J = 8.2 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ 20.1, 22.9, 25.0, 32.1, 41.3, 51.1, 55.6, 57.4, 59.4, 59.5,
64.9(2C), 126.8 (2C), 129.2(2C), 137.8, 143.4, 172.2. HRMS (ESI) calcd for C19H31N2O6S (M+H)+
415.1903, obsd 415.1904.
3.8 Synthesis and glycoalkylation of KPV-NH2
3.8.1 Fmoc-K(Boc)-PV-NH2 (22). N-Hydroxysuccinimide (143.3 mg, 1.28 mmol, 1.0 equiv) and DCC (264.1
mg, 1.28 mmol, 1.0 equiv) were added to a solution of Fmoc-Lys(Boc)-OH 21 (600.0 mg, 1.28 mmol, 1.0
equiv) in CH2Cl2 (20 mL) at 0 ˚C. The mixture was stirred for 20 min, warmed to rt, stirred for 4 h and filtered
through a plug of cotton in a Pasteur pipette. The filtrate was concentrated, placed in the freezer for 2 h,
filtered a second time and the filtrate concentrated. The residue was dissolved in DMF (6 mL) and cooled
in an ice bath. To the stirred mixture was added L-proline (147.4 mg, 1.28 mmol, 1.0 equiv) and
diisopropylethylamine (268 µL, 199.0 mg, 1.54 mmol, 1.2 equiv). The mixture was stirred at 0 ˚C for 10 min,
warmed to rt and stirred for 14 h. Dimethylformamide was removed by a stream of air. The residue was
taken up in EtOAc (100 mL) and washed with 2M HCl (80 mL). The layers were separated, and the aqueous
layer was further extracted with EtOAc (3 x 20 mL). The organic fractions were combined, filtered through
anhydrous MgSO4 and concentrated to afford the dipeptide acid that was used directly without purification
Rf 0.32 (9:1 CH2Cl2-MeOH).
Valine amide hydrochloride (195.4 mg, 1.28 mmol, 1.0 equiv), HATU (535.5 mg, 1.41 mmol, 1.1
equiv), and 2,4,6-collidine (340 µL, 312.8 mg, 2.58 mmol, 2.0 equiv) were added to a stirred solution of
Boc-Lys(Fmoc)-Pro-OH in CH2Cl2 (6 mL) at 0 ˚C. After 10 min, the reaction was warmed to rt and stirred
for 18 h under N2. The mixture was concentrated and the tripeptide 22 was isolated by flash column
chromatography, eluting with 20:1 CH2Cl2-MeOH, as a colorless solid (134 mg, 44%) Rf 0.55 (9:1 CH2Cl21
MeOH). [α]25
D +56.7 (c 1.4, DMSO). H NMR (400 MHz, CD3OD) δ 0.94 (d, J = 6.1 Hz, 3H), 0.96 (d, J = 6.6
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Hz, 3H), 1.42 (s, 9H), 1.32-1.58 (m, 4H), 1.58-1.70 (m, 1H), 1.71-1.76 (m, 1H), 2.01-2.11 (m, 5H), 2.933.18 (m, 2H), 3.57-3.76 (m, 1H), 3.76-3.82 (m, 1H), 4.17-4.22 (m, 2H), 4.29-4.45 (m, 3H), 4.50 (dd, J = 7.6,
3.9 Hz, 1H), 6.70 (d, J = 7.5 Hz, NH*), 7.07 (t, J = 5.5 Hz, NH*) 7.30 (t, J = 7.4 Hz, 2H), 7.39 (t, J = 7.4 Hz,
2H), 7.61 (d, J = 7.2 Hz, 2H), 7.76 (d, J = 7.5 Hz, 2H);

13C

NMR (100 MHz, DMSO-d6) δ 18.2, 19.8, 23.0,

25.1, 28.7, 29.0, 29.7, 31.0 (2C), 39.9, 47.1 (2C), 52.9, 57.7, 59.8, 66.1, 77.8, 120.5, 125.8, 127.5, 128.0,
141.2, 144.3, 156.0, 156.6, 171.4, 171.5, 173.3; HRMS (ESI) calcd for C36H50N5O7 (M+H)+ 664.3705, found
664.3688.
*Does not integrate to a full proton due to proton exchange with CD3OD
3.8.2 αG’-K(Boc)PV-NH2 (25). Piperidine (552 µL, 475.8 mg, 5.59 mmol, 5.6 equiv) was added to a solution
of tripeptide 22 (797.8 mg, 1.20 mmol, 1.0 equiv) in dry DMF (20 mL). The reaction was stirred at rt for 30
min. The solvent was evaporated by a stream of air, the residue partitioned between CH 2Cl2 (20 mL) and
H2O (10 mL), and the layers separated. The aqueous layer was further washed with CH 2Cl2 (3 x 10 mL)
and lyophilized to afford the free amine that was used in the next reaction without further purification (Rf
0.59, 6:4:1 CHCl3-MeOH-H2O).
Triethylamine (250 µL, 181.4 mg, 1.79 mmol, 3.0 equiv) and flame dried 4Å powdered molecular
sieves (75.0 mg) were added to a solution of tripeptide amine (263.4 mg, 0.60 mmol, 1.0 equiv) in dry
MeOH (3 mL). The mixture was stirred at rt and a solution of the aldehyde (328.3 mg, 1.91 mmol, 3.2 equiv)
in dry MeOH (3 mL) was added. The mixture was left to stir at rt for 24 h. The reaction was filtered through
a pad of Celite® that was washed well with MeOH. The filtrate was cooled to 0 ˚C, NaBH 4 (73.2 mg, 1.93
mmol, 3.2 equiv) was added, and the mixture was stirred for 4 h under N 2. The reaction was quenched by
dropwise addition of 2M HCl (250 µL). The mixture was concentrated, and the residue purified by flash
column chromatography, eluting with 9:1 CH2Cl2-MeOH to afford the tripeptide 25 (194 mg, 27%) Rf 0.54
1
(9:1 CH2Cl2-MeOH). [α]25
D -68.7 (c 1.9, CHCl3). H NMR (500 MHz, CD3OD) δ 1.00 (d, J = 6.6 Hz, 3H), 1.01

(d, J = 6.8 Hz, 3H), 1.31 (s, 3H), 1.45 (s, 9H), 1.48 (s, 3H), 1.40-1.53 (m, 3H), 1.54-1.62 (m, 2H), 1.63-1.73
(m, 2H), 1.98-2.07 (m, 3H), 2.08-2.14 (m, 2H), 2.14-2.20 (m, 1H), 2.58 (dd, J = 12.7, 6.6 Hz, 1H), 2.79 (dd,
J = 12.7, 3.5 Hz, 1H) 2.89-3.12 (app. t, J = 5.1 Hz, 3H), 3.62-3.74 (m, 2H), 3.77- 3.82 (m, 1H), 4.21 (d, J =
6.5 Hz, 1H), 4.25-4.30 (m, 1H), 4.59 (dd, J = 8.2, 4.3 Hz, 1H), 4.76 (app. t, J = 4.2 Hz, 1H), 5.78 (d, J = 3.7
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Hz, 1H);

13C

NMR (125 MHz, CD3OD)* δ 17.1, 18.5, 22.4, 24.6, 25.0, 25.6, 27.4, 28.7, 29.4, 30.7, 32.4,

36.1, 39.7, 47.1, 50.0, 58.3, 58.8, 59.9, 77.9, 80.3, 105.7, 110.8, 157.1, 172.8 (2C), 174.2, 174,7. HRMS
(ESI) calcd for C29H52N5O8 (M+H)+ 598.3810, obsd 598.3809.
* Reported for the major conformation only two species were observed that were presumed to be rotamers
about the prolyl amide bond.
3.8.3 αG*-KPV-NH2 (26). A solution of compound 25 (78.0 mg, 0.13 mmol, 1.0 equiv) in TFA-H2O (2:1 v/v,
4.5 mL) was stirred for 3.5 h. The mixture was diluted with toluene (20 mL) and concentrated. The residue
was dissolved in MeOH and stirred at 0 ˚C. Solid NaHCO 3 (35.3 mg) was added to neutralize the solution.
NaBH3CN (16.3 mg, 0.26 mmol, 2.0 equiv) was added and the mixture stirred for 15 h. The reaction was
quenched by the dropwise addition of 2M HCl (~600 µL), concentrated, and the residue subjected to HPLC
to afford compound 26 (17.8 mg, 31 %). tR 15.5 min. Rf 0.13 (6:4:1 CHCl3-MeOH-H2O). [α]25
D -28.9 (c 0.1,
MeOH); 1H NMR (500 MHz, CD3OD) δ 1.01 (d, J = 6.8 Hz, 3H), 1.02 (d, J = 6.7 Hz, 3H), 1.24 (app. q, J =
10.7 Hz, 1H), 1.29-1.52 (m, 2H), 1.62-1.78 (m, 3H), 1.79-1.92 (m, 1H), 1.94-2.13 (m, 5H), 2.15-2.28 (m,
2H), 2.31 (t, J = 10.0 Hz, 1H), 2.87-3.02 (m, 4H), 3.56 (dd, J = 10.1, 3.9 Hz, 1H), 3.60-3.78 (m, 3H), 3.883.92 (m, 1H), 4.18 (d, J = 6.8 Hz, 1H), 4.53 (dd, J = 8.4, 4.0 Hz, 1H); 13C NMR (125 MHz, CD3OD) δ 17.2,
18.4, 22.7, 24.4, 24.5, 27.0, 29.4, 30.7, 39.2, 41.6, 47.4, 55.3, 56.9, 58.5, 60.3, 65.2, 65.7 (2C), 171.0,
173.2, 174.7; HRMS (ESI) calcd for C21H40N5O5 (M+H)+ 442.3024, obsd 442.3029.
3.8.4 Ac-KPV-NH2 (27). A solution of tripeptide 22 (362.2 mg, 0.55 mmol, 1.0 equiv) in piperidine (544 µL,
470.0 mg, 5.50 mmol, 10.0 equiv) and DMF (5 mL) was stirred for 30 min. The solvent was evaporated by
a stream of air, and the residue partitioned between CH 2Cl2 (50 mL) and H2O (30 mL). The aqueous layer
was further washed with CH2Cl2 (2 x 20 mL) and lyophilized to afford the free amine (232 mg, 96%). Rf 0.28
(9:1 CH2Cl2-MeOH).
A portion of the free amine (94 mg, 0.213 mmol) was dissolved in a mixture of Ac 2O-pyridine (1:1
v/v, 6 mL) and stirred for 15 h, concentrated and purified by flash column chromatography, eluting with
100:7 CH2Cl2-MeOH to give the acetylated tripeptide, Ac-K(Boc)-PV-NH2 (72 mg, 70 %). Rf 0.50 (20:3
1
CH2Cl2-MeOH). [α]25
D -65.4 (c 1.5, CHCl3). H NMR (400 MHz, CD3OD) δ 0.99 (d, J = 3.4 Hz, 3H), 1.00 (d,

J = 3.4 Hz, 3H), 1.43-1.56 (m, 4H), 1.45 (s, 9H), 1.59-1.72 (m, 1H), 1.77-1.87 (m, 1H), 1.96-2.19 (m, 5H),
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1.98 (s, 3H), 3.06 (app. t, J = 6.0 Hz, 2H), 3.66-3.73 (m, 1H), 3.73-3.92 (m, 1H), 4.22 (app. t, J = 6.3 Hz,
1H), 4.54 (dd, J = 8.0, 3.9 Hz, 1H), 4.54-4.59 (m, 1H), 6.59 (br s, NH*), 7.91 (d, J = 8.2 Hz, NH*), 8.18 (d,
J = 7.0 Hz, NH*);

13C

NMR (100 MHz, CD3OD) δ 17.1, 18.5, 20.9, 22.6, 24.7, 27.4(3C), 28.8, 29.3, 30.7

(2C), 39.6, 47.3, 51.3, 58.3, 60.1, 78.4, 157.1, 171.8, 171.9, 172.8, 174.7. HRMS (ESI) calcd for C 23H42N5O6
(M+H)+ 484.3135, obsd 484.3130.
*Does not integrate for a full proton due to deuterium exchange
The acetylated tripeptide, Ac-K(Boc)PV-NH2 (72.0 mg, 0.19 mmol) was dissolved in a mixture
CH2Cl2-TFA (1:1 v/v, 4 mL) and stirred at rt for 30 min. The mixture was concentrated, and the residue
dissolved in toluene and concentrated again. The residue was purified by HPLC to afford the free amine 27
1
(40.8 mg, 71 %). tR 16.2 min. Rf 0.36 (20:13:3:1 CHCl3-MeOH-H2O-NH3). [α]25
D -85.5 (c 0.6, MeOH). H

NMR (400 MHz, CD3OD) δ 1.00 (d, J = 2.5 Hz, 3H), 1.01 (d, J = 2.5 Hz, 3H), 1.42-1.55 (m, 2 H), 1.62-1.73
(m, 3 H), 1.75-1.84 (m, 1 H), 1.96-2.15 (m, 4H), 1.99 (s, 3H), 2.18-2.24 (m, 1H), 2.78 (t, J = 7.0 Hz, 2H),
3.66-3.71 (m, 1H), 3.86-3.92 (m, 1H), 4.18 (d, J = 6.9 Hz, 1H), 4.53 (dd, J = 8.4, 4.6 Hz, 1H), 4.60 (dd, J =
8.1, 5.9 Hz, 1H);

13C

NMR (100 MHz, CD3OD) δ 17.1, 18.5, 20.9, 22.2, 24.7, 29.0 (2C), 30.6, 30.7, 39.7,

47.4, 51.1, 58.5, 60.1, 171.6, 171.8, 172.9, 174.7; HRMS (ESI) calcd for C18H34N5O4 (M+H)+ 384.2611,
obsd 384.2606.
3.8.5 Boc-K(Fmoc)-PV-NH2 (24). Boc-Lys(Fmoc)-OH 23 (600.0 mg, 1.28 mmol) was treated, by analogy
to the procedure described for the conversion of 21 to 22, to afford 24 (360.0 mg, 42%) Rf 0.43 (9:1 CH2Cl21
MeOH). [α]25
D -55.7 (c 0.8, MeOH). H NMR (400 MHz, CD3OD) δ 0.98 (d, J = 2.1 Hz, 3H), 0.99 (d, J = 2.1

Hz, 3H), 1.43 (s, 9H), 1.43-1.64 (m, 5H), 1.72-1.81 (m, 1H), 1.95-2.17 (m, 5H), 3.13 (app. t, J = 6.2 Hz, 2H),
3.63 (dd, J = 16.0 Hz, 9.6 Hz, 1H), 3.79 (dd, J =16.0 Hz, 6.8 Hz, 1H), 4.17-4.22 (m 1H), 4.21 (d, J = 6.6 Hz,
1H), 4.27-4.34 (m, 1H), 4.35 (d, J = 6.9 Hz, 2H), 4.55 (dd, J = 8.0 Hz, 3.8 Hz, 1H), 7.31 (t, J = 7.4 Hz, 2H),
7.39 (t, J = 7.4 Hz, 2H), 7.65 (d, J = 7.4 Hz, 2H), 7.79 (d, J = 7.4 Hz, 2H);

13C

NMR (100 MHz, CD3OD) δ

17.2, 18.5, 22.5, 24.7, 27.4, 28.7, 29.1, 30.6, 30.9, 39.9, 47.1, 52.4, 58.3, 60.1, 66.2, 79.2, 119.6, 124.8,
126.8, 127.4, 141.2, 144.0, 157.4, 157.5, 172.6, 172.8, 174.7; HRMS (ESI) calcd for C 36H50N5O7 (M+H)+
664.3705, obsd 664.3710.
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3.8.6 Boc-K(εG’)PV-NH2 (28). Following the same series of reactions in the conversion of 22 to 25 above,
compound 24 (125.0 mg, 0.19 mmol) was converted to 28 (41 mg, 60%). Rf 0.78 (6:4:1 CHCl3-MeOH-H2O).
1
[α]25
D -59.3 (c 1.1, MeOH). H NMR (400 MHz, CD3OD) δ 1.00 (d, J = 2.1 Hz, 3H), 1.01 (d, J = 2.1 Hz, 3H),

1.33 (s, 3H), 1.45 (s, 9H), 1.49 (s, 3H), 1.40-1.55 (m, 1H), 1.61-1.84 (m, 5H), 1.99-2.27 (m, 6H), 2.95-3.03
(m, 3H), 3.25 (dd, J = 12.8, 2.4 Hz, 1H), 3.66-3.27 (m, 1H), 3.83-3.88 (m, 1H), 4.18 (d, J = 6.6 Hz, 1H), 4.37
(t, J = 6.7 Hz, 1H), 4.42-4.48 (m, 1H), 4.55 (dd, J = 8.2, 4.2 Hz, 1H), 4.84 (t, J = 4.1 Hz, 1H), 5.89 (d, J =
3.5 Hz, 1H); 13C NMR (100 MHz, CD3OD,) δ 17.2, 18.5, 22.3, 24.7, 25.0, 25.7, 25.9, 27.3, 29.0, 30.7, 30.8,
36.2, 47.4, 48.0, 50.7, 52.0, 58.5, 60.3, 74.0, 79.2, 80.4, 105.9, 111.3, 156.5, 172.2, 172.9, 174.7. HRMS
(ESI) calcd for C29H51N5O8 (M+H)+ 598.3810, obsd 598.3817.
3.8.7 H-K(εG*)PV-NH2 (29). By analogy to the procedure described for conversion of 25 to 26, compound
28 (139.0 mg, 0.23 mmol) was converted to 29. The crude product was purified by HPLC to afford εglycoalkylated tripeptide x (24 mg, 23 %). tR 15.6 min). Rf 0.20 (6:4:1 CHCl3-MeOH-H2O). [α]25
D -35.5 (c 0.4,
MeOH). 1H NMR (500 MHz, CD3OD) δ 1.00 (d, J = 6.8 Hz, 3H), 1.01 (d, J = 6.7 Hz, 3H), 1.19-1.35 (m, 1H),
1.41-1.54 (m, 2H), 1.42-1.64 (m, 2H), 1.66-1.76 (m, 1H), 1.78-1.92 (m, 3H), 1.96-2.16 (m, 4H), 2.20-2.29
(m, 2H), 2.50 (app. t, J = 7.7 Hz, 2H), 2.98 (dd, J = 10.6, 3.7 Hz, 2H), 3.63-3.66 (m, 1H), 3.68-3.75 (m, 3H),
3.91 (t, J = 6.2 Hz, 1H), 4.20 (d, J = 6.7 Hz, 1H), 4.58 (dd, J = 8.1, 4.6 Hz, 1H); 13C NMR (125 MHz, CD3OD)
δ 17.1, 18.4, 22.5, 24.6, 25.8, 28.8, 30.7, 32.4, 41.7, 47.2, 51.9, 57.5, 58.4, 59.6 (2C), 60.1, 65.0 (2C),
171.4, 172.6, 174.7. HRMS (ESI) calcd for C21H40N5O5 (M+H)+ 442.3024, obsd 442.3032.
3.9 Discussion
3.9.1 Synthesis of the aldehyde 12
The aldehyde 12 (Scheme 3) was synthesized from commercially available diacetone-D-glucose
11 through Barton-McCombie deoxygenation at C3.126 Compound 11 was reacted with excess NaH and
catalytic quantities of imidazole. Addition of carbon disulfide to the reaction mixture led to the formation of
dithiocarbonate salt which was alkylated with iodomethane to afford the S-methyl xanthate ester 15.
Reductive homolytic cleavage of C-O bond in 15 with tributyltin hydride, driven by the formation of a strong
Sn-S bond, afforded 16. Subjection of compound 16 to mild acid hydrolysis led to deprotection of C5,6-diol
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and oxidative cleavage of the C5,6-diol by NaIO4, afforded 12. The NMR spectra are provided in Appendix
B-1.
Scheme 3. Synthesis of the aldehyde (12)

3.9.2 Synthesis of the glycoalkylated lysine derivative 2
Reductive alkylation of 13 with the aldehyde 12 afforded compound 18 which was subjected to
hydrolysis and intramolecular reductive alkylation to form the piperidine diol. Acid hydrolysis of 18 exposes
the hemiacetal 19, which in equilibrium with the aldehyde 14. The aldehyde condenses with the ε-NH
leading to compound 2. Multiple mineral acids were investigated for the hydrolysis of the acetal compound
18. Treatment of compound 18 with a 1:1 10% H2SO4-MeOH (v/v) solution led to ring opening and trapping
of the aldehyde 14 as cyclic methylated acetal 20.
An extensive search of the literature for hydrolysis conditions that preceded successful
intramolecular ring formation led to the use of a TFA-H2O acid system. Different TFA-H2O ratios: 2:1,131, 132
4:1,120 and 3:2121,

123

have been used by different scientists to perform the aminocyclization reactions

outlined in Section 3.3. Treatment of compound 18 with 2:1 TFA/H2O, followed by reduction with sodium
borohydride, afforded compound 2. Formation of the product was confirmed by NMR, ESI-MS, and X-ray
crystallography. A solution of purified 2 in methanol formed crystals following storage at 4 °C. The crystal
structure is shown in Figure 43A and the CCDC deposition number is 1825648. The NMR spectra are
provided in Appendix B-2.
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Scheme 4. Synthesis of the glycoalkylated lysine derivative (2)

Figure 43. A) ORTEP drawing of compound 2. B) The piperidine ring of compound 2 showing the three
pairs of equivalent hydrogens Hx, Hy, and Hz.
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From the crystal structure, it can be seen that the piperidine-2,4-diol ring is symmetric along the
ring plane passing through N and C3. Each hydroxyl group of the diol adopts an equatorial orientation. 1H
NMR analysis of compound 2 confirms the symmetry of the piperidine, showing three pairs of equivalent
protons (Figure 43A): Hx (H1e and H5e); Hy (H1a and H5a); and Hz (H2 and H4). A doublet of doublet
peak was observed at δ 2.94 corresponding to H1e, H5e with a large geminal coupling constant (J1e,1a and
J5e,5a = 10.4 Hz) and a small vicinal coupling constant (J1e,2a and J5e,4a = 3.3 Hz). This small vicinal coupling
constant places H2 and H4 in axial positions, consistent with the equatorial orientation of the hydroxyl
groups in the crystal structure.
3.9.3 Synthesis of Ac-KPV-NH2 and the glycoalkylated analogs
Following the success of our model system, the possibility of applying the same modification to a
short peptide sequence containing a lysine residue was explored. From the list of the biologically relevant
tripeptides and tripeptide motifs provided by Ung and Winkler, 11 the tripeptide Ac-KPV-NH2 was selected.
Its dual functionality as an antimicrobial and anti-inflammatory peptide would be used to assess the effect
of glycoalkylation on the biological activity. Three derivatives of H-KPV-NH2 were synthesized:
αG*-KPV-NH2

26,

H-K(εG*)PV-NH2

29,

and

the

parent

peptide

Ac-KPV-NH2

27 were synthesized (with G* defined in Scheme 6). The core tripeptides 22 and 24 were synthesized and
used for α- and ε-glycoalkylation respectively (Scheme 5). The activated acid of 21 was coupled with proline
to give the dipeptide acid which was coupled with valine amide to afford 22. Compound 24 was synthesized
from 23 by analogy.
Scheme 5. Synthesis of the α- and ε-protected tripeptides 22 and 24
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Fmoc deprotection of the tripeptide 22 followed by reductive alkylation of the resulting primary
amine with compound 12, afforded 25 (scheme 6). Acid hydrolysis of the acetal in 25 unmasked an
aldehyde which condensed with the secondary α-NH of lysine, through intramolecular reductive alkylation
to form the piperidine diol in compound 26 (α-glycoalkylation). The ε-glycoalkylation was accomplished
using compound 24, by analogy, to afford 29 via the intermediate compound 28. The control peptide AcKPV-NH2 (27) was synthesized from tripeptide 22. Fmoc deprotection of 22 gave the primary α-amine which
was acetylated. Cleavage of the Boc group from sidechain amine afforded 27. The NMR spectra are
provided in Appendix B-3 and B-4.
Scheme 6. Synthesis of compounds 26, 27, and 29 from compounds 22, and 24.

During the intramolecular cyclization to form the piperidine diol ring, reduction of the imine by
NaBH3CN, under acidic conditions, led to low yields of 26 and 29. The reduction was therefore done under
basic conditions133 by addition of NaHCO3 to the reaction mixture. The polar diol and amine functionality in
the final products made it impossible to purify the compounds by silica gel column chromatography.
Reverse phase HPLC purification was used, unfortunately, some fractions of the glycopeptides eluted with
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residual borohydride salts. The reported low yields are mainly attributed to losses incurred during
purification.
During subsequent efforts to prepare more of 26, 27, and 29, for biological studies (vide infra), it
was found that all three tripeptides could be synthesized from Boc-K(Fmoc)PV-NH2 following the reaction
steps summarized in Scheme 7. While additional reaction and purification steps are incurred in the
synthesis of the alpha-glycoalkylated tripeptide; this approach has the advantage of a common intermediate
that could be prepared on large scale (hundreds of milligrams) and some practical advantages. Retaining
the Fmoc group, and its inherent UV-activity, during the intramolecular cyclization made it easier to monitor
the reaction by TLC. It was also possible to purify compound 30 by silica gel chromatography, which
removed borohydride salts and thus they are not carried forward to complicate the HPLC purification of 26.
The final purification of compound 26, after Fmoc deprotection, is simplified to a phase separation between,
CH2Cl2 and H2O, followed by lyophilization of the aqueous layer. Chromatographic behavior (TLC and
HPLC) and 1H NMR spectra of 26 and 27 were identical to those obtained for batches synthesized via
Scheme 6.
Following the successful synthesis of the three compounds αG*-KPV-NH2 26, H-K(εG*)PV-NH2 29,
and the parent peptide Ac-KPV-NH2 27. The compounds were used for antimicrobial and and
anti-inflammatory tests to check the effects of glycoalkylation on the biological activity Ac-KPV-NH2 of
(discussed in the next chapter). Stability of the tripeptides towards proteolytic cleavage was also tested.
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Scheme 7. Alternative synthetic route for compounds 26 and 27.
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CHAPTER 4
BIOLOGICAL ACTIVITY AND ENZYMATIC STABILITY TESTS OF KPV TRIPEPTIDE DERIVATIVES
4.1 Antimicrobial activity of Ac-KPV-NH2
The tripeptide Ac-KPV-NH2 has been shown to have similar antimicrobial activity to the
tridecapeptide α-MSH. Cutuli et al. demonstrated the antimicrobial effects of Ac-KPV-NH2 against
Staphylococcus aureus and Candida albicans, with significant activity at concentrations ranging from
picomolar (quantity of α-MSH found in human plasma) to micromolar.116 Charnley et al. showed that altering
the stereochemistry of Ac-KPV-NH2 to Ac-KPDV-NH2 (L-valine substituted with D-valine) did not increase
its antimicrobial activity,134 different from what was observed for its anti-inflammatory activity. The
ant-inflammatory effect was shown to increase with DVal substitution.135 Charnley et al. further reported that
antimicrobial effects of Ac-KPDV-NH2 were similar in both gram negative and Gram positive bacteria
(Escherichia coli and Staphylococcus aureus).134 They demonstrated that replacing lysine with alanine did
not have any significant effect on the antimicrobial activity of Ac-KPV-NH2, implying that the cationic charge
in lysine is not necessary. They therefore proposed an Ac-XP(D/L)V-NH2 sequence for antimicrobial
activity.134
Singh et al. studied the antimicrobial effect of Ac-KPV-NH2 (α-MSH 11-13) against MRSA and
MSSA and compared to that of the full-length peptide, α-MSH 1-13. Their findings showed that the Cterminal tripeptide retained similar activity as the α-MSH 1-13 and the presence of physiological salt
concentration did not affect the potency of the peptide.136 Their study also indicated that the full-length and
the C-terminal fragment of α-MSH disrupted the bacterial membrane.136
In the current study, the antimicrobial activity of Ac-KPV-NH2 and the glycopeptide analogs were
investigated against Staphylococcus aureus USA300, by agar diffusion test, colony forming units and liquid
culture.

________________
Portions of this chapter previously appeared in PLOS ONE, Songok, et al. PLoS ONE 2018, 13, e0199686..
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4.2 Anti-inflammatory activity of Ac-KPV-NH2
The tripeptide Ac-KPV-NH2 has been shown to have similar anti-inflammatory properties to αMSH.113, 135 However, there is no evidence that Ac-KPV-NH2 modulates this process through melanocortin
receptors. There was dose-dependent response on anti-inflammatory effect of Ac-KPV-NH2 in activated
microglia,113 which is not characteristic of a receptor signaling pathway. On the other hand, KdPT (IL-1β193195)

an analog of Ac-KPV-NH2 (containing D-proline) and an antagonist of IL-1β has been shown to compete

with IL-1β for the same receptor site. The analgesic effect of IL-1β, given intraperitoneally, was attenuated
by subcutaneous pretreatment with KdPT (85 µg/150 g) in rat. 137 This inhibition was overcome by larger
doses of IL-1β which confirmed competitive antagonism.137
Although the actual mechanism of KPV’s action is not fully determined, it has been shown to have
anti-inflammatory activity both in vitro (summarized in Table 7) and in vivo as observed in different cell
lines.12 KPV and its derivatives suppressed the production of proinflammatory cytokines (TNF-α, IL-6113 and
IL-8), inhibited the activation of NF-κB138 for nuclear translocation, and reduced production of NO during
the inflammation process.139 The anti-inflammatory effects of Ac-KPV-NH2 and the glycopeptides have
been assessed in the current study, for inhibition of NF-κB nuclear translocation in 3T3-L1 adipocyte cells,
with the inflammation induced by TNFα.
4.3 Enzymatic stability of therapeutic peptides
The high target specificity and good tolerance achieved in the use of therapeutic peptides has
enabled their broad range of application in treatment of various diseases, including cancer and metabolic
disorders.140 The use of natural peptide drugs is faced with the challenge of low oral bioavailability, due to
proteolytic degradation and minimal absorption across the epithelial barrier. To minimize enzymatic
degradation of the peptides, structural modifications such as C-terminal amidation, N-terminal acetylation,
site specific modifications, and the use of unnatural amino have been implemented. 36
Structural modification of Ac-KPV-NH2 by reductive glycoalkylation is expected to confer proteolytic
stability to the tripeptide. To evaluate the effect of this modification on proteolytic stability, the gylcoalkylated
KPV analogs were exposed to pronase and the reactivity compared with that of the parent peptide Ac-KPV-
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NH2. Pronase comprises of a mixture of aminopeptidases, endopeptidases, serine-type proteases, and a
carboxypeptidase.141 It is extracted from Streptomyces griseus and often used for complete degradation of
proteins to their constituent amino acids.141
Table 7. Anti-inflammatory effects of KPV analogs in vitro.12
Target molecule
/process
Proinflammatory
cytokines

Peptide
KPV
KPV
KPV
KPV
KdPT

Transcription
factor NF-B

Non-cytokine
pro-inflammatory
mediators

Effect of α-MSH
LPS/PMA-induced TNF-α
expression
LPS/IFN-γ-induced TNF-α and IL- 6
expression
βA/IFN-γ-induced NO2production, iNOS expression
IL-1β-induced IL-8 expression

KPV

IL-1β-induced IL-6 and IL-8
expression
TNF-α-induced NF-κB activation

KdPV

LPS-induced NF-κB activation

KPV
KPV, KPdV

LPS/IFN-γ-induced NF-κB
activation
TNF-α-induced NF-κB activation

KPV

IL-1β-induced NF-κB activation

KdPT

IL-1β-induced NF-κB activation

KPV

IFN-γ/LPS-induced NO2production
LPS/IFN-γ-induced NO production

KPV
Cyclic KPV,
KPdV
Derivatives
KPV

LPS/IFN-γ-induced NO production

Cell type
Murine connective tissue
fibroblasts cell line L292
Murine microglial cell
line (N9 clone)
Murine microglial cell
line (N9 clone)
Human colon, Jurkat
cells
SZ95 human sebocytes
HIV-1-infected
promonocytic U1 cell line
Rat alveolar type II
epithelial cells
RAW 264.7 murine
macrophage cell line
HaCaT keratinocytes,
human keratinocytes
Human colon, Jurkat
cells
SZ95 human sebocytes
Murine microglial cell
line (N9 clone)
RAW 264.7 murine
macrophage cell line
RAW 264.7 murine
macrophage cell line

Cytokine
IL-10 production
Human peripheral blood
suppressors
monocytes
βA, β-Amyloid protein; PMA, phorbol-12-myristate-13-acetate; ,decreased; , increased.

4.4 Antimicrobial tests
4.4.1 Disk diffusion method
Agar diffusion testing (Kirby-Bauer testing142) was performed to test the sensitivity of various
bacteria to our synthetic products: Ac-KPV-NH2, H-K(εG*)PV-NH2 and αG*-KPV-NH2. The bacteria tested
were W3110: E. coli K12; WBB06: E. coli Δ(rfaC-rfaF) (an E. coli strain missing two genes involved in
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lipopolysaccharide synthesis and sensitive to numerous antibiotics); 143 Salmonella enterica; Vibrio cholera,
C6706; and Staphyloccocus aureus USA300. Ampicillin and water were used as positive and negative
controls, respectively. Disks of filter paper were spotted with 5 L of water or 10 mg/mL solutions of
ampicillin, Ac-KPV-NH2, H-K(εG*)PV-NH2 or αG*-KPV-NH2. Each bacterium and compound was tested by
placing the disks on a lawn of bacterial cells and incubating overnight at 37 ˚C. Visual inspection of the
plates for zones of inhibited cell growth around each disc was used to determine the sensitivity of the
bacteria for each compound.
4.4.2 Colony forming units
An overnight culture of Staphylococcus aureus JE2144 was grown in Luria-Bertani (LB) medium. 1
mL was centrifuged and washed in MOPS minimal medium (Teknova Inc., Hollister CA) and resuspended
in the same medium. Cells were diluted to approximately 107 cells/mL in MOPS medium, MOPS medium +
10 mM CaCl2, MOPS medium + 10% laked horse blood (Thermo-Fisher Scientific), or MOPS medium + 10
mM CaCl2 + 10% laked horse blood both with and without 0.1 mM Ac-KPV-NH2 (Bachem, Bubendorf,
Switzerland). Cells were incubated for 2 hours at 37 °C at which time viability was determined by colony
counting of serially diluted cells.
4.4.3 Liquid culture
Staphylococcus aureus cells were cultured overnight in 2 mL Luria-Bertani broth medium in
presence of Ac-KPV-NH2 (50 µg/mL, 100 µg/mL, 200 µg/mL, 500 µg/mL, 1000 µg/mL), αG*-KPV-NH2 (50
µg/mL), K(εG*)PV-NH2 (50 µg/mL), and ampicillin (10 µg/mL). Visual inspection of the cell density in the LB
medium was used to assess the inhibition.
4.5. Anti-inflammatory tests
4.5.1 Adipocytes cell culture, treatment with KPV tripeptides, and TNFα induction
A monolayer of murine 3T3-L1 adipocyte cells145 were grown in 4 mL Dulbecco’s Modified Eagle’s
Medium (DMEM) containing 10% bovine serum. The cells were serum deprived by changing the media to
DMEM containing 0.3% bovine serum albumin (BSA) 20 h before treatment with the peptides. The cells
were treated with the KPV tripeptide derivatives, 26, 27, or 29 (25 µM), at 37 °C for 2h, and inflammation
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was induced by addition of TNFα (0.5 nM) with incubation at 37 °C for 20 min. The cells were fractionated
to separate the cytosolic and nucleic proteins.
4.5.2 Cell fractionation and SDS PAGE analysis

Culture plates were aspirated and 2 mL nuclear homogenization buffer (NHB) containing 20 mM
Tris pH 7.4, 10 mM NaCl, 3 mM MgCl2, with protease inhibitors (1 µM phenylmethylsulfonyl fluoride, 1 µM
1,10-phenanthrolin, 10 µM leupeptin, 50 mU trypsin inhibitory aprotinin) and phosphatase inhibitors (0.1
µM NaF, 1 mM Na3VO4 and 1 mM Na2MoO4) was added. The cells were scrapped off and transferred to
15 mL tubes. Nonidet P-40 was added to a 0.5% final concentration. The mixture was homogenized in a
Dounce homogenizer with 16 strokes and centrifuged at 3500 rpm, 4 °C for 5 min. 1 mL of the supernatant
(cytosol) was transferred to a clean tube and the rest discarded. The pellet was washed by resuspending
in NHB buffer (1 mL), centrifuged and the supernatant discarded. The washed pellet was then suspended
using a P1000 pipetor in 600 µL NEB buffer (20 mM HEPES pH 7.9, 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM
EDTA, 25% glycerol) to yield the nuclear proteins. The cytosolic and nucleic extracts were frozen at -80 °C
for 15 min. The extracts were thawed and 1.5 µL of DNase added to the nuclear extracts. The mixture was
passed through a 20 gauge needle 5x to homogenize and centrifuged at 10,000 rpm, 4 °C for 10 min. The
supernatant (nuclear extract) and the cytosol were quantified by BCA assay.
4.5.3 Gel electrophoresis, Western blot and imaging
Extracted proteins (100 µg) and the loading controls (PDC-E2 and ERK) were loaded and separated
on an SDS-polyacrylamide gel (7.5%). The protein bands were transferred to a nitrocellulose membrane
with 192 mM glycine, 25 mM Tris, and 20% methanol. 145 The nitrocellulose was removed and dried on a
Whatman filter paper, and the molecular weight of the bands marked. Strips containing proteins of interest
were cut from the nitrocellulose and blocked with 4% nonfat milk (overnight, 4 °C) or 1 h at room
temperature. Strips were washed two times for 5 min with 1X Tris buffered saline (TBS-T) and incubated
with 15 mL of the primary antibody solution (in a Kapak “seal a meal” bag) for 90 min at rt in the orbital
shaker (150 rpm). Rinsing was done 3x using 1X TBST-T for 15 min each, and the strips incubated with
the secondary antibody, antibody-HRP (horseradish peroxidase) conjugate, for 90 min, rt, 150 rpm. The
blots were rinsed 3x for 10 min each in 1X TBS-T solution and visualized by enhanced chemiluminescence.
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The imaging process was done in the dark room by incubating the blot for 2 min with the luminolperoxidase mixture. The strips were wrapped in a plastic bag and glow-in-the-dark labels placed on the top
right corner. The film was opened in the dark and placed in the developer cartridge for one to five minutes
after which the film was developed.
4.6 Enzymatic stability tests

Pronase incubation solutions were prepared in D2O by adding 20 µL of 1M NH4HCO3 and 40 µL of
50 mM CaCl2 to a solution of the tripeptide (200 µg Ac-KPV-NH2 and K(G*)PV-NH2 or 100 µg G*-KPV-NH2
in 300 µL D2O). The pH of the resulting mixture was adjusted to 7.0 with 3.7% HCl (10-12 µL). The volume
was adjusted to 395 µL and 1H-NMR spectra were recorded on a 500 MHz Bruker instrument. Pronase
(VWR, Streptomyces griseus, ≥45,000 proteolytic units/g dry weight) solution (5 µL of 2 mg/mL stock
solution) was added to the incubation solution and 1H NMR spectra were recorded at 15 min intervals for 3
h. The first hour of incubation was at room temperature, after which the reaction was warmed to 37 ˚C and
spectra were recorded at this temperature for the next 2 h. The reaction was then incubated at 37 ˚C and
monitored by recording the spectra at additional times up to 48 h, 96 h, and 24 h for 26, 29, and 27,
respectively.

4.7 Discussion
The antimicrobial activity of the three compounds, 26, 27, and 29, were tested by Pradip Panta, a
graduate student in Dr. William Doerrler’s laboratory (Department of Biological Sciences, LSU), using the
agar diffusion method against bacterial strains E. coli K12; WBB06: E. coli Δ(rfaC-rfaF); Salmonella
enterica; Vibrio cholera, C6706; and Staphyloccocus aureus USA300. Ampicillin was used as a positive
control. None of the H-KPV-NH2 derivatives inhibited growth; however, an inhibition zone was observed for
ampicillin (Figure 44). The discs with the positive control of ampicillin (indicated with a + on the disc) are
surrounded by zones where cell growth was inhibited. No inhibition zones are visible for the negative
control, water, or any of the tripeptides. These results were surprising because Ac-KPV-NH2 has been
reported as an anti-microbial agent116,

134, 136

To verify the activity of Ac-KPV-NH2, the peptide was

purchased from Bachem (Bubendorf, Switzerland), the same supplier as was used in Charnley et al.134 The
same protocols were followed as reported by Cutuli et al.116, 134 but negative results were observed again.
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Figure 44. (a) Compounds, spotted on filter disks and placed on cultures, include ampicillin (designated by
+), water, H-K(εG*)PV-NH2, Ac-KPV-NH2, and αG*-KPV-NH2 (starting with ampicillin and moving clockwise). Several strains of bacteria were tested: (b) W3110: E. coli K12; (c) WBB06: E. coli Δ(rfaC-rfaF); (d)
Salmonella enterica; (e) Vibrio cholera, C6706; and (f) Staphyloccocus aureus USA300.
Additional tests were conducted to compare the colony forming units of the cells exposed or not
exposed to the Ac-KPV-NH2. Staphylococcus aureus cells grown overnight and suspended in MOPS
minimal media were exposed to the Ac-KPV-NH2 for 2 h and cultured in LB agar plates. Visual counts of
the colony forming units showed no difference between the cells exposed (+ peptide) or not exposed (peptide) to the peptide. The images of plates used for colony counting are shown in Figure 45. Exposure
of the cells to the commercial Ac-KPV-NH2 at 0.1 mM did not affect the viability of the cells. Media with
calcium and laked horse blood were also tested, but these additives did not alter the negative results.
Lastly, the cells were grown in LB broth with varying concentration of the peptide and ampicillin as
positive control. The respective culture tubes are shown in Figure 46. None of the KPV derivatives hindered
growth.
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Figure 45. Staphylococcus aureus JE2 cells were incubated in the absence (- peptide) and presence (+
peptide) of 0.1 mM Ac-KPV-NH2 in various buffers: (a) MOPS minimal medium, (b) MOPS medium + 10
mM CaCl2, (c) MOPS medium + 10% laked horse blood, and (d) MOPS medium + 10 mM CaCl 2 + 10%
laked horse blood. Viability was determined by colony counting of serially diluted cells (10 cells/plate).

Figure 46. Overnight cell culture of Staphylococcus aureus in LB media containing KPV tripeptides at
varying concentrations as indicated.
The three antimicrobial tests discussed above were negative, contrary to earlier reports by Cutuli
et al.116, Charnley et al.134, and Singh et al136. Our findings paralleled the later report by Lau et al146., which
showed no antimicrobial activity. Additionally, previous tests by Rauch et al. failed to show the antimicrobial
activity of the Ac-KPV-NH2 against Candida albicans. Conflicting reports in the literature are summarized
in Table 8.
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Table 8. Conflicting reports on the antimicrobial activity of Ac-KPV-NH2
Pathogen

Activity

Reference

MRSA USA 100, MRSA USA 300

No activity (>100 µM)

Lau et al. 2015146

S. aureus

Activity (nM- µM)

Charnley et al. 2008134

S. aureus, Candida albicans

Activity (fM- µM)

Cutuli et al. 2000116

MSSA ATCC 29213, MRSA ATCC 33591

Activity (nM- µM)

Singh et al. 2011136

After failing to demonstrate antimicrobial activity for Ac-KPV-NH2, its anti-inflammatory activity was
investigated. The anti-inflammatory experiments were conducted in Dr. Jacqueline Stephens’ laboratory at
the Pennington Biomedical Research Center, with the help of Jasmine Burrell (graduate student) and Dr.
Allison Richard (postdoctoral associate). The inhibition of nuclear factor kappa B (NFκB) and the
translocation of p65 to the nucleus by the KPV peptides was investigated. Steps in the procedure and the
peptide inhibition mechanism are illustrated in Figure 47.

Figure 47. A) Steps in the procedure for determination of p65 localization; B) expected inhibition
mechanism of p65 translocation to the nucleus (right). IKK, inhibitor kappa B kinase; TNF, tumor necrosis
factor.
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The gel images (Figures 48 and 49) indicate some degree of inhibition of p65 translocation by AcKPV-NH2 and the glycopeptides. However, these results could not be reproduced in subsequent
experiments, including positive results for the Ac-KPV-NH2 control. There is a need to optimize parameters,
such as the peptide concentration and exposure time, in order to make accurate conclusions. There is also
a possibility that the adipocytes have a different response pathway to TNFα induction; such as the inhibition
of nitric oxide production.

Figure 48. Western blot images showing the effect of Ac-KPV-NH2 on the translocation of p65 to the
nucleus. ERK 1&2, extracellular signal regulated kinase (cytosol protein); PDC, phosducin.

Figure 49. Western blot images showing the effects of the tripeptides, 26, 27, and 29, on p65 translocation
to the nucleus. N, Nuclear proteins; C, Cytosol proteins; ERK 1&2, extracellular signal regulated kinase
(cytosol protein); DBC1, Deleted brain cancer 1 (nuclear protein). ERK and DBC1 were used as gel loading
standards.
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Since the antimicrobial and anti-inflammatory tests were negative and not reproducible,
respectively, we investigated the proteolytic stability of the modified tripeptides, 26 and 29, compared to the
parent tripeptide, 27. The peptides were exposed to pronase, and the peptide cleavage reactions were
monitored by NMR spectroscopy. Pronase is a mixture of proteases and aminopeptidases that cleave
proteins to their constituent amino acids. The peptide bonds in Ac-KPV-NH2 (20:1 peptide-pronase w/w)
were cleaved in less than 24 h. This result is indicated by the upfield shifts of proline (about 0.2 ppm) and
valine (about 0.5 ppm) Hα peaks in the 1H NMR spectrum, Figure 50C. The shift is attributed to the removal
of the electron-withdrawing N-acyl group. Additionally, the change in proline’s Hα peak from the apparent
triplet to a doublet of doublet is an indicator of a conformational change in the pyrrolidine ring. The pronase
reaction with the alpha modified tripeptide 26 (10:1 peptide-pronase w/w) was monitored for 35 h and no
change in the spectrum was observed, Figure 50A. To further test this stability, the ratio was adjusted to
5:1 peptide-pronase w/w, and the reaction was monitored for seven days. There was no change in the
spectrum, confirming that the peptide is highly resistant to pronase cleavage.
The reaction of pronase with the ε-glycoalkylated peptide 29 (20:1 peptide-pronase w/w) was less
clear. Within 50 hours of incubation, the lysine and the piperidine diol proton peaks were shifted upfield.
The broad peaks attributed to piperidine and the lysine ε-CH protons may be due to incomplete reaction.
The broadening can also be caused by the interaction of lysine side-chain with the autoproteolytic products
of pronase. Prolonged incubation for 96 hours revealed an additional valine Hα peak (Figure 50B) at the
same chemical shift of valine Hα in the cleaved Ac-KPV-NH2. Based on the ratio of peak intensities between
the two valine Hα peaks (original and cleaved), the pronase cleaved one-third of the peptide at the P-V
bond under this condition. Since the proline peaks were unchanged, it suggests that the K-P peptide bond
is stable and the P-V bond is starting to cleave (additional NMR spectra provided in Appendix B-5).
4.8. Conclusion
The lysine derivative, Ts-Lys-OMe, was successfully modified by double reductive alkylation with
a sugar derivative at the epsilon amine. The modification was confirmed by a crystal structure showing the
location and conformation of the dihydroxy piperidine ring. The same modification was applied to the
tripeptide sequence, KPV, the C-terminal sequence of the peptide α-MSH. A regioselective glycoalkylation
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was accomplished independently at each of the alpha and epsilon amines of lysine. The two glycoalkylated
peptides and the parent peptide did not show any antimicrobial activity against Staphylococcus aureus
under the conditions tested; even though the same protocol and conditions were followed to test the
antimicrobial activity as reported in literature.116, 134 The unexpected results were corroborated by a 2015
report by Lau et al146., that was published during our studies. They also observed no antimicrobial activity
for Ac-KPV-NH2 against Staphylococcus aureus.
The effect of the “glycoalkylation” modification was alternatively assessed through a proteolytic
stability assay. Glycoalkylation induced resistance of αG-KPV-NH2 against proteolytic cleavage by pronase.
The parent peptide was cleaved in less than 24 hours while the epsilon glycoalkylated peptide H-K(εG*)PVNH2 was resistant to cleavage for several days.
Considering the amount of effort directed to the synthesis of the glycopeptides, it was very
disappointing to learn of the inactivity of the parent peptide. It is now apparent that it would have been
prudent to test the antimicrobial activity of Ac-KPV-NH2 before proceeding to synthesize the glycoalkylated
analogs. This strategy should be applied to other selected peptide sequences used in the future for
glycoalkylation. While there were several literature reports indicating the antimicrobial activity of Ac-KPVNH2, most primary reports were given by the same group of authors and the others were review articles.
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Figure 50. Stability of the tripeptides to pronase cleavage, monitored by 1H NMR at 500 MHz in D2O. (A)
Compound 26; (B) Compound 29; and (C) Compound 27. Time of incubation is shown in hours at the center
of each spectrum.
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CHAPTER 5
CONCLUSION
Based on the NMR analysis of the Scc4 protein, it was determined that the backbone structure for
the Scc4 homodimer protein was different from that of the Scc4 heterodimer (in complex with Scc1His).
While there is a need to solve the 3D structure of the Scc4 homodimer for transcription regulation studies,
determination of the binding interface should be studied using the Scc1His-Scc4 complex and the mixed
complex samples. Two protocols were developed for purification of untagged Scc4 and for selective isotopic
labeling of Scc4 or Scc1His in Scc1His:Scc4 complex. A methodology was developed for triple resonance
backbone assignment for individual proteins from the NMR data of the complex. The backbone assignment
task was initialized; however, more NMR data is needed to complete backbone assignment and to
determine the binding interface.
The in vitro disruption of the binding interface in Scc1His:Scc4 protein complex using sarkosyl,
indicates that there is possibility that the complex can serve as a pathogenic protein target. Identification of
the interface epitopes will help in designing drugs for in vivo complex disruption. These drugs will inhibit
types III secretion system processes thus limiting chlamydial invasion and replication.
The structural modification of the tripeptide KPV by reductive glycoalkylation was accomplished.
The modification was shown to confer proteolytic stability to the glycopeptides against pronase cleavage.
The effect of the modification on the biological activity of the peptides could not be determined. The initial
positive anti-inflammatory results indicated that the peptides may have anti-inflammatory effects.
Optimization of the conditions, such as incubation time and peptide concentration, may enhance the
reproducibility. The choice of the cell line may also play a major role in determining the inflammation
pathway.
Glycoalkylation should be investigated for broad application in the structural modification of lysine
containing peptide drugs. Considering that pronase is a mixture of proteases and amino peptidases, the
stability to pronase cleavage by the modified peptides imply that glycoalkylation could be used to enhance
oral bioavailability of peptide drugs.

86

REFERENCES
1.

Lara, J. M. Intracellular management of information: From DNA to proteins. Triple C:
Communication, Capitalism & Critique 2009, 7, 376-385.

2.

Guarracino, D. A.; Gentile, K.; Grossman, A.; Li, E.; Refai, N.; Mohnot, J.; King, D. Salt-bridging
effects on short amphiphilic helical structure and introducing sequence-based short beta-turn
motifs. Journal of Biomolecular Structure & Dynamics 2018, 36, 475-485.

3.

Ponomarenko, E. A.; Poverennaya, E. V.; Ilgisonis, E. V.; Pyatnitskiy, M. A.; Kopylov, A. T.;
Zgoda, V. G.; Lisitsa, A. V.; Archakov, A. I. The size of the human proteome: The width and
depth. International Journal of Analytical Chemistry 2016, 2016, 7436849-6p.

4.

Gonzalez, M. W.; Kann, M. G. Chapter 4: Protein interactions and disease. Plos Computational
Biology 2012, 8, e1002819

5.

Bull, S. C.; Doig, A. J. Properties of protein drug target classes. PLoS ONE 2015, 10,
e0117955.

6.

Sosa, E. J.; Burguener, G.; Lanzarotti, E.; Defelipe, L.; Radusky, L.; Pardo, A. M.; Marti, M.;
Turjanski, A. G.; Fernández DoPorto, D. Target-pathogen: A structural bioinformatic approach
to prioritize drug targets in pathogens. Nucleic Acids Research 2018, 46, D413-D418.

7.

Green, E. R.; Mecsas, J. Bacterial secretion systems – An overview. Microbiology spectrum
2016, 4, 10.1128/microbiolspec.VMBF-0012-2015.

8.

Russo, A. F. Overview of neuropeptides: Awakening the senses? Headache 2017, 57 Suppl 2,
37-46.

9.

Zanin, J. P.; Unsain, N.; Anastasia, A. Growth factors and hormones pro-peptides: the
unexpected adventures of the BDNF prodomain. Journal of Neurochemistry 2017, 141, 330340.

10.

Andersen, D. C.; Krummen, L. Recombinant protein expression for therapeutic applications.
Current Opinion in Biotechnology 2002, 13, 117-123.

11.

Ung, P.; Winkler, D. A. Tripeptide motifs in biology: targets for peptidomimetic design. Journal
of Medicinal Chemistry 2011, 54, 1111-1125.

12.

Brzoska, T.; Luger, T. A.; Maaser, C.; Abels, C.; Bohm, M. Alpha-melanocyte-stimulating
hormone and related tripeptides: Biochemistry, antiinflammatory and protective effects in vitro
and in vivo, and future perspectives for the treatment of immune-mediated inflammatory
diseases. Endocrine Reviews 2008, 29, 581-602.

13.

Myers, R. D. Neuroactive peptides: Unique phases in research on mammalian brain over three
decades. Peptides 1994, 15, 367-381.

14.

Hartmann, R.; Meisel, H. Food-derived peptides with biological activity: from research to food
applications. Current Opinion in Biotechnology 2007, 18, 163-169.

15.

Korhonen, H.; Pihlanto, A. Bioactive peptides: Production and functionality. International Dairy
Journal 2006, 16, 945-960.

87

16.

Mains, R. E.; Eipper, B. A. Chapter 20 - Peptides A2 - Brady, Scott T. In: Basic Neurochemistry
(8th edition). Edited by Siegel, G. J.;Albers, R. W.;Price, D. L. New York: Academic Press; 2012,
390-407.

17.

Latham, P. W. Therapeutic peptides revisited. Nature. Biotechnology. 1999, 17, 755-757.

18.

Marqus, S.; Pirogova, E.; Piva, T. J. Evaluation of the use of therapeutic peptides for cancer
treatment. Journal of Biomedical Science 2017, 24, 21.

19.

Daliri, E. B.-M.; Oh, D. H.; Lee, B. H. Bioactive peptides. Foods 2017, 6, 32.

20.

Singh, M.; Mukhopadhyay, K. Alpha-melanocyte stimulating hormone: an emerging antiinflammatory antimicrobial peptide. BioMed Research International 2014, 2014, 10.

21.

Matsuzaki, K. Why and how are peptide–lipid interactions utilized for self-defense? Magainins
and tachyplesins as archetypes. Biochimica et Biophysica Acta - Biomembranes 1999, 1462,
1-10.

22.

Nguyen, L. T.; Haney, E. F.; Vogel, H. J. The expanding scope of antimicrobial peptide
structures and their modes of action. Trends in Biotechnology, 29, 464-472.

23.

Pálffy, R.; Gardlík, R.; Behuliak, M.; Kadasi, L.; Turna, J.; Celec, P. On the physiology and
pathophysiology of antimicrobial peptides. Molecular Medicine 2009, 15, 51-59.

24.

Yeaman, M. R.; Yount, N. Y. Mechanisms of antimicrobial peptide action and resistance.
Pharmacological Reviews 2003, 55, 27-55.

25.

Zhang, M.; Zhao, J.; Zheng, J. Molecular understanding of a potential functional link between
antimicrobial and amyloid peptides. Soft Matter 2014, 10, 7425-7451.

26.

Otvos, L.; Wade, J. D. Current challenges in peptide-based drug discovery. Frontiers in
Chemistry 2014, 2, 62.

27.

Böttger, R.; Hoffmann, R.; Knappe, D. Differential stability of therapeutic peptides with different
proteolytic cleavage sites in blood, plasma and serum. PLoS ONE 2017, 12, e0178943.

28.

Ahmed, B.; Robert, L.; Martin, M.; Gerhard, W. Challenges for PEGylated proteins and
alternative half-life extension technologies based on biodegradable polymers. In: Tailored
Polymer Architectures for Pharmaceutical and Biomedical Applications. vol. 1135: American
Chemical Society; 2013, 215-233.

29.

Ikeda, Y.; Katamachi, J.; Kawasaki, H.; Nagasaki, Y. Novel protein PEGylation chemistry via
glutalaldehyde-functionalized PEG. Bioconjugate Chemistry 2013, 24, 1824-1827.

30.

Moosmann, A.; Blath, J.; Lindner, R.; Müller, E.; Böttinger, H. Aldehyde PEGylation kinetics: a
standard protein versus a pharmaceutically relevant single chain variable fragment.
Bioconjugate Chemistry 2011, 22, 1545-1558.

31.

Fernandes, A. I.; Gregoriadis, G. The effect of polysialylation on the immunogenicity and
antigenicity of asparaginase: Implication in its pharmacokinetics. International Journal of
pharmaceutics 2001, 217, 215-224.

32.

Jain, S.; Hreczuk-Hirst, D. H.; McCormack, B.; Mital, M.; Epenetos, A.; Laing, P.; Gregoriadis,
G. Polysialylated insulin: Synthesis, characterization and biological activity in vivo. Biochimica
et Biophysica Acta - General Subjects 2003, 1622, 42-49.
88

33.

Pasut, G. Polymers for protein conjugation. Polymers 2014, 6, 160-178.

34.

Treib, J.; Baron, J. F.; Grauer, M. T.; Strauss, R. G. An international view of hydroxyethyl
starches. Intensive Care Medicine 1999, 25, 258-268.

35.

Schellenberger, V.; Wang, C.-w.; Geething, N. C.; Spink, B. J.; Campbell, A.; To, W.; Scholle,
M. D.; Yin, Y.; Yao, Y.; Bogin, O.; Cleland, J. L.; Silverman, J.; Stemmer, Willem, P. C. A
recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable
manner. Nature Biotechnology 2009, 27, 1186-1190.

36.

Mahajan, A.; Rawat, A. S.; Bhatt, N.; Chauhan, M. K. Structural modification of proteins and
peptides. Indian Journal of Pharmaceutical Education and Research 2014, 48, 34-47.

37.

Wang, J.; Breslow, E.; Sykes, B. D. Differential binding of desmopressin and vasopressin to
neurophysin-II. Journal of Biological Chemistry 1996, 271, 31354-31359.

38.

Qureshi, S.; Galiveeti, S.; Bichet, D. G.; Roth, J. Diabetes insipidus: Celebrating a century of
vasopressin therapy. Endocrinology 2014, 155, 4605-4621.

39.

Trüssel, S.; Dumelin, C.; Frey, K.; Villa, A.; Buller, F.; Neri, D. New strategy for the extension
of the serum half-life of antibody fragments. Bioconjugate Chemistry 2009, 20, 2286-2292.

40.

Verdine, G. L.; Hilinski, G. J. Stapled peptides for intracellular drug targets. Methods in
Enzymology 2012, 503, 3-33.

41.

Craik, D. J.; Fairlie, D. P.; Liras, S.; Price, D. The future of peptide-based drugs. Chemical
Biology & Drug Design 2013, 81, 136-147.

42.

Pavlou, A. K.; Reichert, J. M. Recombinant protein therapeutics--success rates, market trends
and values to 2010. Nature Biotechnology 2004, 22, 1513-1519.

43.

Jozala, A. F.; Geraldes, D. C.; Tundisi, L. L.; Feitosa, V. d. A.; Breyer, C. A.; Cardoso, S. L.;
Mazzola, P. G.; Oliveira-Nascimento, L. d.; Rangel-Yagui, C. d. O.; Magalhães, P. d. O.;
Oliveira, M. A. d.; Pessoa, Adalberto. Biopharmaceuticals from microorganisms: From
production to purification. Brazilian Journal of Microbiology 2016, 47, 51-63.

44.

Biopharmaceuticals
Market-Growth,
Trends
&
Forecasts
(2017-2022)
[https://www.mordorintelligence.com/industry-reports/global-biopharmaceuticals-marketindustry]

45.

Leader, B.; Baca, Q. J.; Golan, D. E. Protein therapeutics: A summary and pharmacological
classification. Nature Reviews Drug Discovery 2008, 7, 21-39.

46.

Demain, A. L.; Vaishnav, P. Production of recombinant proteins by microbes and higher
organisms. Biotechnology Advances 2009, 27, 297-306.

47.

Vlieghe, P.; Lisowski, V.; Martinez, J.; Khrestchatisky, M. Synthetic therapeutic peptides:
science and market. Drug Discovery Today 2010, 15, 40-56.

48.

Farrokhi, N.; Hrmova, M.; Burton, R. A.; Fincher, G. B. Heterologous and cell free protein
expression systems. Methods in Molecular Biology 2009, 513, 175-198.

49.

Bennett, P. M. Plasmid encoded antibiotic resistance: acquisition and transfer of antibiotic
resistance genes in bacteria. British Journal of Pharmacology 2008, 153, S347-S357

89

50.

Khan, K. H. Gene expression in mammalian cells and its applications. Advanced
Pharmaceutical Bulletin 2013, 3, 257-263.

51.

Gerngross, T. U. Advances in the production of human therapeutic proteins in yeasts and
filamentous fungi. Nature Biotechnology 2004, 22, 1409-1414.

52.

Jarvis, D. L. Baculovirus-insect cell expression systems. Methods in Enzymology 2009, 463,
191-222.

53.

Kost, T. A.; Condreay, J. P.; Jarvis, D. L. Baculovirus as versatile vectors for protein expression
in insect and mammalian cells. Nature Biotechnology 2005, 23, 567-575.

54.

Tekoah, Y.; Shulman, A.; Kizhner, T.; Ruderfer, I.; Fux, L.; Nataf, Y.; Bartfeld, D.; Ariel, T.;
Gingis–Velitski, S.; Hanania, U.; Shaaltiel, Y.Large‐scale production of pharmaceutical proteins
in plant cell culture—the protalix experience. Plant Biotechnology Journal 2015, 13, 1199-1208.

55.

Bloch, F. Nuclear induction. Physical Review 1946, 70, 460-474.

56.

Alvarez, L. W.; Bloch, F. A quantitative determination of the neutron moment in absolute
nuclear magnetons. Physical Review 1940, 57, 111-122.

57.

Pake, G. E. Fundamentals of nuclear magnetic resonance absorption .1. American Journal of
Physics 1950, 18, 438-452.

58.

Kleckner, I. R.; Foster, M. P. An introduction to NMR-based approaches for measuring protein
dynamics. Biochimica et Biophysica Acta 2011, 1814, 942-968.

59.

Atta ur, R.; Choudhary, M. I.; Atia tul, W. Chapter 2 - Creating NMR Signals. In: Solving
problems with NMR spectroscopy (2nd Edition). Edited by Atta ur, R.;Choudhary, M. I.;Atia tul,
W. Boston: Academic Press; 2016, 35-98.

60.

Bodenhausen, G.; Kogler, H.; Ernst, R. R. Selection of coherence-transfer pathways in NMR
pulse experiments. Journal of Magnetic Resonance (1969) 1984, 58, 370-388.

61.

Shapiro, L. M.; Matzat, S. J.; Gold, G. E. 41 - Functional magnetic resonance imaging. In:
Rheumatology (6th Edition). Edited by Hochberg, M. C.;Silman, A. J.;Smolen, J. S.;Weinblatt,
M. E.;Weisman, M. H. Philadelphia. 2015, 322-330.

62.

Jeener, J.; Meier, B. H.; Bachmann, P.; Ernst, R. R. Investigation of exchange processes by 2dimensional NMR-spectroscopy. Journal of Chemical Physics 1979, 71, 4546-4553.

63.

Morris, G. A.; Freeman, R. Selective excitation in Fourier transform nuclear magnetic
resonance. Journal of Magnetic Resonance 2011, 213, 214-243.

64.

Rinaldi, P. L. Three-dimensional solution NMR spectroscopy of complex structures and
mixtures. Analyst 2004, 129, 687-699.

65.

Atta ur, R.; Choudhary, M. I.; Atia tul, W. Chapter 8 - Playing with dimensions in NMR
spectroscopy. In: Solving Problems with NMR Spectroscopy (2nd edition). Edited by Atta ur,
R.;Choudhary, M. I.;Atia tul, W. Boston: Academic Press; 2016, 387-413.

66.

Marion, D.; Wüthrich, K. Application of phase sensitive two-dimensional correlated
spectroscopy (COSY) for measurements of 1H-1H spin-spin coupling constants in proteins.
Biochemical and Biophysical Research Communications 1983, 113, 967-974.

90

67.

Grzesiek, S.; Wingfield, P.; Stahl, S.; Kaufman, J. D.; Bax, A. Four-dimensional 15N-separated
NOESY of slowly tumbling perdeuterated 15N-enriched proteins. Application to HIV-1 Nef.
Journal of the American Chemical Society 1995, 117, 9594-9595.

68.

Lee, W.; Tonelli, M.; Dashti, H.; Eghbalnia, H. R.; Markley, J. L. I-PINE, an intergrative
probabilistic NMR assignment system. In preparation (cited as requested by the authors).

69.

Grzesiek, S. B. A. An efficient experiment for seqeuntial backbone assignment of mediumsized isotopically enriched proteins. Journal of Magnetic Resonance 1992, 99, 201-207.

70.

Venters, R. A.; Thompson, R.; Cavanagh, J. Current approaches for the study of large proteins
by NMR. Journal of Molecular Structure 2002, 602-603, 275-292.

71.

Meyer, B.; Peters, T. NMR spectroscopy techniques for screening and identifying ligand
binding to protein receptors. Angewandte Chemie International Edition 2003, 42, 864-890.

72.

Breeze, A. L. Isotope-filtered NMR methods for the study of biomolecular structure and
interactions. Progress in Nuclear Magnetic Resonance Spectroscopy 2000, 36, 323-372.

73.

Yu, F.; Roy, S.; Arevalo, E.; Schaeck, J.; Wang, J.; Holte, K.; Duffner, J.; Gunay, N. S.; Capila,
I.; Kaundinya, G. V. Characterization of heparin–protein interaction by saturation transfer
difference (STD) NMR. Analytical and Bioanalytical Chemistry 2014, 406, 3079-3089.

74.

Acton, T. B.; Xiao, R.; Anderson, S.; Aramini, J.; Buchwald, W. A.; Ciccosanti, C.; Conover, K.;
Everett, J.; Hamilton, K.; Huang, Y. J.; Janjua, H.; Kornhaber, G.; Lu, J.; Lee, D. Y.; Liu, G.;
Maglagui, M.; Ma, L.; Patel, D.; Rossi. P.; Sahdev, S.; Shastry, R.; Swapna, G. V. T.; Tang, Y.;
Tong, S.; Wang, D.; Wamg, H.; Zhao, L.; Montelione, G. T. Preparation of protein samples for
NMR structure, function, and small molecule screening studies. Methods in Enzymology 2011,
493, 21-60.

75.

Wheelhouse, N.; Longbottom, D. Endemic and emerging chlamydial infections of animals and
their zoonotic implications. Transboundary and Emerging Diseases 2012, 59, 283-291.

76.

Malhotra, M.; Sood, S.; Mukherjee, A.; Muralidhar, S.; Bala, M. Genital Chlamydia trachomatis:
An update. The Indian Journal of Medical Research 2013, 138, 303-316.

77.

Paavonen, J.; Eggert-Kruse, W. Chlamydia trachomatis: Impact on human reproduction.
Human Reproduction Update 1999, 5, 433-447.

78.

Cai, S.; He, F.; Samra, H. S.; de la Maza, L. M.; Bottazzi, M. E.; Joshi, S. B.; Middaugh, C. R.
Biophysical and stabilization studies of the Chlamydia trachomatis mouse pneumonitis major
outer membrane protein. Molecular Pharmacology 2009, 6, 1553-1561.

79.

Beagley, K. W.; Timms, P. Chlamydia trachomatis infection: incidence, health costs and
prospects for vaccine development. Journal of Reproductive Immunology 2000, 48, 47-68.

80.

Rao, X.; Deighan, P.; Hua, Z.; Hu, X.; Wang, J.; Luo, M.; Wang, J.; Liang, Y.; Zhong, G.;
Hochschild, A.; Shen, L. A regulator from Chlamydia trachomatis modulates the activity of RNA
polymerase through direct interaction with the beta subunit and the primary sigma subunit.
Genes & Development 2009, 23, 1818-1829.

81.

Hanson, B. R.; Slepenkin, A.; Peterson, E. M.; Tan, M. Chlamydia trachomatis Type III
secretion proteins regulate transcription. Journal of Bacteriology 2015, 197, 3238-3244.

91

82.

Newman, L.; Rowley, J.; Vander Hoorn, S.; Wijesooriya, N. S.; Unemo, M.; Low, N.; Stevens,
G.; Gottlieb, S.; Kiarie, J.; Temmerman, M. Global estimates of the prevalence and incidence
of four curable sexually transmitted infections in 2012 based on systematic review and global
reporting. PLoS ONE 2015, 10, e0143304.

83.

2016
Sexually
transmitted
[https://www.cdc.gov/std/stats16/chlamydia.htm]

84.

Sandoz, K. M.; Rockey, D. D. Antibiotic resistance in Chlamydiae. Future Microbiology 2010,
5, 1427-1442.

85.

Somani, J.; Bhullar, V. B.; Workowski, K. A.; Farshy, C. E.; Black, C. M. Multiple drug-resistant
Chlamydia trachomatis associated with clinical treatment failure. The Journal of Infectious
Diseases 2000, 181, 1421-1427.

86.

Mestrovic, T.; Ljubin-Sternak, S. Molecular mechanisms of Chlamydia trachomatis resistance
to antimicrobial drugs. Frontier in Bioscience (Landmark edition) 2018, 23, 656-670.

87.

Brunham, R. C.; Kimani, J.; Bwayo, J.; Maitha, G.; Maclean, I.; Yang, C.; Shen, C.; Roman, S.;
Nagelkerke, N. J.; Cheang, M.; Plummer, F. A. The epidemiology of Chlamydia trachomatis
within a sexually transmitted diseases core group. Journal of Infectious Disease 1996, 173,
950-956.

88.

de la Maza, L. M.; Zhong, G.; Brunham, R. C. Update on Chlamydia trachomatis vaccinology.
Clinical and Vaccine Immunology 2017, 24.

89.

Coburn, B.; Sekirov, I.; Finlay, B. B. Type III secretion systems and disease. Clinical
Microbiology Reviews 2007, 20, 535-549.

90.

Archuleta, T. L.; Du, Y.; English, C. A.; Lory, S.; Lesser, C.; Ohi, M. D.; Ohi, R.; Spiller, B. W.
The Chlamydia effector chlamydial outer protein N (CopN) sequesters tubulin and prevents
microtubule assembly. Journal of Biological Chemistry 2011, 286, 33992-33998.

91.

Silva-Herzog, E.; Joseph, S. S.; Avery, A. K.; Coba, J. A.; Wolf, K.; Fields, K. A.; Plano, G. V.
Scc1 (CP0432) and Scc4 (CP0033) function as a type III secretion chaperone for CopN of
Chlamydia pneumoniae. Journal of Bacteriology 2011, 193, 3490-3496.

92.

Hsia, R.-c.; Pannekoek, Y.; Ingerowski, E.; Bavoil, P. M. Type III secretion genes identify a
putative virulence locus of Chlamydia. Molecular Microbiology 1997, 25, 351-359.

93.

Fields, K. A.; Hackstadt, T. Evidence for the secretion of Chlamydia trachomatis CopN by a
type III secretion mechanism. Molecular Microbiology 2000, 38, 1048-1060.

94.

Balsara, Z. R.; Misaghi, S.; Lafave, J. N.; Starnbach, M. N. Chlamydia trachomatis infection
induces cleavage of the mitotic cyclin B1. Infection and Immunity 2006, 74, 5602-5608

95.

Shen, L.; Macnaughtan, M. A.; Frohlich, K. M.; Cong, Y.; Goodwin, O. Y.; Chou, C.-w.; LeCour,
L.; Krup, K.; Luo, M.; Worthylake, D. K. Multipart chaperone-effector recognition in the type III
secretion system of Chlamydia trachomatis. Journal of Biological Chemistry 2015, 290, 2814128155.

96.

Froger, A.; Hall, J. E. Transformation of plasmid DNA into E. coli using the heat shock method.
Journal of Visualized Experiments : JoVE 2007, 253.

92

disease

surveillance

97.

Marley, J.; Lu, M.; Bracken, C. A method for efficient isotopic labeling of recombinant proteins.
Journal of Biomolecular NMR 2001, 20, 71-75.

98.

Ying, J.; Delaglio, F.; Torchia, D. A.; Bax, A. Sparse multidimensional iterative lineshapeenhanced (SMILE) reconstruction of both non-uniformly sampled and conventional NMR data.
Journal of Biomolecular NMR 2017, 68, 101-118.

99.

Lee, W.; Tonelli, M.; Markley, J. L. NMRFAM-SPARKY: enhanced software for biomolecular
NMR spectroscopy. Bioinformatics 2015, 31, 1325-1327.

100.

Neduva, V.; Russell, R. B. DILIMOT: Discovery of linear motifs in proteins. Nucleic Acids
Research 2006, 34, W350-W355.

101.

Hann, M. M.; Leach, A. R.; Harper, G. Molecular complexity and its impact on the probability
of finding leads for drug discovery. Journal of Chemical Information and Computer Sciences
2001, 41, 856-864.

102.

Zamyatnin, A. A. Fragmentomics of natural peptide structures. Biochemistry-Moscow 2009, 74,
1575-1585.

103.

Mountjoy, K. G. Functions for pro-opiomelanocortin-derived peptides in obesity and diabetes.
Biochemical Journal 2010, 428, 305-324.

104.

Harris, R. M.; Dijkstra, P. D.; Hofmann, H. A. Complex structural and regulatory evolution of
the pro-opiomelanocortin gene family. General and Comparative Endocrinology 2014, 195,
107-115.

105.

Manna, S. K.; Aggarwal, B. B. Alpha-melanocyte-stimulating hormone inhibits the nuclear
transcription factor NF-kappa B activation induced by various inflammatory agents. Journal of
Immunology 1998, 161, 2873-2880.

106.

Madhuri; Shireen, T.; Venugopal, S. K.; Ghosh, D.; Gadepalli, R.; Dhawan, B.; Mukhopadhyay,
K. In vitro antimicrobial activity of alpha-melanocyte stimulating hormone against major human
pathogen Staphylococcus aureus. Peptides 2009, 30, 1627-1635.

107.

MacNeil, D. J.; Howard, A. D.; Guan, X. M.; Fong, T. M.; Nargund, R. P.; Bednarek, M. A.;
Goulet, M. T.; Weinberg, D. H.; Strack, A. M.; Marsh, D. J. et al The role of melanocortins in
body weight regulation: opportunities for the treatment of obesity. European Journal of
Pharmacology 2002, 440, 141-157.

108.

Coll, A. P. Effects of pro-opiomelanocortin (POMC) on food intake and body weight:
mechanisms and therapeutic potential? Clinical Science 2007, 113, 171.

109.

Lu, D. S.; Willard, D.; Patel, I. R.; Kadwell, S.; Overton, L.; Kost, T.; Luther, M.; Chen, W. B.;
Woychik, R. P.; Wilkison, W. O.; Cone, R. D. Agouti protein is an antagonist of the melanocytestimulating-hormone receptor. Nature 1994, 371, 799-802.

110.

Galván, I.; Alonso-Alvarez, C. The expression of melanin-based plumage is separately
modulated by exogenous oxidative stress and a melanocortin. Proceedings of the Royal
Society B: Biological Sciences 2009, 276, 3089.

111.

McNulty, J. C.; Jackson, P. J.; Thompson, D. A.; Chai, B.; Gantz, I.; Barsh, G. S.; Dawson, P.
E.; Millhauser, G. L. Structures of the agouti signaling protein. Journal of Molecular Biology
2005, 346, 1059-1070.

93

112.

Sankar, G. May, M. J.; Kopp, E. B. NF-κB and Rel proteins: Evolutionarily conserved mediators
of immune responses. Annual Review of Immunology 1998, 16, 225-260.

113.

Delgado, R.; Carlin, A.; Airaghi, L.; Demitri, M. T.; Meda, L.; Galimberti, D.; Baron, P.; Lipton,
J. M.; Catania, A. Melanocortin peptides inhibit production of proinflammatory cytokines and
nitric oxide by activated microglia. Journal of Leukocyte Biology 1998, 63, 740-745.

114.

Brogden, N. K.; Mehalick, L.; Fischer, C. L.; Wertz, P. W.; Brogden, K. A. The emerging role of
peptides and lipids as antimicrobial epidermal barriers and modulators of local inflammation.
Skin Pharmacology and Physiology 2012, 25, 167-181.

115.

Catania, A.; Colombo, G.; Rossi, C.; Carlin, A.; Sordi, A.; Lonati, C.; Turcatti, F.; Leonardi, P.;
Grieco, P.; Gatti, S. Antimicrobial properties of alpha-MSH and related synthetic melanocortins.
Scientific World Journal 2006, 6, 1241-1246.

116.

Cutuli, M.; Cristiani, S.; Lipton, J. M.; Catania, A. Antimicrobial effects of alpha-MSH peptides.
Journal of Leukocyte Biology 2000, 67, 233-239.

117.

Bhattacharya, A.; Datta, A. Effect of cyclic AMP on RNA and protein synthesis in Candida
albicans. Biochemical and Biophysical Research Communications 1977, 77, 1438-1444.

118.

Sawyer, T. K.; Staples, D. J.; Castrucci, A. M. L.; Hadley, M. E.; Al-Obeidi, F. A.; Cody, W. L.;
Hruby, V. J. α-Melanocyte stimulating hormone message and inhibitory sequences:
Comparative structure-activity studies on melanocytes. Peptides 1990, 11, 351-357.

119.

Schlimme, E.; Frister, H.; Raezke, K. P. Glycosylation of mono- and bicyclic dicarbonic acid
amides. Nucleoside & Nucleotide 1988, 7, 577-580.

120.

Roy, A.; Sanjayan, G. J. Sugar–amino acid cyclic conjugates as novel conformationally
constrained hydroxyethylamine transition-state isosteres. Tetrahedron Letters 2012, 53, 33613363.

121.

Jabgunde, A. M.; Kalamkar, N. B.; Chavan, S. T.; Sabharwal, S. G.; Dhavale, D. D. Synthesis
of new six- and seven-membered 1-N-iminosugars as promising glycosidase inhibitors.
Bioorganic & Medicinal Chemistry 2011, 19, 5912-5915.

122.

Begoña, P. M.; Fernández, F.; Estévez, J. C.; Estévez, R. J. A nitro sugar mediated synthesis
of 6-amino-1,5,6-trideoxy-1,5-imino-d-glucitol (6-amino-1,6-dideoxynojirimycin). Tetrahedron:
Asymmetry 2009, 20, 503-507.

123.

Dhavale, D. D.; Chaudhari, V. D.; Tilekar, J. N. An expeditious synthesis of a (3S,4S,5R)trihydroxyazepane. Tetrahedron Letters 2003, 44, 7321-7323.

124.

Iacono, S.; Rasmussen, J. R. Deoxygenation of secondary alcohols: 3‐Deoxy‐1,2:5,6‐Di‐O‐
isopropylidene‐α‐D‐ribo‐hexofuranose. In: Organic Syntheses. vol. 64: John Wiley & Sons, Inc.;
1986, 57-62.

125.

Cui, L.; Ling, C. C.; Sadowska, J.; Bundle, D. R. Synthesis of modified Trichinella spiralis
disaccharide epitopes and a comparison of their recognition by chemical mapping and
saturation transfer difference NMR. Carbohydrate Research 2014, 383, 1-13.

126.

Barton, D. H. R.; McCombie, S. W. A new method for the deoxygenation of secondary alcohols.
Journal of the Chemical Society, Perkin Transactions 1 1975, 1574-1585.

94

127.

Manna, S.; Viala, J.; Yadagiri, P.; Falck, J. R. Synthesis of 12(S),20-, 12(S),19(R)-, and
12(S),19(S)-dihydroxyeicosa-cis-5,8,14-trans-10-tetraenoic acids, metabolites of 12(S)-hete.
Tetrahedron Letters 1986, 27, 2679-2682.

128.

Gurjar, M. K.; Nagaprasad, R.; Ramana, C. V.; Karmakar, S.; Mohapatra, D. K. Ring-closing
metathesis mediated total synthesis of microcarpalide and herbarumin III. Arkivoc 2005, 237257.

129.

Rauter, A. P.; Figueiredo, J.; Ismael, M.; Canda, T.; Font, J.; Figueredo, M. Efficient synthesis
of α,β-unsaturated γ-lactones linked to sugars. Tetrahedron: Asymmetry 2001, 12, 1131-1146.

130.

Le Bouc, G.; Thomassigny, C.; Greck, C. Diastereoselective syntheses of
1-deoxyhomonojirimycin and two new 1,5,6-trideoxy-1,5-iminoheptitols with d-allo- and l-taloconfiguration. Tetrahedron: Asymmetry 2006, 17, 2006-2014.

131.

Chakraborty, C.; Dhavale, D. D. Short and efficient synthesis of (2S,3R,4R,5R) and
(2S,3R,4R,5S)-tetrahydroxyazepanes via the Henry reaction. Carbohydrate Research 2006,
341, 912-917.

132.

Dhavale, D. D.; Markad, S. D.; Karanjule, N. S.; PrakashaReddy, J. Asymmetric dihydroxylation
of D-glucose derived α,β-unsaturated ester: Synthesis of azepane and nojirimycin analogues.
The Journal of Organic Chemistry 2004, 69, 4760-4766.

133.

Borch, R. F.; Bernstein, M. D.; Durst, H. D. Cyanohydridoborate anion as a selective reducing
agent. Journal of the American Chemical Society 1971, 93, 2897-2904.

134.

Charnley, M.; Moir, A. J. G.; Douglas, C. W. I.; Haycock, J. W. Anti-microbial action of
melanocortin peptides and identification of a novel X-Pro-d/l-Val sequence in Gram-positive
and Gram-negative bacteria. Peptides 2008, 29, 1004-1009.

135.

Hiltz, M. E.; Catania, A.; Lipton, J. M. Anti-inflammatory activity of α-MSH(11–13) analogs:
Influences of alteration in stereochemistry. Peptides 1991, 12, 767-771.

136.

Singh, M.; Mukhopadhyay, K. C-terminal amino acids of alpha-melanocyte-stimulating
hormone are requisite for its antibacterial activity against Staphylococcus aureus. Antimicrobial
Agents and Chemotherapy 2011, 55, 1920-1929.

137.

Ferreira, S. H.; Lorenzetti, B. B.; Bristow, A. F.; Poole, S. Interleukin-1[beta] as a potent
hyperalgesic agent antagonized by a tripeptide analogue. Nature 1988, 334, 698-700.

138.

Moustafa, M.; Helen Kemp, E.; MacNeil, S.; Szabo, M.; Haycock, J. W.; Ghanem, G. E.;
Morandini, R. Inhibition of tumor necrosis factor-α stimulated NFκB/p65 in human keratinocytes
by α-melanocyte stimulating hormone and adrenocorticotropic hormone peptides. Journal of
Investigative Dermatology 2002, 119, 1244-1253.

139.

Galimberti, D.; Baron, P.; Meda, L.; Prat, E.; Scarpini, E.; Delgado, R.; Catania, A.; Lipton, J.
M.; Scarlato, G. α-MSH peptides inhibit production of nitric oxide and tumor necrosis factor-α
by microglial cells activated with β-amyloid and interferon γ. Biochemical and Biophysical
Research Communications 1999, 263, 251-256.

140.

Fosgerau, K.; Hoffmann, T. Peptide therapeutics: current status and future directions. Drug
Discovery Today 2015, 20, 122-128.

141.

Sweeney, P. J.; Walker, J. M. Pronase (EC 3.4.24.4). In: Enzymes of Molecular Biology. Edited
by Burrell, M. M. Totowa, NJ: Humana Press; 1993, 271-276.
95

142.

Bauer, A. W.; Perry, D. M.; Kirby, W. M. Single-disk antibiotic-sensitivity testing of
Staphylococci; an analysis of technique and results. AMA Arch Intern Med 1959, 104, 208-216.

143.

Brabetz, W.; Muller-Loennies, S.; Holst, O.; Brade, H. Deletion of the heptosyltransferase
genes rfaC and rfaF in Escherichia coli K-12 results in an Re-type lipopolysaccharide with a
high degree of 2-aminoethanol phosphate substitution. European Journal of Biochemistry
1997, 247, 716-724.

144.

Fey, P. D.; Endres, J. L.; Yajjala, V. K.; Widhelm, T. J.; Boissy, R. J.; Bose, J. L.; Bayles, K. W.
A genetic resource for rapid and comprehensive phenotype screening of nonessential
Staphylococcus aureus genes. MBio 2013, 4, e00537-00512.

145.

Zhao, P.; Stephens, J. M. STAT1, NF-κB and ERKs play a role in the induction of lipocalin-2
expression in adipocytes. Molecular Metabolism 2013, 2, 161-170.

146.

Lau, Q. Y.; Choo, X. Y.; Lim, Z. X.; Kong, X. N.; Ng, F. M.; Ang, M. J. Y.; Hill, J.; Brian Chia, C.
S. A head-to-head comparison of the antimicrobial activities of 30 ultra-short antimicrobial
peptides against Staphylococcus aureus, Pseudomonas aeruginosa and Candida albicans.
International Journal of Peptide Research and Therapeutics 2015, 21, 21-28.

96

APPENDIX A
SUPPLEMENTARY ON PROTEIN EXPRESSION AND NMR ANALYSIS
A-1 Protein sequences
A-1.1 Scc1His
MSGHHHHHHSSSSGTENLYFQGAMQNQFEQLLTELGTQINSPLTPDSNNACIVRFGYNNVAVQIEEDGN
SGFLVAGVMLGKLPENTFRQKIFKAALSINGSPQSNIKGTLGYGEISNQLYLCDRLNMTYLNGEKLARYLV
LFSQHANIWMQSISKGELPDLHALGMYHL
Theoretical pI/Mw: 6.28 / 18783.19; 169 amino acids
A-1.2 HisScc4
MASHHHHHHMLEKLIKNFVAYMGVASELEFDADGSYVFPISSLVRMRVRQNADEEIIISAFLGEIPASMDIE
KAYARMMEGNLFGQETGGAALGLDSDGHAVLVRRVPGEVSQEDFASYIESVLNYAEAWLEDLGLSKTE
QE
Theoretical pI/Mw: 4.69 / 15786.75; 142 amino acids
A-2. Minimal media recipe (1 L)
100 mL of 10X M9 salts (50 mM Na2HPO4, 20 mM KH2PO4, 10 mM NaCl) without NH4Cl, 1mL of
1M MgSO4, 100µL of 1M CaCl2, 1mL of trace metals (5 μM FeCl3, 20 μM CaCl2, 10 μM MnSO4, ZnSO4, 2
μM CoCl2, CuSO4, NiCl2, H3BO3, Na2MoO4, Na2SeO3), 10 mL BME vitamins, 1 mg thiamine, 0.4% glucose,
1 g of 15N ammonium chloride, and the respective antibiotics.
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A-3 Acquisition parameters for 3D NMR experiments
Table 9 Parameters used for triple resonance backbone NMR experiments

A-4 DNA sequences
A-4.1 His-Scc4-22-end DNA sequence
TAT ACC ATG GGCAGCAGCCATCACCACCATCACCATTCTAGT GAT GCA GAC GGC TCT TAC GTT
TTC CCG ATT TCC AGC CTG GTT CGC ATG CGT GTC CGC CAG AAC GCC GAT GAA GAG ATC ATC
ATC TCC GCG TTC CTG GGT GAA ATC CCG GCG AGC ATG GAC ATC GAA AAA GCG TAT GCG CGC
ATG ATG GAA GGC AAC CTG TTC GGC CAG GAA ACT GGC GGT GCT GCT CTG GGT CTG GAC
TCC GAC GGT CAC GCT GTA CTG GTC CGT CGT GTT CCG GGC GAA GTG TCT CAG GAG GAT TTC
GCC TCC TAT ATC GAA TCT GTG CTG AAT TAT GCG GAA GCC TGG CTG GAG GAT CTG GGT CTG
TCT AAG ACC GAG CAG GAG TAA CTC GAG CAC CAC
A-4.2 pET28(+)-His-Scc4-22-end DNA sequences
1 ATCCGGATAT AGTTCCTCCT TTCAGCAAAA AACCCCTCAA GACCCGTTTA
51 GAGGCCCCAA GGGGTTATGC TAGTTATTGC TCAGCGGTGG CAGCAGCCAA
101 CTCAGCTTCC TTTCGGGCTT TGTTAGCAGC CGGATCTCAG TGGTGGTGGT
151 GGTGGTGCTC GAGTTACTCC TGCTCGGTCT TAGACAGACC CAGATCCTCC
201 AGCCAGGCTT CCGCATAATT CAGCACAGAT TCGATATAGG AGGCGAAATC
251 CTCCTGAGAC ACTTCGCCCG GAACACGACG GACCAGTACA GCGTGACCGT
98

301 CGGAGTCCAG ACCCAGAGCA GCACCGCCAG TTTCCTGGCC GAACAGGTTG
351 CCTTCCATCA TGCGCGCATA CGCTTTTTCG ATGTCCATGC TCGCCGGGAT
401 TTCACCCAGG AACGCGGAGA TGATGATCTC TTCATCGGCG TTCTGGCGGA
451 CACGCATGCG AACCAGGCTG GAAATCGGGA AAACGTAAGA GCCGTCTGCA
501 TCACTAGAAT GGTGATGGTG GTGATGGCTG CTGCCCATGG TATATCTCCT
551 TCTTAAAGTT AAACAAAATT ATTTCTAGAG GGGAATTGTT ATCCGCTCAC
601 AATTCCCCTA TAGTGAGTCG TATTAATTTC GCGGGATCGA GATCTCGATC
651 CTCTACGCCG GACGCATCGT GGCCGGCATC ACCGGCGCCA CAGGTGCGGT
701 TGCTGGCGCC TATATCGCCG ACATCACCGA TGGGGAAGAT CGGGCTCGCC
751 ACTTCGGGCT CATGAGCGCT TGTTTCGGCG TGGGTATGGT GGCAGGCCCC
801 GTGGCCGGGG GACTGTTGGG CGCCATCTCC TTGCATGCAC CATTCCTTGC
851 GGCGGCGGTG CTCAACGGCC TCAACCTACT ACTGGGCTGC TTCCTAATGC
901 AGGAGTCGCA TAAGGGAGAG CGTCGAGATC CCGGACACCA TCGAATGGCG
951 CAAAACCTTT CGCGGTATGG CATGATAGCG CCCGGAAGAG AGTCAATTCA
1001 GGGTGGTGAA TGTGAAACCA GTAACGTTAT ACGATGTCGC AGAGTATGCC
1051 GGTGTCTCTT ATCAGACCGT TTCCCGCGTG GTGAACCAGG CCAGCCACGT
1101 TTCTGCGAAA ACGCGGGAAA AAGTGGAAGC GGCGATGGCG GAGCTGAATT
1151 ACATTCCCAA CCGCGTGGCA CAACAACTGG CGGGCAAACA GTCGTTGCTG
1201 ATTGGCGTTG CCACCTCCAG TCTGGCCCTG CACGCGCCGT CGCAAATTGT
1251 CGCGGCGATT AAATCTCGCG CCGATCAACT GGGTGCCAGC GTGGTGGTGT
1301 CGATGGTAGA ACGAAGCGGC GTCGAAGCCT GTAAAGCGGC GGTGCACAAT
1351 CTTCTCGCGC AACGCGTCAG TGGGCTGATC ATTAACTATC CGCTGGATGA
1401 CCAGGATGCC ATTGCTGTGG AAGCTGCCTG CACTAATGTT CCGGCGTTAT
1451 TTCTTGATGT CTCTGACCAG ACACCCATCA ACAGTATTAT TTTCTCCCAT
1501 GAAGACGGTA CGCGACTGGG CGTGGAGCAT CTGGTCGCAT TGGGTCACCA
1551 GCAAATCGCG CTGTTAGCGG GCCCATTAAG TTCTGTCTCG GCGCGTCTGC
1601 GTCTGGCTGG CTGGCATAAA TATCTCACTC GCAATCAAAT TCAGCCGATA
1651 GCGGAACGGG AAGGCGACTG GAGTGCCATG TCCGGTTTTC AACAAACCAT
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1701 GCAAATGCTG AATGAGGGCA TCGTTCCCAC TGCGATGCTG GTTGCCAACG
1751 ATCAGATGGC GCTGGGCGCA ATGCGCGCCA TTACCGAGTC CGGGCTGCGC
1801 GTTGGTGCGG ATATCTCGGT AGTGGGATAC GACGATACCG AAGACAGCTC
1851 ATGTTATATC CCGCCGTTAA CCACCATCAA ACAGGATTTT CGCCTGCTGG
1901 GGCAAACCAG CGTGGACCGC TTGCTGCAAC TCTCTCAGGG CCAGGCGGTG
1951 AAGGGCAATC AGCTGTTGCC CGTCTCACTG GTGAAAAGAA AAACCACCCT
2001 GGCGCCCAAT ACGCAAACCG CCTCTCCCCG CGCGTTGGCC GATTCATTAA
2051 TGCAGCTGGC ACGACAGGTT TCCCGACTGG AAAGCGGGCA GTGAGCGCAA
2101 CGCAATTAAT GTAAGTTAGC TCACTCATTA GGCACCGGGA TCTCGACCGA
2151 TGCCCTTGAG AGCCTTCAAC CCAGTCAGCT CCTTCCGGTG GGCGCGGGGC
2201 ATGACTATCG TCGCCGCACT TATGACTGTC TTCTTTATCA TGCAACTCGT
2251 AGGACAGGTG CCGGCAGCGC TCTGGGTCAT TTTCGGCGAG GACCGCTTTC
2301 GCTGGAGCGC GACGATGATC GGCCTGTCGC TTGCGGTATT CGGAATCTTG
2351 CACGCCCTCG CTCAAGCCTT CGTCACTGGT CCCGCCACCA AACGTTTCGG
2401 CGAGAAGCAG GCCATTATCG CCGGCATGGC GGCCCCACGG GTGCGCATGA
2451 TCGTGCTCCT GTCGTTGAGG ACCCGGCTAG GCTGGCGGGG TTGCCTTACT
2501 GGTTAGCAGA ATGAATCACC GATACGCGAG CGAACGTGAA GCGACTGCTG
2551 CTGCAAAACG TCTGCGACCT GAGCAACAAC ATGAATGGTC TTCGGTTTCC
2601 GTGTTTCGTA AAGTCTGGAA ACGCGGAAGT CAGCGCCCTG CACCATTATG
2651 TTCCGGATCT GCATCGCAGG ATGCTGCTGG CTACCCTGTG GAACACCTAC
2701 ATCTGTATTA ACGAAGCGCT GGCATTGACC CTGAGTGATT TTTCTCTGGT
2751 CCCGCCGCAT CCATACCGCC AGTTGTTTAC CCTCACAACG TTCCAGTAAC
2801 CGGGCATGTT CATCATCAGT AACCCGTATC GTGAGCATCC TCTCTCGTTT
2851 CATCGGTATC ATTACCCCCA TGAACAGAAA TCCCCCTTAC ACGGAGGCAT
2901 CAGTGACCAA ACAGGAAAAA ACCGCCCTTA ACATGGCCCG CTTTATCAGA
2951 AGCCAGACAT TAACGCTTCT GGAGAAACTC AACGAGCTGG ACGCGGATGA
3001 ACAGGCAGAC ATCTGTGAAT CGCTTCACGA CCACGCTGAT GAGCTTTACC
3051 GCAGCTGCCT CGCGCGTTTC GGTGATGACG GTGAAAACCT CTGACACATG
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3101 CAGCTCCCGG AGACGGTCAC AGCTTGTCTG TAAGCGGATG CCGGGAGCAG
3151 ACAAGCCCGT CAGGGCGCGT CAGCGGGTGT TGGCGGGTGT CGGGGCGCAG
3201 CCATGACCCA GTCACGTAGC GATAGCGGAG TGTATACTGG CTTAACTATG
3251 CGGCATCAGA GCAGATTGTA CTGAGAGTGC ACCATATATG CGGTGTGAAA
3301 TACCGCACAG ATGCGTAAGG AGAAAATACC GCATCAGGCG CTCTTCCGCT
3351 TCCTCGCTCA CTGACTCGCT GCGCTCGGTC GTTCGGCTGC GGCGAGCGGT
3401 ATCAGCTCAC TCAAAGGCGG TAATACGGTT ATCCACAGAA TCAGGGGATA
3451 ACGCAGGAAA GAACATGTGA GCAAAAGGCC AGCAAAAGGC CAGGAACCGT
3501 AAAAAGGCCG CGTTGCTGGC GTTTTTCCAT AGGCTCCGCC CCCCTGACGA
3551 GCATCACAAA AATCGACGCT CAAGTCAGAG GTGGCGAAAC CCGACAGGAC
3601 TATAAAGATA CCAGGCGTTT CCCCCTGGAA GCTCCCTCGT GCGCTCTCCT
3651 GTTCCGACCC TGCCGCTTAC CGGATACCTG TCCGCCTTTC TCCCTTCGGG
3701 AAGCGTGGCG CTTTCTCATA GCTCACGCTG TAGGTATCTC AGTTCGGTGT
3751 AGGTCGTTCG CTCCAAGCTG GGCTGTGTGC ACGAACCCCC CGTTCAGCCC
3801 GACCGCTGCG CCTTATCCGG TAACTATCGT CTTGAGTCCA ACCCGGTAAG
3851 ACACGACTTA TCGCCACTGG CAGCAGCCAC TGGTAACAGG ATTAGCAGAG
3901 CGAGGTATGT AGGCGGTGCT ACAGAGTTCT TGAAGTGGTG GCCTAACTAC
3951 GGCTACACTA GAAGGACAGT ATTTGGTATC TGCGCTCTGC TGAAGCCAGT
4001 TACCTTCGGA AAAAGAGTTG GTAGCTCTTG ATCCGGCAAA CAAACCACCG
4051 CTGGTAGCGG TGGTTTTTTT GTTTGCAAGC AGCAGATTAC GCGCAGAAAA
4101 AAAGGATCTC AAGAAGATCC TTTGATCTTT TCTACGGGGT CTGACGCTCA
4151 GTGGAACGAA AACTCACGTT AAGGGATTTT GGTCATGAAC AATAAAACTG
4201 TCTGCTTACA TAAACAGTAA TACAAGGGGT GTTATGAGCC ATATTCAACG
4251 GGAAACGTCT TGCTCTAGGC CGCGATTAAA TTCCAACATG GATGCTGATT
4301 TATATGGGTA TAAATGGGCT CGCGATAATG TCGGGCAATC AGGTGCGACA
4351 ATCTATCGAT TGTATGGGAA GCCCGATGCG CCAGAGTTGT TTCTGAAACA
4401 TGGCAAAGGT AGCGTTGCCA ATGATGTTAC AGATGAGATG GTCAGACTAA
4451 ACTGGCTGAC GGAATTTATG CCTCTTCCGA CCATCAAGCA TTTTATCCGT
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4501 ACTCCTGATG ATGCATGGTT ACTCACCACT GCGATCCCCG GGAAAACAGC
4551 ATTCCAGGTA TTAGAAGAAT ATCCTGATTC AGGTGAAAAT ATTGTTGATG
4601 CGCTGGCAGT GTTCCTGCGC CGGTTGCATT CGATTCCTGT TTGTAATTGT
4651 CCTTTTAACA GCGATCGCGT ATTTCGTCTC GCTCAGGCGC AATCACGAAT
4701 GAATAACGGT TTGGTTGATG CGAGTGATTT TGATGACGAG CGTAATGGCT
4751 GGCCTGTTGA ACAAGTCTGG AAAGAAATGC ATAAACTTTT GCCATTCTCA
4801 CCGGATTCAG TCGTCACTCA TGGTGATTTC TCACTTGATA ACCTTATTTT
4851 TGACGAGGGG AAATTAATAG GTTGTATTGA TGTTGGACGA GTCGGAATCG
4901 CAGACCGATA CCAGGATCTT GCCATCCTAT GGAACTGCCT CGGTGAGTTT
4951 TCTCCTTCAT TACAGAAACG GCTTTTTCAA AAATATGGTA TTGATAATCC
5001 TGATATGAAT AAATTGCAGT TTCATTTGAT GCTCGATGAG TTTTTCTAAG
5051 AATTAATTCA TGAGCGGATA CATATTTGAA TGTATTTAGA AAAATAAACA
5101 AATAGGGGTT CCGCGCACAT TTCCCCGAAA AGTGCCACCT GAAATTGTAA
5151 ACGTTAATAT TTTGTTAAAA TTCGCGTTAA ATTTTTGTTA AATCAGCTCA
5201 TTTTTTAACC AATAGGCCGA AATCGGCAAA ATCCCTTATA AATCAAAAGA
5251 ATAGACCGAG ATAGGGTTGA GTGTTGTTCC AGTTTGGAAC AAGAGTCCAC
5301 TATTAAAGAA CGTGGACTCC AACGTCAAAG GGCGAAAAAC CGTCTATCAG
5351 GGCGATGGCC CACTACGTGA ACCATCACCC TAATCAAGTT TTTTGGGGTC
5401 GAGGTGCCGT AAAGCACTAA ATCGGAACCC TAAAGGGAGC CCCCGATTTA
5451 GAGCTTGACG GGGAAAGCCG GCGAACGTGG CGAGAAAGGA AGGGAAGAAA
5501 GCGAAAGGAG CGGGCGCTAG GGCGCTGGCA AGTGTAGCGG TCACGCTGCG
5551 CGTAACCACC ACACCCGCCG CGCTTAATGC GCCGCTACAG GGCGCGTCCC
5601 ATTCGCCA
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APPENDIX B
NMR SPECTRA FOR THE SYNTHESIZED COMPOUNDS
B-1 1H and 13C NMR spectra of compounds in Scheme 3

Figure 51. 1H NMR spectrum of compound 15
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Figure 52. 13C NMR spectrum of compound 15
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Figure 53. 1H NMR spectrum of compound 16
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Figure 54. 13C NMR spectrum of compound 16
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Figure 55. 1H NMR spectrum of compound 17
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Figure 56. 13C NMR spectrum of compound 17
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Figure 57. 1H NMR spectrum of compound 12
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Figure 58. 13C NMR spectrum of compound 12
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B-2 1H and 13C NMR spectra of compounds in Scheme 4

Figure 59. 1H NMR spectrum of compound 18
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Figure 60. 13C NMR spectrum of compound 18
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Figure 61. 1H NMR spectrum of compound 2
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Figure 62. 13C NMR spectrum of compound 2
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B-3 1H and 13C NMR spectra of compounds in Scheme 5

Figure 63. 1H NMR spectrum of compound 22
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Figure 64. 13C NMR spectrum of compound 22
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Figure 65. 1H NMR spectrum of compound 24
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Figure 66. 13C NMR spectrum of compound 24
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B-4 1H and 13C NMR Spectra of compounds in Scheme 6

Figure 67. 1H NMR spectrum of compound 25
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Figure 68. 13C NMR spectrum of compound 25
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Figure 69. 1H NMR spectrum of compound 28
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Figure 70. 13C NMR spectrum of compound 28
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Figure 71. 1H NMR spectrum of compound 27a
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Figure 72. 13C NMR spectrum of compound 27a
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Figure 72. 1H NMR spectrum of compound 26
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Figure 74. 13C NMR spectrum of compound 26
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Figure 75. 1H NMR spectrum of compound 27
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Figure 76. 13C NMR spectrum of compound 27
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Figure 77. 1H NMR spectrum of compound 29
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Figure 78. 13C NMR spectrum of compound 29
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B-5 1H NMR spectra of compounds 26, 27, and 29 on pronase cleavage reaction

Figure 79. 1H NMR spectrum of compound 26, pronase reaction
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Figure 80. 1H NMR spectrum of compound 29, pronase reaction
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Figure 81. 1H NMR spectrum of compound 27, pronase reaction
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Figure 82. 1H NMR spectrum of compounds 26, 27, and 29, pronase reaction
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